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Abstract 
Chronic myeloid leukaemia (CML) is a myeloproliferative disease of stem cell origin. It 
is characterised by the Philadelphia chromosome and Bcr-Abl oncoprotein which is a 
constitutively activated tyrosine kinase that is causative in CML. Treatment of CML 
was revolutionized by tyrosine kinase inhibitors (TKIs) in the last decade. TKIs target 
Bcr-Abl and block its tyrosine kinase activity. Despite the success of TKI in eliminating 
differentiated CML cells, primitive quiescent CML stem cells still resist or persist with 
TKI  treatment.  In  this  study,  several  strategies  have  been  investigated  towards 
elimination of TKI-insensitive primitive CML stem cells.  
 
At first, the effect of nuclear entrapment of Bcr-Abl protein in CML cells was studied. 
Although  Bcr-Abl  protein  is  located  in  the  cytoplasm  of  CML  cells,  TKIs,  such  as 
imatinib mesylate (IM), can induce the nuclear translocation of Bcr-Abl. Nuclear Bcr-
Abl  tyrosine  kinase  is  capable  of  inducing  apoptosis  after  drug  washout,  and 
leptomycin B (LMB) can trap translocated Bcr-Abl in the nucleus. Primary CML CD34
+ 
cells were treated with IM and LMB either continuously or sequentially. It was found 
that neither regimen significantly increased the anti-proliferative effect of IM in primary 
CML CD34
+ cells. It was also observed that the majority of Bcr-Abl was still retained 
in the cytoplasm of CML cells treated with IM and LMB, suggesting other mechanisms 
apart from its tyrosine kinase activity retained Bcr-Abl protein in the cytoplasm of CML 
cells. Next the subcellular distribution of Bcr-Abl was investigated in TKI-insensitive 
CML progenitors which survived 12-Day treatment of a potent TKI dasatinib (150nM). Peixun Zhou, 2011                                                                                                                                    
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It was demonstrated that about 50% of Bcr-Abl was still retained in the cytoplasm of 
TKI-insensitive primary CML progenitors, although there was a significant increase in 
nuclear Bcr-Abl level in these survived cells compared to the no drug control (NDC). It 
was  hypothesised  that  the  cytoplasmic  retention  of  Bcr-Abl  was  caused  by  its 
cytoplasmic binding partners, and it was found that a proportion of Bcr-Abl protein 
was associated with 14-3-3 proteins in the surviving cells, indicating the cytoplasmic 
retention of Bcr-Abl might be due to its binding with 14-3-3 proteins.  
 
In addition, due to the rapid nature of kinase inhibition and nuclear transportation, 
studies are required to measure the earliest time-point of inhibition of Bcr-Abl tyrosine 
kinase by IM. The common method to do this is to employ p-CrkL which has been 
widely  used  as  a  surrogate  marker  of  Bcr-Abl  tyrosine  kinase  activity,  but  the 
accuracy of p-CrkL as an indicator of Bcr-Abl tyrosine kinase status at early time-
points during in vitro TKI treatment has not been examined. It was demonstrated that 
p-CrkL was not a reliable indicator of Bcr-Abl kinase activity within 24 hours of IM 
treatment in vitro and indicated that the early responses to IM and dasatinib were 
different. It was also observed that there was a rapid and active dephosphorylation of 
Bcr-Abl  within  1  hour  of  TKI  treatment,  driven  at  least  in  part  by  protein  tyrosine 
phosphatase activity.  
 
Furthermore, a farnesyltransferase inhibitor (FTI) BMS-214662 preferentially induces 
apoptosis in CML stem and progenitor cells compared to their normal counterparts, 
but another similar FTI BMS-225975 does not. However, the mechanism of action of Peixun Zhou, 2011                                                                                                                                    
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BMS-214662 in inducing apoptosis of CML cells is not clear. When BMS-214662 was 
used as a negative control in the p-CrkL study, it was unexpectedly observed that the 
drug accumulated Bcr-Abl protein in CML cells. Thus, it was hypothesised that BMS-
214662 may function as a proteasome inhibitor, which could result in accumulation of 
Bcr-Abl protein and further elevation of intracellular ROS level, leading to apoptosis of 
CML  cells.  Although  BMS-214662  treatment  induced  accumulation  of  total 
ubiquitinated proteins and specifically Bcr-Abl protein in K562 cells, BMS-225975 had 
very  similar  effects,  and  this  might  result  from  the  common  mechanism  of  BMS-
214662 and BMS-225975, which is their FTI activity. On the other hand, BMS-214662 
induced significantly higher levels of intracellular ROS in both proliferating and non-
proliferating K562 cells with respect to BMS-225975, indicating the production of ROS 
may be involved in the non-FTI mechanism of action of BMS-214662. However it was 
concluded that BMS-214662 was not a proteasome inhibitor like bortezomib. 
 
Finally,  the  use  of  synthetic  low  density  lipoprotein  (sLDL)  as  a  vehicle  for  drug 
delivery  to  overcome  the  insufficient  intracellular  drug  concentration  in  CML  stem 
cells was investigated. Uptake and internalization of unloaded sLDL particles by CML 
cell line K562 and for the first time by CML stem cells was observed, demonstrating 
the targeting potential of sLDL particles in CML when they are loaded with drugs.  
 
Overall,  this  study  provides  further  understanding  of  CML  treatment  and  identifies 
some alternative strategies to target CML stem cells that may be used in combination 
with TKI to enhance the eradication of this stem cell-driven disease. Peixun Zhou, 2011                                                                                                                                    
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FSC                         Forward scatter 
GAP                         GTPase activation protein 
GAPDH                 Glyceraldehyde-3-phosphate dehydrogenase 
G-CSF                   Granulocyte colony-stimulating factor 
GDP                         Guanosine diphosphate  
GEF      Guanine nucleotide exchange factor 
GFs                          Growth factors  Peixun Zhou, 2011                                                                                                                                    
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GM1      Monosialotetrahexosylganglioside 
GM-CSF    Granulocyte macrophage colony-stimulating factor 
GMP       Granulocyte-macrophage progenitor 
G-protein            Guanosine-nucleotide-binding protein 
Grb2       Growth factor receptor bound protein 2 
GTP                         Guanosine triphosphate 
GTPase      Guanosine triphosphatase 
Hck      Haemopoietic cell kinase 
hOCT1    human organic cation transporter 
HRP                         Horseradish peroxidise 
HSC      Haemopoietic stem cell 
IFN-α      Interferon-alpha 
IGF-IR    Type 1 insulin-like growth factor receptor 
IL1RAP    IL-1 receptor accessory protein 
IL-3                          Interleukin-3 
IL-6                          Interleukin-6 
IM                            Imatinib mesylate 
IP                             Immunoprecipitation    
JAK                         Janus kinase 
JNK                         c-Jun N-terminal kinase 
kDa      KiloDalton 
LDL      Low density lipoprotein 
LDLR                         Low density lipoprotein receptor 
LMB                         Leptomycin B 
LREC                       Local Research Ethics Committee 
LSC      Leukaemic stem cell 
LTC-IC               Long-Term Culture-Initiating Cell 
LT-HSC    long-term HSC 
MAPK     Mitogen activated protein kinase 
M-bcr      Major break point cluster region Peixun Zhou, 2011                                                                                                                                    
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m-bcr      minor break point cluster region  
MCgR     Major cytogenetic response 
mCgR     Minor cytogenetic response 
Mcl-1      Myeloid cell leukaemia-1   
MDM2      Murine double minute 2 
MEP      Megakaryocyte-erythroid progenitor 
MFI                          Mean fluorescence intensity 
MMR      Major molecular response 
MNC      Mononuclear cells 
MPP      Multipotent progenitor       
mRNA      messenger RNA  
NDC                        No drug control 
NES                         Nuclear export signal 
NHL      non-Hodgkin's Lymphoma 
NLS                          Nuclear localisation signal 
NOD/SCID     Nonobese diabetic/severe combined immunodeficient 
PBS                           Phosphate buffered saline 
PCgR     Partial cytogenetic response 
PCR                         Polymerase chain reaction 
p-CrkL    Phosphorylated CrkL 
PDGF-R    Platelet-derived growth factor receptors 
PGFs                       Physiological growth factors 
Ph                            Philadelphia  
PH domain    Pleckstrin homology domain 
PHR      Partial haematologic response 
PI                             Propidium iodine   
PI3K      Phosphatidylositol 3-kinase 
PKCβ                       Protein kinase Cβ 
PLCγ      Phospholipase Cγ   
PP2A     Protein phosphatase 2A Peixun Zhou, 2011                                                                                                                                    
 
 
22 
PTP1B    Protein tyrosine phosphatase 1B 
PTP                    Protein tyrosine phosphatase  
PTK      Protein tyrosine kinase 
p-Tyr                        Phosphorylated tyrosine 
p-Tyr Bcr-Abl           tyrosine phosphorylated Bcr-Abl 
PVDF                       Polyvinylidene fluoride 
qRT-PCR    quantitative reverse transcription PCR 
Ras      Rat sarcoma 
RNA                         Ribonucleic acid 
ROS                         Reactive oxygen species 
Rpm                         Revolutions per minute 
RT                            Reverse transcription 
RTK                         Receptor tyrosine kinase 
SCF                         Stem cell factor 
SCT      Stem cell transplantation  
SDS-PAGE             Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SFM                         Serum free medium 
SH                     Src homology 
Shc      Src homology-containing 
siRNA                        small interfering RNA 
sLDL                        synthetic low density lipoprotein 
SL-IC     SCID leukaemia-initiating cell 
SOS      Son of sevenless 
SRC      SCID-repopulating cell 
SSC                        Side scatter  
SSG                         Sodium Stibogluconate 
ST-HSC    Short-term HSC 
STAT     Signal transducers and activators of transcription 
Syp      Synaptophysin 
TK      Tyrosine kinase Peixun Zhou, 2011                                                                                                                                    
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TKI      Tyrosine kinase inhibitor 
Ub      Ubiquitin 
WB                           Western blotting 
WCL              Whole cell lysate 
WCC      white cell count 
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1  Introduction 
1.1  Haemopoiesis and haemopoietic stem cells 
Haemopoiesis  is  the  production  of  blood  cells  as  a  result  of  differentiation  of 
haemopoietic stem cells (HSCs) (1;2). HSCs are multipotent cells which are capable 
of both self-renewal and differentiation into all types of blood cells by a hierarchically 
progressive lineage commitment of haemopoietic stem and progenitor cells (Figure 
  1-1). In addition, HSCs reside in the bone marrow, and account for no more than 
0.05%  of  bone  marrow  cells  (1).  Since  most  mature  blood  cells  are  terminally 
differentiated and short-lived in blood circulation, it is essential to generate functional 
blood  cells  to  maintain  the  haemopoietic  system  in  a  steady  state  through  the 
proliferation  and  differentiation  of  haemopoietic  stem  and  progenitor  cells  (2). 
Furthermore, about 1.5 x 10
6 blood cells are continuously generated every second in 
an adult human (3).  
 
The  balance  between  self-renewal  and  differentiation  is  regulated  to  maintain  the 
HSC  pool  while  generating  sufficient  progeny,  and  this  can  be  achieved  by 
asymmetrical cell division where one HSC gives rise to an identical daughter cell and 
a  differentiated  progeny  (4).  In  addition,  HSC  can  also  divide  symmetrically  to 
generate two identical daughter cells or two differentiated progeny (4). The fate of 
HSCs is thought to be regulated by factors in their bone marrow microenvironment, 
i.e. stem cell niche (5).  Peixun Zhou, 2011                                                                                          Chapter 1                                            
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HSC function is usually assessed in vitro by colony-forming cell (CFC) and long-term 
culture initiating-cell (LTC-IC) assays or in vivo by bone marrow engraftment of non-
obese diabetic/severe combined immunodeficient (NOD/SCID) mice (6). CFC assays 
detect  multipotent  and  committed  progenitors,  while  LTC-IC  assays  detect  more 
primitive progenitors which are able to form colonies after 5-8 weeks culture on a 
stromal  feeder  layer  (7;8).  SCID-repopulation  cells  (SRCs)  are  capable  of 
reconstituting NOD/SCID mice with a singe cell and are more primitive than most 
CFC or LTC-IC (9).  
 
Based on their ability to reconstitute the haemopoietic system of lethally irradiated 
mice, HSCs can be separated into three distinct groups: long-term HSCs (LT-HSCs) 
which are able to generate all types of blood cells for the lifetime of the animals and 
reconstitute  secondary  hosts;  short-term  HSCs  (ST-HSCs)  which  derive  from  LT-
HSCs but can only reconstitute myeloid and/or lymphoid lineages for a limited period 
of time; multipotent progenitors (MPPs), which are generated by ST-HSCs, have no 
detectable  self-renewal  capacity  and only  transiently  reconstitute  lethally  irradiated 
mice  (10;11).  MPPs  can  differentiate  into  common myeloid  progenitors  (CMPs)  or 
common lymphoid progenitors (CLPs) which then give rise to myeloid or lymphoid 
lineage, respectively (12;13).  
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Figure   1-1: The model of haemopoietic hierarchy.  
Long-term and short-term HSCs have self-renewal capacity, which is lost in MPPs. The 
multi-potent progenitors differentiate into CLPs or CMPs, which give rise to mature 
cells  after  several  differentiation  steps.  MEP:  megakaryocyte-erythroid  progenitor, 
GMP: granulocyte-macrophage progenitor. Adapted from Passegue et al., 2003 (14) 
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There is evidence to suggest that the majority of HSCs are out of cell cycle and in a 
quiescent  state  (in  G0  phase  of  the  cell  cycle),  as  illustrated  by  the  resistance  of  
murine primitive haemopoietic cells to a anti-mitotic drug, 5-fluorouracil (5-FU) (15). It 
was also found that primitive human haemopoietic progenitors could remain in culture 
as single cells for more than 14 days and only started to divide with stimulation of 
some growth factors (16). Furthermore, it was estimated by mathematical modelling 
that HSCs only divide once every year, and each HSC could divide about 70 times in 
its  lifetime  (17). Thus,  it  is  thought  that  at steady  state  homeostasis  only  a  small 
fraction of HSCs are in cell cycle and repopulate the haemopoietic system (18) to 
ensure the stem cell pool is not exhausted throughout life. In addition, cell cycle arrest 
in G0 also allows cells to repair any DNA damage and maintain genomic stability (19).   
 
Cell surface antigens can be used to distinguish HSCs from differentiated cells in a 
heterogeneous haemopoietic population. CD34 is a widely used cell surface marker 
to identify HSCs, since the most primitive haemopoietic cells are contained in the 
CD34
+ population. The frequency of LTC-IC in an enriched CD34
+ population is 200-
400 times higher than in total human bone marrow mononuclear cells (8). In addition, 
human bone marrow CD34
+ compartment
 contains primitive HSCs which are capable 
of  generating  all  haemopoietic  lineages  (20).  Furthermore,  purified  mobilized 
peripheral blood CD34
+ cells are capable of reconstituting the whole haemopoietic 
system  after  human  allogeneic  transplantation  (21).  CD34
+  cells  represent  about 
1.5% of normal human bone marrow mononuclear cells (22), and the level of CD34 
expression decreases progressively along with increased differentiation of these cells Peixun Zhou, 2011                                                                                          Chapter 1                                            
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(23). CD34 is a 115 kiloDaltons (kDa) transmembrane glycoprotein which may be 
involved in cell localisation, adhesion and signal transduction of haemopoietic stem 
and progenitor cells, but the understanding of its precise function is limited (22;24). 
 
However, haemopoietic CD34
+ population is heterogeneous, and it contains primitive 
and committed haemopoietic progenitors (25). Thus, other cell surface markers are 
used together with CD34 to identify more primitive progenitors (26). It was found that 
SRCs are exclusively CD34
+CD38
–, and the frequency was calculated as 1 SRC in 
617  CD34
+CD38
–  cells  by  limiting  dilution  analysis  (26).  CD34
+CD38
–  cells  are 
capable  of  repopulating  lethally  irradiated  mice  in  a  continuous  and  multi-lineage 
manner  (26;27),  while  CD34
+CD38
+  cord  blood  cells  repopulate  lethally  irradiated 
mice rapidly but only transiently (27). CD38 is a transmembrane glycoprotein, and its 
expression on the cell surface is elevated in correlation with increased differentiation 
(28). CD38 is expressed in more than 90% of CD34
+ cells, and CD34
+CD38
– cells 
represent  about  0.05%  of  bone  marrow  or  cord  blood  mononuclear  cells  (28). 
CD34
+CD38
–  cells  are  mainly  quiescent  in  the  absence  of  cytokine  stimulation 
(28;29).  After  transplantation  into  irradiated  mice,  human  CD34
+CD38
–  cells  are 
located  at  the  stem  cell  niche  in  a  quiescent  state,  and  these  cells  can  engraft 
secondary  recipient  mice  (30).  Overall,  the  primitive  HSCs  are  within  the 
CD34
+CD38
– compartment.        
 
In  addition,  human  CD34
+CD38
–  cells  can  be  further  fractionated  based  on  cell-
surface HLA-DR expression. Human bone marrow CD34
+CD38
– HLA-DR
+ cells can Peixun Zhou, 2011                                                                                          Chapter 1                                            
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differentiate  into  all  lineages  of  haemopoietic  system,  while  the  more  primitive 
CD34
+CD38
– HLA-DR
– cells can generate not only all haemopoietic lineages but also 
stromal cells which can support HSCs in the bone marrow microenvironment (20). In 
addition, CD133 (also known as AC133 or Prominin 1) is another cell surface marker 
to identify human HSCs (31). CD133 is a 5-transmembrane glycoprotein, and can be 
present on the cell surface of CD34 bright haemopoietic
 progenitors (31). Enriched 
human mobilized peripheral CD133
+ cells effectively engraft NOD/SCID mice, as well 
as secondary recipient mice (32). Purified human CD133
+ cells contain more primitive 
progenitors  than  CD34
+  cells  as  demonstrated  by  LTC-IC  assay  (33).  Human 
CD34
+CD133
+ haemopoietic cells have a higher engraftment capacity of NOD/SCID 
mice than CD34
+CD133
– cells (34), indicating CD34
+CD133
+ cells are more primitive 
than CD34
+CD133
– cells.  
1.1.1  Leukaemic stem cells 
The hypothesis of cancer stem cells (CSCs) describes the existence of a small subset 
of  cancer  cells  which  are  likely  responsible  for  tumourigenesis,  metastasis  and 
disease  relapse  (35).  CSCs  have  characteristics  of  normal  stem  cells,  especially 
extensive self-renewal capability (35).  
 
The leukaemic stem cell (LSC) is a paradigm of CSC model. Early studies suggested 
that only a small fraction of leukaemic cells was able to proliferate extensively in vitro 
and in vivo (14). Park et al. demonstrated that about 1 in 100-10,000 leukaemic cells 
form colonies in CFC assay in vitro (36), and only 1-4% of leukaemic cells formed Peixun Zhou, 2011                                                                                          Chapter 1                                            
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colonies in spleen after murine transplantation (37). These clonogenic leukaemic cells 
were thought to be LSCs (14). In 1997, Bonnet and Dick showed that a tiny proportion 
of  human  acute  myeloid  leukaemia  (AML)  blasts  were  capable  of  engrafting 
NOD/SCID mice, and producing a disease same as human AML (38). These cells 
were defined as SCID leukaemia-initiating cells (SL-ICs) and they were exclusively 
CD34
+CD38
– in every patient, which is very similar to the phenotype of normal SRCs 
(38).  In  addition,  these  SL-ICs  have  great  self-renewal  capacity  as  assessed  by 
successful engraftment of secondary recipient mice (38). These observations suggest 
that leukaemic transformations occur in primitive normal haemopoietic cells, which 
then give rise to leukaemia through clonal expansion (38). On the other hand, the 
leukaemic transformation may also occur in committed normal progenitors which then 
regain self-renewal capability and initiate leukaemias (14) (Figure   1-2). 
     
       
Figure   1-2: Model of leukaemic stem cell transformation.  
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Leukaemogenesis  can  occur  in  HSCs  which  give  rise  to  a  LSC  with  self-renewal 
capability. Alternatively, it can happen in progenitor cells which then reacquire self-
renewal capacity. Adapted from Passegue et al., 2003 (14) 
1.2  Chronic myeloid leukaemia  
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disease of stem cell 
origin (39). The Bcr-Abl protein is present in multiple haemopoietic lineages including 
myeloid,  erythroid,  B-lymphoid  and  occasionally  T-lymphoid  cells  in  most  CML 
patients,  suggesting  the  Bcr-Abl  oncogene  is  formed  in  HSCs  (14).  By  studying 
female  patients  with  X  chromosome  linked  heterozygous  alleles,  CML  was 
demonstrated  to  be  a  clonal  disease  with  origin  in  a  single  multipotent  stem  cell 
(39;40).    
 
The incidence of CML each year is 1 to 2 cases per one hundred thousand of the 
population, and it affects all age groups with median age of onset about 45-55 years 
(2;41). It accounts for about 20% of leukaemias in adults (41). CML is characterised 
by the presence of the Philadelphia (Ph) chromosome and Bcr-Abl oncogene. The 
reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)-
(q34;q11), results in a shortened chromosome 22, which is termed the Philadelphia 
(Ph) chromosome (Figure   1-3)(42;43). It is found in 95% of CML patients, and in 5% 
of  children  and  15-30%  of  adults  with  acute  lymphoid  leukaemia  (ALL)  (41).  In 
addition, it is also present in 2% of patients with recently diagnosed AML (41).  
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Figure   1-3: Formation of the Philadelphia chromosome and Bcr-Abl oncogene.  
The reciprocal translocation between long arms of chromosome 9 and 22 results in a 
fused  oncogene  Bcr-Abl  and  a  shortened  chromosome  22,  the  Philadelphia 
chromosome. Adapted from Smith et al., 2003 (2). 
 
The reciprocal translocation results in a fusion gene Bcr-Abl on the Ph chromosome 
(44).  The  fusion  gene  product,  Bcr-Abl  protein,  significantly  affects  cell  growth, 
turnover, differentiation, apoptosis and adhesion (44). The Abl (Abelson kinase) gene 
located on chromosome 9 has 11 exons and is 230 kilobase (kb). The breakpoint in 
Abl gene is usually upstream of exon 2 (41). In most cases, Abl gene exons 2 to 11 
are translocated to the major break point cluster region(M-bcr) of the Bcr gene on 
chromosome 22, forming a hybrid Bcr-Abl gene. It is then transcribed into an 8.5 kb 
chimeric messenger ribonucleic acid (mRNA) with an e14a2 or e13a2 (also known as 
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b3a2 or b2a2) junction, and then mRNA is translated into a p210
Bcr-Abl fusion protein 
(41;44;45).  In  rare  cases  of  CML  and  in  common  cases  of  Ph  positive  ALL,  the 
breakpoint of chromosome 22 occurs in a minor break point cluster region (m-bcr), 
and results in a e1a2 junction mRNA and a 190 kDa Bcr-Abl fusion protein, which is 
termed as p190
Bcr-Abl (41;44). In very rare cases of CML, a third breakpoint is detected 
downstream of the M-bcr between exons e19 and e20 of Bcr gene, it is termed µ-bcr. 
Its transcription product is a mRNA with e19a2 junction and its final product is a 230 
kDa Bcr-Abl protein which is termed p230
Bcr-Abl (41;44) (Figure   1-4).  
 
 
Figure   1-4: Three forms of Bcr-Abl oncogene.   
Adapted from Franklin et al., 1999 (41).  
 
CML  is  characterized  by  a  triphasic  clinical  course  (45),  comprising  initial  chronic 
phase (CP), secondary accelerated phase (AP) and terminal blast crisis (BC) (41). 
About  85%  of  CML  patients  are  diagnosed  in  CP,  with  common  symptoms  at 
presentation  being  abdominal  fullness,  anaemia,  bleeding,  fatigue,  leukocytosis, 
purpura, splenomegaly, thrombocytosis and weight loss (41;46). CP CML features 
abnormal elevation of the number of myeloid progenitor and mature cells in the blood 
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and  bone  marrow  (4;46;47).  Bcr-Abl
+  CML  is  diagnosed  and  monitored  by  the 
presence of Ph chromosome with cytogenetics, visualization of Bcr-Abl oncogene by 
double-fusion fluorescent in situ hybridization (D-FISH), or detection of Bcr-Abl mRNA 
with quantitative reverse-transcription polymerase chain reaction (qRT-PCR) (48;49).   
 
The diagnostic criteria for AP and BC CML defined by the World Health Organisation 
are listed in the following table (Table   1-1). If left untreated, CP CML progresses to 
AP and BC about 3-5 years after onset (50). However, transformation of AP into BC 
can  happen  in  several  weeks  or  months  (2).  In  the  later  stages,  differentiation  is 
blocked and non-functional immature blast cells accumulate in the blood and bone 
marrow,  resembling  acute  leukaemias  (2;47).  Most  patients  acquire  additional 
cytogenetic  abnormality  while  progressing  into  BC  CML  (51),  and  the  BC 
transformation can be myeloid, lymphoid or both lineages with very poor prognosis 
(2). The median survival time for myeloid and lymphoid BC CML is 4-5 months and 12 
months, respectively (2).  
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AP CML (Diagnosed if one or more of the following present) 
 
● 10 to 19% of peripheral blood white cells or bone marrow cells are blasts 
● Peripheral blood basophils  ≥20% 
● Persistent thrombocytopenia (100 x 10
9/L) unrelated to therapy, or persistent 
thrombocytosis (1000 x 10
9/L) unresponsive to therapy 
● Increasing spleen size and increasing WC count unresponsive to therapy 
● Cytogenetic evidence of clonal evolution 
 
BC CML (Diagnosed if one or more of the following present) 
 
● ≥20% of peripheral blood white cells or bone marrow cells are blasts 
● Extramedullary blast proliferation 
● Large foci or clusters of blasts in BM biopsy 
 
 
Table   1-1: Criteria for the diagnosis of AP and BC CML.  
Adapted from Vardiman et al., 2002 (52) 
1.2.1  The causal relationship between Bcr-Abl and CML 
Bcr-Abl  is  thought  to  play  an  essential  role  in  the  leukaemic  transformation  of 
haemopoietic  cells  and  in  the  pathogenesis  of  CML  (44).  Nowell  and  Hungerford 
described that an abnormally short chromosome in 1960, which was lately named Ph 
chromosome,  was  consistently  present  in  seven  patients  with  chronic  granulocytic 
leukaemia  but  not  in  normal  cells  of  those  patients  or  cells  of  other  leukaemias, 
suggesting  there  was  a  causal  relationship  between  Ph  chromosome  and  chronic 
granulocytic  leukaemia  (53).  Then  Rowley  discovered  in  1973  that  the  Ph 
chromosome was a hybrid of chromosome 9 and 22 (54), and the fusion gene Bcr-Abl Peixun Zhou, 2011                                                                                          Chapter 1                                            
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was  revealed  on  the  Ph  chromosome  in  1980s  (55).  In  1990,  Elefanty  et  al. 
introduced  Bcr-Abl  bearing  retrovirus  into  bone  marrow  cells,  and  reconstituted 
lethally irradiated mice with these cells, resulting in a mild CML-like syndrome among 
several haemopoietic neoplasms (56). In the same year, introduction of Bcr-Abl by 
retrovirus into murine haemopoietic stem cells was employed to reconstitute lethally 
irradiated mice, and a myeloproliferative syndrome similar to human CP CML was 
developed  prominently  among  half  of  recipient  mice  (57).  Several  years  later,  an 
improved  method  produced  a  human  CML-like  myeloproliferative  disease  in  all 
recipient mice after transplantation of bone marrow cells with virally transfected Bcr-
Abl,  and  it  is  transplantable  to  secondary  recipients  (58).  In  addition,  Bcr-Abl  is 
associated with emergence of additional genomic abnormality and progression of CP 
CML  into  BC  (59;60).  Therefore,  the  leukaemogenic  nature  of Bcr-Abl  makes  it a 
therapeutic target in treating CML (2).  
1.3  Structures and functions of Bcr, c-Abl and Bcr-Abl  
1.3.1  Bcr 
Bcr is a 160 kDa protein with several structural and functional domains (61). There is 
a  coiled-coil  oligomerization  domain  in  the  N-terminus  of  Bcr  (62).  This  domain 
enables Bcr to form a homotetramer. Downstream of the coiled-coil domain, there is a 
Src homology (SH) 2 binding domain (63). This domain is able to interact with the 
SH2 domain on c-Abl in a phosphotyrosine independent manner (63). In addition, 
there is a serine/threonine kinase located in the N-terminus encoded by the first exon Peixun Zhou, 2011                                                                                          Chapter 1                                            
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of Bcr (64). Located in the C-terminal of Bcr is a GTPase activating domain, which 
can  increase  the  guanosine  triphosphate  (GTP)  hydrolysis  rate  of  a  p21
Rac  GTP 
binding  protein  (G  protein)  (65).  Also  in  the  C-terminal  of  Bcr,  there  is  a  domain 
homologous to guanine nucleotide exchange factors (GEFs) of p21
Rho/Rac family of G 
proteins (66). There is also a pleckstrin homology domain (PH domain) and a calcium 
dependent lipid binding (CaLB) domain in the Bcr protein (61) (Figure   1-5A). Having 
different types of structural and functional properties, Bcr protein may be involved in 
different signalling pathways and serve as the cross point of these pathways, but the 
understanding of the biological function of Bcr protein is limited (49;61).     
1.3.2  Abl 
C-Abl protein is a 145 kDa non-receptor tyrosine kinase (41). There are two splice 
variants of c-Abl, encoding two proteins with their difference in the first exon (1a and 
1b).  C-Abl  1b  is  slightly  longer  than  1a  and  contains  a  myristoyl  group  at  its  N-
terminus, and this myristoyl group links c-Abl 1b with lipid membrane (67). Located in 
the N-terminus of c-Abl are three SH domains: SH3, SH2 and SH1. The SH3 domain 
binds to proline-rich (PxxP) motifs (68;69), and negatively regulates c-Abl tyrosine 
kinase activity (41). C-Abl tyrosine kinase can be activated by deletion of the SH3 
domain  (70).  The  SH2  domain  binds  to  phosphotyrosine  residues  in  a  sequence 
specific  manner  (68;69).  The  phosphotyrosine  binding  ability  and  transforming 
potential of activated Abl is reduced by point mutations in the SH2 domain (71). The 
following  SH1  domain  carries  a  tyrosine  kinase  (68).  Downstream  there  are  three 
proline-rich sequences which can interact with SH3-containing proteins (69). Towards Peixun Zhou, 2011                                                                                          Chapter 1                                            
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the C-terminus of c-Abl are three nuclear localisation signals (NLSs) and a nuclear 
export  signal  (NES),  enabling  it  to  shuttle  between  cell  nucleus  and  cytoplasm 
(49;72).  Located  in  the  C-terminus  are  DNA  and  actin  binding  domains  (49;73) 
(Figure   1-5B).  
 
C-Abl is mainly located in the cytoplasm of human haemopoietic cells with a low-level 
presence in the nucleus (74), whereas it is largely present in the nucleus of fibroblasts 
(75). The tyrosine kinase activity of c-Abl is tightly regulated in vivo, and its activity is 
very low in normal context (76). C-Abl can be activated by cell cycle progression, 
DNA damage and integrin mediated adhesion (68). C-Abl tyrosine kinase is increased 
during  cell  cycle  progression  to  S  phase  (68).  Activated  c-Abl  phosphorylates  C-
terminal  domain  of  RNA  polymerase  II  and  enhances  transcription  (68;77).  In 
addition, c-Abl is activated in response to DNA damage and induces cell cycle arrest 
or  apoptosis  (78).  Furthermore,  integrin  mediated  adhesion  can  induce  transient 
cytoplasmic translocation and activation of c-Abl in fibroblasts, which then activates 
mitogen activated protein kinase (MAPK) cascade (79;80).        
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Figure   1-5: The structural and functional domains of Bcr, c-Abl and Bcr-Abl proteins.  
(A) In Bcr, the coiled-coil oligomerization domain resides at the N-terminus. This is 
followed by a SH2 binding domain. Then there is a serine/threonine kinase domain, a 
Rho  guanine  nucleotide  exchange  factor  (Rho-GEF)  domain,  a  pleckstrin  homology 
domain  (PH  domain),  a  calcium  dependent  lipid  binding  (CaLB)  domain  and  a  Rac 
GTPase activating protein (Rac-GAP) domain. (B) In c-Abl, there is a myristoyl group 
(in c-Abl 1b but not 1a), a Src homology  3 (SH3) domain, a SH2 domain and a SH1 
tyrosine  kinase  (TK)  domain  at  the  N-terminus,  followed  by  several  proline-rich 
domains (P) and three nuclear localisation signals (NLSs). At the C-terminus there are 
DNA-  and  actin-binding  domains  and  a  nuclear  export  signal  (NES).  (C)  Bcr-Abl 
contains the first five domains of Bcr and all the c-Abl domains except the N-terminus 
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encoded by its first exon. Adapted from Smith et al., 2003 (2) and Deininger et al., 2003 
(49). 
1.3.3  Bcr-Abl 
The p210 Bcr-Abl protein forms dimers or tetramers in vivo that autophosphorylate 
each  other  (81).  Fusion  of  Bcr  to  c-Abl  inhibits  the  latter’s  SH3  kinase  regulatory 
domain, resulting in constitutive activation of the Abl tyrosine kinase in Bcr-Abl (41). 
Two domains of Bcr are thought to be essential for Abl tyrosine kinase activation and 
transforming potential of the Bcr-Abl oncoprotein: amino acids 1-63 and 176-242 (62). 
The first domain is the coiled-coil oligomerization domain, and it is involved in the 
deregulation  of  Abl  tyrosine  kinase and enhancement  of filament  (F)-actin  binding 
ability of Abl (82). Mutations in the oligomerization domain abolished the transforming 
activity of Bcr-Abl protein (62). Disruption of the Bcr-Abl tetramer by a competitive 
peptide of the coiled-coil oligomerization domain of Bcr efficiently inhibited tyrosine 
kinase activity and transforming function of Bcr-Abl protein (83). The second critical 
domain for kinase activation and transforming potential is the SH2 binding domain of 
Bcr (62), which deregulates tyrosine kinase by binding to Abl SH2 domain (63). On 
the  other  hand,  Abl  tyrosine  kinase  impairs  Bcr  serine/threonine  kinase  by 
phosphorylating Y360 residue on Bcr and Bcr-Abl (84). A deleted form of Bcr which 
cannot be tyrosine phosphorylated, inhibits tyrosine kinase activity of active c-Abl and 
Bcr-Abl,  suggesting  tyrosine  phosphorylation  of  Bcr  abolishes  its  inhibitory  activity 
(85).  Peixun Zhou, 2011                                                                                          Chapter 1                                            
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Bcr-Abl can interact and/or phosphorylate many proteins, making Bcr-Abl involved in 
diverse intracellular signalling pathways, including Ras-MAPK, PI3K-Akt, and JAK-
STAT pathways (44;86) (Figure   1-6 and Table   1-2). Bcr-Abl was found to bind several 
adaptor proteins, such as growth factor receptor bound protein 2 (Grb2), v-Crk avian 
sarcoma  virus  CT10  oncogene  homologue-like  (CrkL)  protein  and  Src  homology-
containing (Shc) protein (41). Grb2 is an SH2/3 domain-containing adaptor protein. 
The SH2 domain of Grb2 interacts with the phosphorylated Y177 residue located in 
the N-terminal part of Bcr-Abl (84). Y177F mutation impaired binding of Bcr-Abl with 
Grb2, and inhibited Ras signalling which can be activated by wild type Bcr-Abl (87). 
Interaction with Grb2 is essential for the transforming ability of Bcr-Abl. The Y177F 
Bcr-Abl mutant was not able to transform Rat1 fibroblasts and murine bone marrow 
cells (87).  
   
 
 
 
 
 
 
 
 
 
     Peixun Zhou, 2011                                                                                          Chapter 1                                            
 
 
42 
   
 
 
 
 
 
 
 
 
 
 
Figure   1-6: Major signalling pathways activated by Bcr-Abl protein in CML cells.  
IL-3 activates these signalling pathways (PI3K-Akt, Ras-Raf-MEK-ERK and JAK-STAT) 
in Bcr-Abl
– cells to promote growth, survival and differentiation. In CML cells, these 
pathways  can  be  activated  by  Bcr-Abl  in  the  absence  of  IL-3,  leading  to  cell 
proliferation and survival. 
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Substrate  Full Name  Function  Reference 
Akt  Protein kinase B  Serine/Threonine  
kinase  (88) 
Bad  Bcl-2-associated death 
promoter  Pro-apoptotic  (89) 
Bap-1  Bcr-associated protein 1  14-3-3 protein  (61) 
Bcl-XL  B-cell lymphoma-extra large  Anti-apoptotic  (90) 
Cbl  Casitas B-lineage 
lymphoma  E3-ubiquitin ligase   (91) 
Crk  Avian sarcoma virus CT10 
oncogene homologue  Adaptor molecule  (92) 
CrkL  Crk-like protein  Adaptor molecule  (93) 
Fak  Focal adhesion kinase  Cytoskeleton  (94) 
Grb2  Growth factor receptor 
bound protein 2  Adaptor molecule  (87) 
PI3K  Phosphatidylinositol 3-
kinase  Phospholipid kinase  (95) 
PLCγ  Phospholipase Cγ  Phospholipase  (96) 
Raf  Ras-activated factor  Serine/Threonine 
kinase  (97) 
Ras  Rat sarcoma  Small G-protein  (98) 
Ras-GAP  Ras GTPase-activating 
protein 
Ras-GTPase 
activating  (99) 
Shc  Src homology containing 
protein  Adaptor molecule  (100) 
SOS  Son of sevenless  Guanine nucleotide 
exchange factor   (101) 
STAT1/5  Signal transducer and 
activator of transcription 
Transcriptional 
activator  (102;103) 
Syp  Synaptophysin  Protein phosphatase  (104) 
 
Table   1-2: Examples of an extensive group of Bcr-Abl tyrosine kinase substrates.  
Adapted from Raitano et al., 1997 (68) and Smith et al., 2003 (2). Peixun Zhou, 2011                                                                                          Chapter 1                                            
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Binding of Grb2 to Bcr-Abl links it with Rat sarcoma (Ras) cascade. Activation of Ras 
protein results in subsequent activation of Raf, MEK and ERK, leading to activation of 
gene transcription (105). Ras regulates cell proliferation and differentiation, and plays 
a central role in the pathogenesis of CML (41;106). Impairment of Ras signalling by 
dissociation of Grb2/SOS complex inhibits proliferation of primary CML cells and Bcr-
Abl
+ cell lines (107). 
 
Bcr-Abl protects CML cells from apoptosis. Expression of Bcr-Abl in haemopoietic cell 
lines  elevates  anti-apoptotic  signals,  such  as  B-cell  lymphoma-2  (Bcl-2),  B-cell 
lymphoma-extra  large  (Bcl-xL)  and  myeloid  cell  leukaemia-1  (Mcl-1)  (88;90;108). 
CML CD34
+ cells are more resistant to a range of cytotoxic agents compared with 
their normal counterparts (109). Expression of Bcr-Abl in murine Bcr-Abl
– cell lines 
confers  significantly  increased  resistance  to  cytotoxic  agents  compared  with  their 
parental cell lines (109). HL60 is a human Bcr-Abl
– promyelocytic cell line which is 
very sensitive to apoptosis inducing agents, while expression of Bcr-Abl in HL60 cells 
makes them very resistant to apoptosis induced by a range of cytotoxic agents (90).  
 
Furthermore, Bcr-Abl can activate Phosphoinositide 3-kinase (PI3K)-Akt and Janus 
kinase (JAK)-signal transducers and activators of transcription (STAT) pathways to 
inhibit apoptosis. PI3K is a heterodimer containing an 85 KDa regulatory subunit and 
a 110 KDa catalytic subunit (68). The regulatory subunit is tyrosine phosphorylated in 
Bcr-Abl
+  cells,  and  PI3K  activity  is  elevated  in  Bcr-Abl  expressing  fibroblasts  and 
haemopoietic cells (68). Activation of PI3K by Bcr-Abl is mediated by adaptor proteins Peixun Zhou, 2011                                                                                          Chapter 1                                            
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CrkL, Crk and Cbl (2). Then a downstream serine/threonine kinase Akt (also known 
as protein kinase B) is activated which phosphorylates the pro-apoptotic protein Bcl-2 
associated death promoter (Bad), leading to dissociation of Bad from anti-apoptotic 
signals (such as Bcl-xL) and suppression of apoptosis (110). Activated Akt also inhibit 
the tumour suppressor p53 via activation of murine double minute 2 (MDM2) protein, 
leading to cell survival (111). In addition, there is constitutive activation of JAK and 
STAT in Bcr-Abl
+ primary cells and cell lines (112;113). In the normal cellular context, 
cytokine stimulation activates JAKs which then phosphorylate and activate STATs. 
Activated STATs translocate to the nucleus and upregulate gene transcription (114). 
Activated  STAT5  is  involved  in  the  malignant  transformation  of  Bcr-Abl
+  cells 
(112;115;116). Activation of STAT5 by Bcr-Abl upregulates anti-apoptotic protein Bcl-
xL, leading to suppression of apoptosis (117;118). However, activation of STAT5 is 
not always induced by activated JAKs in CML cells, as Bcr-Abl can phosphorylate 
STAT5 via haemopoietic cell kinase (Hck) (119).  
 
Bcr-Abl transforms haemopoietic cell lines into interleukin (IL)-3 independence in vitro 
(59;120). The proliferation of Bcr-Abl
+ quiescent CML cells can be initiated without 
any added growth factor (121), but normal quiescent haemopoietic cells can not (16). 
Bcr-Abl  also  promotes  IL-3  and  granulocyte  colony-stimulating  factor  (G-CSF) 
secretion and autocrine proliferation in CML stem and progenitor cells (122;123). IL-3 
and G-CSF are growth factors which regulate proliferation, differentiation and survival 
of  haemopoietic  cells  by  activating  intracellular  signalling  pathways  including  Ras-
MAPK, PI3K-Akt, and JAK-STAT (86;124). Normal haemopoietic primitive cells are Peixun Zhou, 2011                                                                                          Chapter 1                                            
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dependent on growth factors to proliferate and survive (18). The aberrant autocrine 
production of IL-3 and G-CSF in CML stem and progenitor cells may confer them with 
a proliferative advantage compared with their normal counterparts (121;123).  
 
Furthermore, Bcr-Abl alters cellular adhesion of CML primitive cells within their bone 
marrow microenvironment. Normal haemopoietic progenitors interact with their bone 
marrow  microenvironment  via  integrin  mediated  adhesion  (125),  which  negatively 
regulates their proliferation (126). Abnormal circulation of immature CML progenitors 
in the peripheral blood and the proliferative advantage of CML progenitors may be 
explained  by  their  altered  adhesion  with  the  bone  marrow  microenvironment 
(127;128).  Primary  CML  progenitors  have  reduced  adhesion  with  bone  marrow 
stromal cells and the extracellular matrix glycoprotein fibronectin in vitro (129;130). 
However, this is controversial as Bcr-Abl transfected human and murine haemopoietic 
cell  lines  have  increased  adhesive  interaction  with  stromal  cells  and  fibronectin 
(131;132). In addition, it was suggested that restoration of normal haemopoiesis by 
interferon-alpha (IFN-α) in some CML patients may be due to recovery of adhesion of 
CML progenitors to the bone marrow stroma (133).  
 
In  summary,  the  constitutively  activated  tyrosine  kinase  of  Bcr-Abl  promotes  cell 
proliferation,  inhibits  apoptosis,  transforms  haemopoietic  cells  into  growth  factor 
independence  and  alters  cellular  adhesion,  which  is  the  driving  force  of 
leukaemogenesis of CML.    Peixun Zhou, 2011                                                                                          Chapter 1                                            
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1.4  Treatment of CML  
1.4.1  Conventional therapies (pre-tyrosine kinase inhibitor era) 
Whole body or splenic radiation was the major treatment of CML until the 1950s, 
which  was palliative and did not improve overall survival (45). Then busulfan was 
employed from the 1950s and it could maintain partial haematologic response (PHR, 
defined  in  Table    1-3)  in  most  CML  patients  with  serious  side-effects  (45;134). 
Hydroxyurea, an inhibitor of DNA synthesis and cell cycle, was introduced to treat 
CML in the 1970s (135). Hydroxyurea can rapidly control blood cell count and achieve 
complete haematologic response (CHR) in 50-80% of CML patients, but cytogenetic 
responses  are  rare  (136;137).  It  is  effective  in  CML  patients  resistant  to  busulfan 
treatment  (135).  However,  both  busulfan  and  hydroxyurea  cannot  block  disease 
progression into BC where median survival remained to be 3 to 6 years (45).  
 
Allogeneic bone marrow transplantation (BMT) or stem cell transplantation (SCT) is 
the  only  curative  therapy  for  CML  in  suitable  patients  (2).  Allogeneic  SCT  with 
peripheral  blood  CD34
+  progenitor  cells  can  fully  reconstitute  the  haemopoietic 
system of recipients (21). HLA matched donors receive G-CSF to mobilize their HSCs 
into peripheral blood. When 1-2% of blood cells are CD34
+, and after leukapheresis, 
CD34
+  cells  are  enriched  by  a  CD34  specific  monoclonal  antibody  for  allogeneic 
transplantation  (21). Haemopoietic  engraftment  by  peripheral  blood  CD34
+  cells  is 
stable,  faster  to  recover  all  haemopoietic  lineages,  and  the  stem  cell  collection 
procedure itself is more comfortable for the donor than bone marrow harvest under Peixun Zhou, 2011                                                                                          Chapter 1                                            
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general anaesthetic (21). Five-year survival after allogeneic BMT or SCT is up to 72% 
in low-risk CML patients but is associated with at least 20% transplantation–related 
mortality,  while  there  is  only  around  20%  survival  in  high-risk  patients  with 
transplantation–related  mortality  as  high  as  73%  (138).  The  high  mortality  rate  is 
usually caused by graft-versus-host disease and opportunistic infections (137). 30-
70% of CML patients achieved long-term disease-free survival after allogeneic SCT 
(45).  However,  only  about  20%  of  CML  patients  are  suitable  for  allogeneic 
transplantation due to limitations of age, fitness and matched donor availability (139).  
 
A human cytokine, IFN-α, became the first line therapy of CML patients who were not 
eligible for allogeneic SCT in the 1980s (140). IFN-α can achieve CHR in 46-80% of 
CML  patients,  partial  cytogenetic  response  (PCgR)  in  11-16%  of  patients  and 
complete cytogenetic response (CCgR) in 13-32% of patients (45). IFN-α achieves 
durable  CCgR  in  a  subset  of  CML  patients  and  is  superior  to  busulfan  and 
hydroxyurea  in  patient  survival  (140).  However,  IFN-α  therapy  results  in  a  high 
possibility  of  neurotoxicity  as  well  as  some  other  intolerable  side  effects  in  older 
patients (45). Combination of IFN-α and cytarabine (or cytosine arabinoside, Ara-C) 
significantly  improved  cytogenetic  response  rates  and  survival  time  of  CP  CML 
patients compared with IFN-α alone (141;142). IFN-α plus cytarabine then became 
the standard therapy for those CML patients who were unsuitable for transplantation 
(142;143). 
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Response  Criteria 
Complete haematologic 
response (CHR) 
Complete normalization of peripheral blood count: 
● Leukocyte count <10 x 10
9 cells/L 
● Platelet count <450 x 10
9 cells/L 
● No immature cells in the peripheral blood  
● No sings or symptoms of disease including  
splenomegaly 
Partial haematologic 
response (PHR) 
Same as those for CHR, except 
● Persistence of immature cells, or 
● Platelet count <50% of the pre-treatment count but 
>450 x 10
9 cells/L, or  
● persistent splenomegaly but >50% of the pre-
treatment extent 
Complete cytogenetic 
response (CCgR) 
No Ph
+ cells detectable by cytogenetics in the bone 
marrow 
Partial cytogenetic 
response (PCgR)  1-34% Ph
+ cells detectable in the bone marrow 
Major cytogenetic 
response (MCgR) 
<35% Ph
+ cells detectable in the bone marrow 
(includes CCgR and PCgR) 
Minor cytogenetic 
response (mCgR)  35-90% Ph
+ cells detectable in the bone marrow 
Complete molecular 
response (CMR) 
● Undetectable Bcr-Abl transcript by qRT-PCR, or  
● ≥4.5 log reduction compared to starting level 
Major molecular 
response (MMR) 
● ≥3 log reduction of Bcr-Abl transcript, or 
● <0.1% Bcr-Abl transcript by qRT-PCR 
 
Table   1-3: Criteria of treatment responses in CML.  
 Peixun Zhou, 2011                                                                                          Chapter 1                                            
 
 
50 
1.4.2  Tyrosine kinase inhibitors (TKI) – imatinib  
As the understanding of the molecular biology of CML progressed further, Bcr-Abl 
became an attractive therapeutic target for CML. Imatinib mesylate (IM; Glivec
® or 
Gleevec
®, Novartis, Basel, Switzerland. Figure   1-7) is an Abl TKI, and it inhibits the 
kinase  activity  of  Abl,  c-Kit  and  platelet-derived  growth  factor  receptors  (PDGF-R) 
(44;144). IM competes with adenosine triphosphate (ATP) for the enzymatic binding 
site of Abl, and blocks Abl tyrosine kinase activity (44) (Figure   1-8). IM was developed 
by  random  screen  of  a  large  number  of  synthesized  ATP-competitive  2-
phenylaminopyrimidine compounds for TKI activity, and CGP57148 (later known as 
STI571  and  IM)  emerged  as  a  potent  inhibitor  of  Abl  tyrosine  kinase  (145).  The 
activation loop in the enzymatic site of Abl controls its kinase activity by switching 
between active and inactive conformations. IM binds to Abl only when it is in the 
inactive state and prevents it from changing into the active conformation (146).   
 
 
    
 
 
Figure   1-7: Structure of IM (147).  
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Figure   1-8: Mechanism of action of IM on Bcr-Abl.  
ATP binding is essential for Bcr-Abl to phosphorylate substrates and subsequently 
activate downstream pathways that promote cell survival, proliferation and regulation. 
IM can bind to the inactive state of Bcr-Abl at its  ATP binding site, and inhibit the 
phosphorylation of substrates that would activate downstream signalling and lead to 
CML. 
 
IM  inhibits  proliferation  and  causes  apoptosis  in  Bcr-Abl
+  cell  lines  and  CML 
progenitors in vitro and in vivo, with very low toxicity to Bcr-Abl negative cell lines and 
normal progenitors, demonstrating the specificity of this drug against Bcr-Abl
+ cells 
(145;148).  In  June  1998  IM  was  taken  into  a  phase  I  clinical  trial  with  CP  CML 
patients who failed IFN-α treatment, and 98% of these patients achieved CHR within 
four weeks at 300mg or more IM once daily (149). Side effects with IM treatment were 
mild,  including  nausea,  myalgias,  oedema,  and  diarrhoea  (149).  A  daily  dose  of 
400mg  IM  or  more  was  recommended  for  future  studies.  A  peak  plasma 
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concentration of 4.6 M and a tough concentration of 1.46 M were achieved with this 
dose at steady-state (149). At the phase II clinical trial, IM was administered orally at 
400mg daily to CP CML patients who had failed IFN-α treatment (150). About 95% 
patients achieved CHR and 60% achieved major cytogenetic response (MCgR) (150). 
AP and BC CML patients were treated with 400mg or 600mg IM daily, and achieved 
higher  response  rates  and  longer  survival  time  than  conventional  treatments 
(151;152).  
 
In June 2000, the phase III International Randomized Study of Interferon and STI571 
(IRIS) study was initiated with newly diagnosed CP CML patients and compared IM 
treatment with IFN-α plus cytarabine (153;154). After a median of 18 months follow-
up, 76.2% patients treated with IM achieved CCgR, while only 14.5% patients treated 
with IFN-α plus cytarabine achieved CCgR (153;154). IM was shown to be superior to 
IFN-α plus cytarabine in treating newly diagnosed CP CML, and subsequently most 
patients  in  the  IFN-α  plus  cytarabine  treatment  arm  crossed  over  to  the  IM  arm 
(153;154). In May 2001, IM was rapidly approved by the United States Food and Drug 
Administration (FDA) for treatment of Ph
+ CML (153). After six years follow-up of the 
IM arm in the IRIS study, the estimated total survival rate was 88%, or 95% when 
counting CML-related deaths only, and the cumulative best rate of CCgR was 83% 
(155). Owing to the efficacy and low toxicity of IM, it is now considered as the first-line 
treatment for newly diagnosed CP CML (153-155).  
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However,  resistance  developed  against  IM.  It  was  shown  that  the  approximate 
relapse rate was 17% after 60 months of IM treatment, and about 7% of all patients 
treated with IM entered AP or BC (143). About 20-25% of patients treated with IM 
never  achieved  CCgR  (156).  Resistance  to  IM  can  be  described  as  primary  or 
acquired.  Primary  resistance  is  where  there  is  no  initial  response  to  IM,  and  it  is 
defined as a failure to achieve CHR within 3 months, cytogenetic response within 6 
months, PCgR within 12 months or CCgR within 18 months of treatment (157;158). 
Acquired resistance is loss of established CHR, or CCgR, or progression to AP or BC 
(157). Acquired resistance to IM is often mediated by point mutations in the kinase 
domain of Bcr-Abl (159). 
1.4.2.1   p-CrkL as a surrogate marker of Bcr-Abl kinase inhibition by TKI   
Phosphorylated CrkL (p-CrkL) is commonly used as a surrogate marker for Bcr-Abl 
tyrosine kinase activity (160-163). It was firstly identified in 1994 that a 39 kDa protein 
was consistently tyrosine phosphorylated in peripheral blood neutrophils from all 18 
chronic phase CML patients screened, but not in normal controls (93). It was also 
found that the same protein was tyrosine phosphorylated in Bcr-Abl
+ cell lines, such 
as  K562  and  BV173  (93).  Later  this  39  kDa  protein  was  identified  as  CrkL  after 
protein purification (93). The CrkL gene had been discovered in 1993; it is located on 
chromosome 22 and centromeric to the Bcr gene (164). Its protein product is very 
similar to the product of a viral oncogene v-Crk which is from avian sarcoma virus 
CT10, and CrkL is 60% homologous to Crk that is the human homolog of v-Crk (164). 
CrkL protein contains a SH2 domain and two tandem SH3 domains without having Peixun Zhou, 2011                                                                                          Chapter 1                                            
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any catalytic domain (164). It was revealed that CrkL interacted with Abl directly (93). 
It  was  also  found  that  CrkL  was  tyrosine  phosphorylated  by  Abl  and  Bcr-Abl  in 
transfected COS-1 cells and complexed with both of them in K562 and transfected 
COS-1 cells (165;166). Subsequently, it was identified that Bcr-Abl phosphorylated 
CrkL on tyrosine 207 (167).  
 
p-CrkL has been used as a marker to assess the effect of IM on inhibition of Abl 
kinase  activity  in  patient  samples  by  Western  blotting  (149;160).  A  method  was 
developed  to  detect  the  level  of  p-CrkL  in  CD34
+  CML  progenitor  cells  using 
intracellular flow cytometry (161). This method takes much less time than Western 
blotting, but more importantly requires as few as 10
4 cells for each test, while Western 
blotting requires more than 10
5 cells, making the flow cytometry method a preferred 
choice with rare stem cell populations (161). A further validation of the flow cytometry 
method  was  reported  in  2009,  it  showed  that  p-CrkL  and  total  tyrosine 
phosphorylation are reduced to the same levels in K562 cells with 48 hours of IM 
treatment (162). However, a direct comparison of p-CrkL and Bcr-Abl tyrosine kinase 
activity has not been made, especially at short time-points (≤24h).   
1.4.3  Second generation TKI – nilotinib and dasatinib 
Second generation TKI drugs have emerged to target Bcr-Abl in order to overcome 
IM  resistance.  Nilotinib  (Tasigna
®; formerly  AMN107,  Novartis,  Basel,  Switzerland) 
(Figure    1-9)  is  a  rationally  designed  and  orally  available  specific  inhibitor  of  Abl 
tyrosine kinase (168). Apart from Abl kinase, nilotinib also inhibits the activity of c-kit Peixun Zhou, 2011                                                                                          Chapter 1                                            
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and PDGF-R (169). Nilotinib was designed to have higher binding affinity than IM to 
the ATP binding site on the kinase domain of Abl (168). Nilotinib binds to the inactive 
conformation of Abl kinase, and blocks its tyrosine kinase activity (170;171). 
 
Nilotinib inhibits 32 out of 33 IM-resistant Bcr-Abl mutants except the T315I mutation 
(168). Nilotinib exhibits ≥20-time more potency than IM in IM sensitive and insensitive 
Bcr-Abl
+ cell lines (170;172;173). Although nilotinib is much more effective than IM in 
Bcr-Abl
+ cell lines, nilotinib and IM are equally potent in human primary CD34
+ CML 
cells, and only have anti-proliferative effect instead of eradicating these cells (172). 
Nonetheless,  clinical  studies  have  demonstrated  the  effectiveness  and  safety  of 
nilotinib in IM resistant or intolerant CML patients (174;175), leading to the approval of 
nilotinib by FDA for treating adult Ph
+ CP and AP CML patients who are resistant to or 
intolerant of prior therapy including IM, and subsequently newly diagnosed adult Ph
+ 
CP CML patients (176).  
 
 
 
 
 
Figure   1-9: Structure of nilotinib (147). Peixun Zhou, 2011                                                                                          Chapter 1                                            
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Dasatinib  (Sprycel
®;  formerly  BMS-354825,  Bristol-Myers  Squibb,  Princeton,  USA) 
(Figure   1-10) is a dual Src/Abl tyrosine kinase inhibitor (177). It also targets c-kit and 
PDGF-R (177). Dasatinib is an orally administrated drug and is 325-fold more potent 
than IM in cells expressing wild-type Bcr-Abl protein (173). Almost all Bcr-Abl kinase 
domain mutations can be inhibited by dasatinib except the T315I mutation (159;173). 
Dasatinib binds to both active and inactive conformations of Abl kinase, rendering it 
much higher binding affinity than IM (159).  
 
Clinical trials demonstrated the efficacy of dasatinib in all phases of IM resistant or 
intolerant CML patients, and it is well tolerated (178-180). Dasatinib was approved by 
FDA  for  treatment  of  adult  Ph
+  CML  and  ALL  patients  who  are  resistant  to  or 
intolerant of prior therapy (such as IM), as well as newly diagnosed adult Ph
+ CP CML 
patients  (181).  However,  dasatinib  is  not  able  to  eliminate  the  primitive  quiescent 
CML stem cell population (163). For this reason, although both nilotinib and dasatinib 
have improved effects in suppressing CML than IM, they are still not able to cure 
CML. 
 
 
 
 
Figure   1-10: Structure of dasatinib (147). Peixun Zhou, 2011                                                                                          Chapter 1                                            
 
 
57 
1.5  Mechanisms of TKI resistance and CML stem cell persistence  
Although most CML patients treated with IM are able to achieve CCgR, many of them 
still have detectable level of Bcr-Abl transcripts, and only 4% of patients treated with 
standard-dose  IM  have  achieved  complete  molecular  response  (CMR)  (143;156). 
After withdrawal of IM, about half of CML patients with durable CMR have disease 
relapse, whilst the other half remain in CMR for at least seven years (182). However, 
Bcr-Abl DNA is still detectable by highly sensitive PCR in the vast majority of these 
patients  with  stable  CMR  after  IM  is  withdrawn  (182).  The  disease  relapse  and 
minimal residual disease indicate that CML is not cured by IM. Resistance of CML to 
TKI can be described as Bcr-Abl independent or dependent (e.g. point mutations) 
(157).  
1.5.1  Bcr-Abl independent resistance 
Bcr-Abl  independent  resistance  can  be  due  to  acquisition  of  additional  oncogenic 
mutations, at which point Bcr-Abl becomes an irrelevant target (157). Aberrant growth 
factor  secretion  is  another  possible  mechanism  of  resistance  to  TKI.  Adaptive 
autocrine  and  paracrine  secretion  of  granulocyte  macrophage  colony-stimulating 
factor  (GM-CSF)  activates  anti-apoptotic  JAK2/STAT5  pathway  in  a  Bcr-Abl 
independent way in primary CML progenitors, and contributes to the resistance of 
CML cells to TKI treatment in vivo (183). Inhibition of JAK2 by AG490 abolishes the 
resistance mediated by GM-CSF (183), indicating the combination of TKI and JAK2 
inhibitor is a potential method to eradicate CML. In addition, the frequency and level Peixun Zhou, 2011                                                                                          Chapter 1                                            
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of expression of type 1 insulin-like growth factor receptor (IGF-IR) is much higher in 
BC CML patients than in CP and AP, and inhibition of IGF-IR partially overcomes 
CML resistance to IM (184). Thus, targeting IGF-IR may facilitate TKI in treating CML 
in advanced stages (184).  
 
Autophagy  is  another  possible  mechanism  for  CML  cells  to  survive  under  TKI 
treatment. Autophagy is a pathway which degrades proteins or organelles to maintain 
cellular homeostasis, and also generates energy under starvation or other cellular 
stress (185). IM induces autophagy in CML cell lines and primary CML cells (186). 
Blockage  of  autophagy  increases  IM  induced  apoptosis  in  CML  cells  (185). 
Importantly,  combination  of  autophagy  inhibitor  chloroquine  and  TKIs  significantly 
induces  apoptosis  in  CML  progenitor  and  stem  cells  (186).  This  indicates  that 
autophagy  serves  as  a  survival  mechanism  in  CML  cells  with  TKI  treatment,  and 
autophagy  inhibition  potentiates  apoptosis  induced  by  TKI  in  primitive  CML  cells 
(186).      
1.5.2  Bcr-Abl dependent resistance 
The  possible  mechanisms  of  Bcr-Abl  dependent  resistance  are  Bcr-Abl  kinase 
domain point-mutations, Bcr-Abl gene amplification, Bcr-Abl protein over-expression 
and drug efflux (157). The major cause of resistance to IM is point-mutations in the 
kinase domain of Bcr-Abl protein (187). Almost all Bcr-Abl kinase domain mutants can 
be inhibited by second-generation TKIs, except the T315I mutant (188). Threonine 
315, located at the Abl kinase domain, forms a pivotal hydrogen bond with TKI (187). Peixun Zhou, 2011                                                                                          Chapter 1                                            
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Mutation at this site disrupts the binding of TKI with Bcr-Abl. CML patients harbouring 
T351I Bcr-Abl mutant are associated with poor clinical prognosis (189).  
1.5.2.1  Drug Efflux 
One  possible  mechanism  of  TKI  resistance  is  drug  efflux,  which  pumps  out 
intracellular  drugs  typically  by  ATP  binding  cassette  (ABC)  transporters.  ABC 
transporters are involved in multi-drug resistance in cancer chemotherapy (190). Drug 
efflux may lead to sub-optimal intracellular TKI concentration and insufficient inhibition 
of Bcr-Abl kinase activity.  
 
It  was  shown  that  overexpression  of  an  ABC  transporter  ABCB1  (MDR1,  p-
glycoprotein) in Bcr-Abl
+ cell lines conferred partial resistance to IM (191). However, 
the  activity  of  ABCB1  in  primary  CML  CD34
+  cells  is  very  low,  and  inhibition  of 
ABCB1  was  not  able  to  increase  intracellular  IM  level  (192).  In  addition,  it  was 
suggested that another ABC transporter ABCG2 (BCRP) was involved in the efflux of 
intracellular IM in ABCG2-overexpressing cell lines (193). ABCG2 transduced human 
BC CML cell line K562 cells become insensitive to IM and nilotinib treatments, and 
both  TKIs  associate  with  ABCG2  at  its  substrate  binding  sites  (194).  Although 
functional ABCG2 is overexpressed in CML CD34
+ cells, IM inhibits ABCG2 activity in 
this primitive CML population and is not a substrate of ABCG2 (195). This indicates 
that ABCG2 is not a regulator of intracellular IM concentration in primitive CML cells 
(195). Furthermore, nilotinib inhibits the activity of a range of transporters, including 
ABCB1,  ABCG2  and  the  influx  transporter  human  organic  cation  transporter  1 Peixun Zhou, 2011                                                                                          Chapter 1                                            
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(hOCT1) in CML cell lines and CML CD34
+ cells (196;197). The uptake and efflux of 
nilotinib is not modulated by these transporters in CML cells (197). Taken together, 
drug efflux is unlikely a mechanism of CML stem cell resistance to IM and nilotinib.    
1.5.2.2  Cytoplasmic retention of Bcr-Abl 
The NLS and NES-containing protein c-Abl may be present both in the nucleus and 
cytoplasm (49;72). Although there are three NLSs present in the Bcr-Abl protein, Bcr-
Abl is located in the cytoplasm of transformed fibroblasts (73;198). In addition, it was 
demonstrated  that  Bcr-Abl  was  localised  to  the  cytoplasm  of  CML  cell  lines  and 
primary cells (74). Export of NES-containing proteins from the nucleus is facilitated by 
the NES receptor CRM1/exportin-1 (199). CRM1/exportin-1 can be inactivated by a 
cytotoxin  called  leptomycin  B  (LMB),  resulting  in  the  inhibition  of  NES  dependent 
protein  export  from  the  nucleus  (72;199).  In  Bcr-Abl  transfected  fibroblasts,  LMB 
treatment  could  not  trap  Bcr-Abl  in  the  nucleus,  showing  that  Bcr-Abl  was  not 
imported into the cell nucleus despite its NLS domains (198). However, in fibroblasts 
transfected  with  kinase–defective  Bcr-Abl,  about  30-35%  kinase–defective  Bcr-Abl 
was accumulated in the cell nucleus by LMB (198). In addition, IM could induce Bcr-
Abl nuclear localisation  and result in Bcr-Abl nuclear entrapment with LMB (198). The 
nuclear  fraction  of  Bcr-Abl  was  demonstrated  to  correlate  with  increased  IM 
concentration and incubation time, reaching a plateau with 10µM IM at about 25-35% 
(198).  This  indicates  that  inhibition  of  Bcr-Abl  tyrosine  kinase  can  induce  nuclear 
transportation of Bcr-Abl protein, and the kinase activity of Bcr-Abl plays a role in its 
cytoplasmic retention.   Peixun Zhou, 2011                                                                                          Chapter 1                                            
 
 
61 
Nuclear  Abl  kinase  can  be  activated  by  DNA  damage,  subsequently  inducing 
activation of protein p73 which is functionally homologous to the tumour suppressor 
protein  p53.  The  activation  of  Abl  and  p73  is  involved  in  DNA  damage-induced 
apoptosis (200). It was demonstrated that nuclear Bcr-Abl kinase could induce cell 
apoptosis in transformed fibroblasts and K562 cells. Bcr-Abl expressing cells were 
treated with both IM and LMB to trap Bcr-Abl inside the nucleus, and then cells were 
washed extensively to get rid of IM to recover the tyrosine kinase activity of Bcr-Abl. 
After that cells were incubated with LMB alone. With this protocol, the apoptotic rate 
of  Bcr-Abl  expressing  cells  was  about  70-80%  higher  than  untransfected  cells 
(198;200).  These  observations  provided  a  new  strategy  for  killing  Bcr-Abl
+  cells. 
Interestingly, only about 20-25% of total Bcr-Abl accumulated in the nucleus of K562 
cells  treated  with  both  IM  and  LMB,  indicating  that  there  were  other  mechanisms 
besides tyrosine kinase activity holding Bcr-Abl in the cytoplasm (198). 
1.5.2.3  Quiescent CML stem cells 
The quiescent (viable and non-dividing) CML stem cell population is insensitive to TKI 
treatment (201). IM and nilotinib have an anti-proliferative effect in the CML stem cell 
population,  resulting  in  an  accumulation  of  quiescent  CML  stem  cells  (172;201). 
Although dasatinib can target the committed CML stem cells, the quiescent CML stem 
cell population is still insensitive to this drug (163). In addition, the quiescent CML 
CD34
+ cells are resistant/persistent to a range of cytotoxic agents, including Ara-C, 
arsenic,  PI-3K  inhibitor  LY294002  and  et  al.  (202;203).  Thus,  eradication  of  this 
primitive Ph
+ stem cell population becomes an interesting research focus (157).  Peixun Zhou, 2011                                                                                          Chapter 1                                            
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In addition, primitive CML CD34
+38
– cells (approximating the in vivo quiescent stem 
cell  pool)  had  significantly  higher  levels  of  Bcr-Abl  mRNA  transcript  and  Bcr-Abl 
protein  compared  to  mature  mononuclear  cells  (MNC)  (163).  Additionally,  total 
phosphotyrosine and p-CrkL levels are increased in CML CD34
+38
– cells with respect 
to MNC population. The level of p-CrkL is significantly elevated in CML CD34
+38
– 
cells compared to bulk CML CD34
+ cells, indicating higher Bcr-Abl tyrosine kinase 
activity  in  CD34
+38
–  cells  than  CML  MNC  and  bulk  CD34
+  cells  (163).  Therefore, 
sufficient inhibition of Bcr-Abl tyrosine kinase in quiescent CML stem cells is required 
to eradicate them.  
 
Type of Resistance   Possible Mechanisms 
Bcr-Abl Dependent  Bcr-Abl kinase domain mutations 
Bcr-Abl gene amplification  
Bcr-Abl protein over-expression  
Drug efflux 
Cytoplasmic retention of Bcr-Abl 
CML stem cell persistence 
Bcr-Abl Independent  Additional oncogenic mutations 
Aberrant growth factor secretion 
Autophagy 
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1.6  Novel treatment approaches 
1.6.1  Farnesyltransferase inhibitors and CML 
Ras (also known as p21
Ras) is a G or guanosine-nucleotide-binding protein. Ras is 
active when bound with guanosine triphosphate (GTP) and inactive with guanosine 
diphosphate (GDP). The Ras family contains H-Ras, K-Ras and N-Ras genes, the 
molecular weight of their protein products are 21 kDa (204). Ras proteins regulate 
several signalling pathways, among which the Ras-Raf-MEK-ERK signalling cascade 
is the pivotal one. In normal cellular context, this cascade is activated by binding of 
external stimuli to receptor tyrosine kinases (RTKs), leading to the dimerization of the 
RTKs  and  phosphorylation  of  an  adaptor  protein  Grb2  (105).  Subsequently, 
phosphorylated Grb2 brings a guanosine nucleotide exchange factor SOS (Son of 
Sevenless) to the membrane bound inactive Ras-GDP, and converts it into active 
Ras-GTP, leading to the sequential activation of Raf, MEK and ERK (105). Activated 
ERK  then  translocates  into  the  cell  nucleus  resulting  in  phosphorylation  of  many 
transcription  factors  and  transcription  of  genes  involved  in  cell  proliferation, 
differentiation and survival (105). Ras activity is regulated by opposite effects of GEFs 
and  GAPs  (205).  GAPs  enhance the  intrinsic  GTPase  activity  of  Ras,  resulting  in 
increased GTP hydrolysis rate. Thus, GAPs negatively regulate Ras activity. On the 
other hand, GEFs facilitate exchange of Ras-GDP to Ras-GTP, making more active 
form of Ras protein. Therefore, GEFs are activators of Ras signalling (205).   
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Ras signalling is a critical pathway activated by Bcr-Abl protein. Experiments have 
demonstrated  that  inactivation  of  Ras  signalling  impaired  the  leukaemic 
transformation ability of Bcr-Abl protein (106). It was reported that the proliferation of 
a Bcr-Abl
+ CML cell line BV173 was blocked by knock down of Ras. It was shown that 
inactivation of Ras dramatically reduced the number of colonies formed in soft agar 
assays with Bcr-Abl expressing Rat-1 fibroblasts (106). In addition, the transformation 
ability  of  Bcr-Abl  in  mouse  bone  marrow  cells  was  completely  inhibited  by  co-
expression  of  inactive  Ras  (106).  These  observations  show  that  Ras  plays  an 
essential role in the Bcr-Abl transformation, which makes Ras a potential therapeutic 
target in treating CML.   
 
Cytosolic  Ras  protein  is  post-translationally  modified  to  enable  its  membrane 
association,  which  is  critical  for  the  signalling  functions  of  Ras  (206).  The  post-
translational  modifications  of  Ras  include  farnesylation,  proteolysis  and  carboxyl 
methylation (207). The first step in this process is addition of a 15-carbon farnesyl 
group to the cysteine residue of Ras C-terminal CAAX consensus sequence (C is 
cysteine, A is any aliphatic amino acid and X is any amino acid). Subsequently, the C-
terminal  tripeptide  AAX  is  removed  by  proteolysis.  Finally,  the  new  C-terminal 
farnesylcysteine residue is carboxyl methylated (208;209). Among these three steps, 
farnesylation of the C-terminal cysteine residue of Ras by farnesyltransferase is the 
key step of this process (208). Therefore, inhibition of the farnesyltransferase activity 
prevents membrane association of cytosolic Ras and its signalling function.  
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Based on this, a range of farnesyltransferase inhibitors (FTI) were developed to inhibit 
the  farnesyltransferase  activity  and  intended  to  block  the  Ras  signalling  pathway. 
These  FTIs  have  potential  applications  in  a  wide  range  of  tumours,  since  mutant 
forms  of  Ras  with  constitutive  activity  are  involved  in  about  90%  of  pancreatic 
adenocarcinoma, 50% of colon adenocarcinoma, 30% of myeloid leukemia and many 
other types of human tumours (210). More importantly, our previous study revealed 
that lonafarnib, a FTI, sensitized primitive quiescent CML cells to IM treatment in vitro 
(202).   
1.6.2  BMS-214662  
BMS-214662 is a potent FTI, which was developed as an inhibitor of Ras signalling 
pathway (Figure   1-11)(206). BMS-214662 has slightly lower FTI activity than another 
FTI, BMS-225975, as measured by in vitro kinase assay and in cell lines with mutant 
Ras (211). However, BMS-214662 exhibits potent apoptotic effects in tumour cells in 
vivo, whereas BMS-225975 only has cytostatic effects in the same context (211). This 
indicates BMS-214662 may induce apoptosis in tumour cells by a novel mechanism 
of action apart from its FTI activity. In addition, previous research demonstrated that 
BMS-214662, but not BMS-225975, selectively induced apoptosis in quiescent CML 
stem  and  progenitor  cells  in  respect  to  their  normal  counterparts,  making  BMS-
214662 a potential drug to eradicate CML (212). BMS-214662 induces apoptosis in 
primary CML stem and progenitor cells via the activation of protein kinase C β (PKCβ) 
and the intrinsic apoptotic pathway including generation of reactive oxygen species 
(ROS) and release of cytochrome c from the mitochondria (213). However, the exact Peixun Zhou, 2011                                                                                          Chapter 1                                            
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mechanism of how BMS-214662 activates the intrinsic apoptotic pathway is still not 
clear. 
 
Figure   1-11: The structure of BMS-214662 and BMS-225975.  
Adopted from Manne et al., 2004 (211).  
1.6.3  Protein tyrosine phosphatases   
Protein  tyrosine  phosphatases  (PTPs)  modulate  signalling  pathways  mediated  by 
protein  tyrosine  kinases  (PTKs)  and  cytokines  (214).  Most  of  PTPs  negatively 
regulate  these  signalling  pathways,  apart  from  a few  PTPs  like  SHP2  and  CD45, 
which increase immune response and cytokine signalling (214). SHP1 and SHP2 are 
SH2 domain-containing, non-receptor PTPs (215). They both have two tandem SH2 
domains  at  the  N-terminus,  then  a  catalytic  domain  and  an  inhibitory  C-terminus 
(215). Although SHP1 and SHP2 are structurally similar, they have different functions 
and  expression  patterns.  SHP1  is  highly  expressed  in  haemopoietic  cells,  and 
negatively regulates cell signalling mediated by a range of cytokine receptors (215). 
However, SHP2 is widely expressed and promotes cell signalling pathways leading to 
differentiation, proliferation, and migration (215). Peixun Zhou, 2011                                                                                          Chapter 1                                            
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Phosphorylation of  Bcr-Abl  is  regulated  by PTPs.  Bcr-Abl  enhances  expression  of 
SET  via  JAK2  kinase  (216;217).  SET  is an  inhibitor  of  tumour suppressor  protein 
phosphatase 2A (PP2A) (218), and PP2A is a serine/threonine phosphatase which 
activates  SHP1  (217).  The  tyrosine  phosphatase  SHP1  associates  with  and 
dephosphorylates Bcr-Abl (217). Thus, Bcr-Abl maintains its tyrosine phosphorylated 
status by inhibiting SHP1 through SET-PP2A-SHP1 pathway. Inhibition of SHP1 by 
Bcr-Abl renders proliferative advantage to Bcr-Abl
+ cells, as it was shown that defect 
of SHP1 gene was associated with hyperproliferation of haemopoietic cells in mice 
(219). In addition, expression of SHP1 is decreased in primary CML cells along with 
disease  progression,  which  may  explain  resistance  of  advanced  CML  to  TKI 
treatment (214). 
 
Activation  of  PP2A  and  SHP1  becomes  a  potential  therapeutic  strategy  in  TKI-
insensitive CML. PP2A activation leads to Bcr-Abl tyrosine dephosphorylation and its 
proteasomal  degradation  via  SHP1  (217).  Besides  Bcr-Abl,  SHP1  also  associates 
with and dephosphorylates JAK2 kinase (220), and triggers proteasomal degradation 
of JAK kinases (221). JAK2 plays a critical role in Bcr-Abl mediated cell signalling 
(222;223). In addition, the substrates of PP2A include MAPK, STAT5, Akt, Myc and 
Bad.  Down-regulation  of  SET  and  overexpression  of  PP2A  in  a  Bcr-Abl
+  cell  line 
inhibited phosphorylation  of  MAPK,  STAT5 and  Akt,  reduced  Myc  expression  and 
elevated the level of pro-apoptotic Bad (217). Activation of PP2A inhibits proliferation 
and clonogenic potential of Bcr-Abl
+ cells, and induces apoptosis greatly in these cells Peixun Zhou, 2011                                                                                          Chapter 1                                            
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(217). Overall, activation of PP2A and SHP1 inhibits Bcr-Abl and JAK2 kinase activity, 
as well as their downstream signalling, and impairs the leukaemogenic potential of 
Bcr-Abl.  
 
Protein tyrosine phosphatase 1B (PTP1B) is another PTP which can dephosphorylate 
Bcr-Abl. Similar as SHP1, PTP1B is an intracellular PTP and a negative modulator of 
tyrosine kinases (224). PTP1B is able to associate with and dephosphorylate Bcr-Abl 
in vivo (225). PTP1B negatively regulates signalling and transformation mediated by 
Bcr-Abl in vitro and in vivo (225;226).  
1.6.4  Disruption of association of Bcr-Abl and its binding partners 
Since there are other mechanisms besides tyrosine kinase retaining Bcr-Abl in the 
cytoplasm (198), impairment of these mechanisms may induce nuclear localisation of 
Bcr-Abl and enhance apoptosis of CML cells. Cytoplasmic binding partners of Bcr-Abl 
may be involved in its cytoplasmic retention, and disruption of their association could 
potentially induce nuclear translocation of Bcr-Abl protein.   
1.6.4.1   Bcr-Abl and actin 
In the Bcr-Abl fusion protein, Bcr not only activates the tyrosine kinase activity of Abl, 
but also enhance the F-actin binding ability of Abl (82). The F-actin binding domain of 
Abl and Bcr-Abl protein is located in their C-terminal end (73). It was shown that Bcr-
Abl with defective F-actin binding ability had decreased transforming potential, but 
was not able to abolish dependence of Ba/F3 cells on IL-3 (73). In transfected COS Peixun Zhou, 2011                                                                                          Chapter 1                                            
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cells, wild type Bcr-Abl co-localises with F-actin, but F-actin binding domain (FABD) 
deleted Bcr-Abl mutant does not (227). The FABD-deleted Bcr-Abl is located in the 
cytoplasm diffusely with punctation (227). Treatment with IM does not induce nuclear 
localisation of FABD-deleted Bcr-Abl (227). However, it is not clear whether FABD-
deleted Bcr-Abl translocates to the nucleus with IM treatment, as Bcr-Abl may shuttle 
back to the cytoplasm very quickly in the absence of LMB.  
1.6.4.2   Bcr-Abl and 14-3-3 
14-3-3 proteins are highly conserved and ubiquitously expressed 28-33 kDa proteins 
involved in a wide variety of cellular processes in eukaryotes (228;229). There are 
seven major members in the mammalian 14-3-3 family (β, γ, ε, σ, ζ, τ and η), and 
these members form homodimers and heterodimers. 14-3-3 proteins have phospho-
serine  and  phospho-threonine  binding  activities  (229).  By  interacting  with  a  wide 
range of proteins, 14-3-3 proteins are involved in cellular processes including signal 
transduction, apoptosis, metabolism, protein trafficking, cell cycle regulation and DNA 
damage/oxidative  stress  responses  (228;229).  14-3-3  dimers  function  as  adaptor 
molecules in signalling to allow un-complexed proteins to associate with each other 
indirectly (230).  
 
14-3-3 proteins are involved in regulating nucleocytoplasmic shuttling of c-Abl. There 
is  a  consensus  14-3-3  binding  site  between  the  second  and  third  NLSs  of  c-Abl 
protein (231). It was revealed that 14-3-3 proteins (β, γ, σ, ε, ζ and η) interacted with 
c-Abl  at  this  site  and  sequestered  c-Abl  in  the  cytoplasm,  as  binding  with  14-3-3 Peixun Zhou, 2011                                                                                          Chapter 1                                            
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masks  the  NLSs  of  c-Abl  (231).  In  addition,  it  was  found  that  upon  exposure  to 
oxidative stress and DNA damage, activated JNK phosphorylated 14-3-3 (on Serine 
184) and resulted in the release of c-Abl from 14-3-3, hence nuclear translocation of 
c-Abl (231). Phosphorylation of c-Abl at Thr735 is crucial for its binding with 14-3-3 
proteins  (231),  and  Thr735  phosphorylation  is  independent  of  DNA  damage  and 
subcellular localisation of c-Abl, and has no effect on the tyrosine kinase activity of c-
Abl (231).  
 
Furthermore,  the  N-terminal  region  of  Bcr  protein  encoded  by  the  first  exon  is 
associated with a member of 14-3-3 family, Bcr-associated protein 1 (Bap-1) (61). 
Bcr-Abl  protein  also  interacts  with  Bap-1  (61).  In  addition,  14-3-3  β  binds  to  the 
serine/threonine kinase domain of Bcr (232), and other 14-3-3 isoforms were found to 
interact with Bcr as well, including 14-3-3 γ, ε, ζ, τ, and η (233). 14-3-3 ζ, 80% of 
amino acid sequence identical to Bap-1, was revealed to be associated with both Bcr 
and Bcr-Abl proteins (61).  
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Figure   1-12: Nuclear translocation of c-Abl and Bcr-Abl in response to DNA damage.  
Following genotoxic stress, activated JNK phosphorylates 14-3-3 and disrupts 14-3-
3/c-Abl complex, leading to nuclear translocation of c-Abl. Then DNA damage activates 
the  tyrosine  kinase  activity  of  c-Abl  and  results  in  apoptosis.  Bcr-Abl  can  also  be 
induced  into  the  nucleus  in  response  to  genotoxic  stress,  which  may  enhance 
genomic instability in Bcr-Abl
+ cells. NLSs are indicated as little blue ovals on Abl. 
Adapted from Yoshida et al., 2005 (231) and Pendergast 2005 (234).  
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1.6.5  Novel stem cell targeted drug delivery 
Stem  cell  targeted  TKI  delivery  may  be  used  in  order  to  overcome  the  elevated 
expression  and  activity  of  Bcr-Abl  kinase  in  CML  stem  cells  (163).  Low  density 
lipoprotein (LDL), the major transporter of cholesterol in human plasma (235), could 
be  an  interesting  drug  delivery  vector  to  primary  haemopoietic  stem  cells.  LDL 
particles are spherical and have a diameter of 22 nanometres (236). A LDL particle 
contains a core of about 1500 esterified cholesterol molecules surrounded by a shell 
of phospholipids, unesterified cholesterol and apoprotein B (237;238). Circulating LDL 
is  taken  up  by  cell  surface  receptors,  then  internalized  and  degraded  to  release 
cholesterol (Figure   1-13). Uptake of LDL is elevated in gynaecological cancer cells 
compared to normal cells (239). LDL receptor (LDLR) activity and cellular LDL uptake 
is markedly increased in primary peripheral blood and bone marrow AML and BC 
CML cells with respect to their healthy counterparts (237). Thus, LDL may be used as 
a selective drug delivery vehicle targeting CML stem cells.  
 
However, as natural LDL is extracted from serum, it has limited availability, as well as 
issues  of  genetic  and  batch-to-batch  variation.  Synthetic  LDL  (sLDL)  is 
physicochemically  and  biologically  equivalent  to  natural  LDL  (240;241).  It  can  be 
routinely produced (242), and does not have the issues associated with natural LDL. 
Furthermore, sLDL has been shown to incorporate drugs (243;244), demonstrating 
the competence of sLDL as a drug delivery vector. The effectiveness of sLDL as a 
drug delivery vehicle in CML stem cells had not been investigated yet. Peixun Zhou, 2011                                                                                          Chapter 1                                            
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Figure   1-13: Internalization of LDL particles via receptor mediated endocytosis.  
LDL particles circulating in the blood are taken up by LDL receptors in clathrin-coated 
pits on cell surface. These pits are internalized and form coated vesicles which fuse 
and  form  endosomes.  In  the  acidic  environment  of  endosomes,  LDL  particles  are 
separated from their receptors and delivered to lysosomes, where they are degraded 
to release free cholesterol. LDL receptors are then recycled to the plasma membrane 
by transport vesicles. Adapted from Brown and Goldstein 1986 (236). 
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1.7  Aims 
The following aims are addressed in this thesis:   
1.  To investigate the efficacy of nuclear entrapment of Bcr-Abl to induce apoptosis in 
CML cells; 
2.  To  visualize  the  subcellular  localisation  of  Bcr-Abl  protein  in  CML  progenitors 
which survive long-term TKI treatment, and to assess with which proteins Bcr-Abl 
is co-localised; 
3.  To determine if p-CrkL is an accurate surrogate marker of Bcr-Abl tyrosine kinase 
activity especially at short time points; 
4.  To  investigate  the  mechanism  of  action  of  the  putative  farnesyltransferase 
inhibitor, BMS-214662 in CML cells; 
5.  To assess the efficacy of sLDL as a drug delivery vehicle to target primitive CML 
cells. Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
 
 
75 
2  Methods and Materials 
2.1  Methods 
2.1.1  Cell Culture  
2.1.1.1  Culture of cell lines 
CML blast crisis cell lines K562 and KCL22, AML cell line HL60, murine cell lines 
Ba/F3  wild  type  and  Ba/F3  Bcr-Abl  were  cultured  in  RPMI
++  (  2.3.7.1).  Cells  were 
grown at 37
°C with 5% CO2 in tissue culture flasks. Cells were fed every one or two 
days to maintain a density of 2-10 x 10
5 cells/mL. 10ng/mL IL-3 was added to Ba/F3 
wild type cell culture medium as these cells are IL-3 dependent.  
2.1.1.2  Cell counting and trypan blue dye exclusion 
The number of cells was counted with a haemocytometer. 10 L of cells were loaded 
into one side of the chamber in the haemocytometer, and at least 100 cells were 
counted to give a statistically significant count. For assessment of cell viability, trypan 
blue dye exclusion method was used. Trypan blue is a vital dye which can penetrate 
through the membrane of dead cells but not viable cells. Thus, dead cells can be 
distinguished with their blue colour under a microscope. At first, trypan blue solution 
was diluted 1 in 10 in PBS, and 90 L of such dilution was mixed with 10 L cells 
giving  a  dilution  factor  of  10.  Then  10 L  of  the  mixture  was  loaded  into  the Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
 
 
76 
haemocytometer and at least 100 cells were counted. Cells without blue staining were 
counted as viable cells.  
2.1.1.3  CML sample collection and enrichment                
The research was approved by the Greater Glasgow and Clyde Health Board Local 
Research Ethics Committee (LREC) and all human participants gave written informed 
consent.  Leukapheresis  samples  from  newly  diagnosed  untreated  patients  with 
chronic phase CML were enriched to more than 90% CD34
+ progenitors by positive 
selection  with  CliniMACS  and  cryopreserved  routinely  in  the  lab.  Enriched  CD34
+ 
samples were validated by Ms Elaine Allan to be Ph
+ by D-FISH.  
2.1.1.4  Cell sorting 
Cell sorting was performed by technicians. Briefly, CD34
+ enriched cells were stained 
with anti-human anti-CD34-APC and anti-CD38-PE antibodies for 15 minutes in the 
dark. Then stained cells were sorted by using a BD FACS Aria into two populations: 
CD34
+38
hi/+  and  CD34
+38
low/−.  The  CD34
+38
low/−  fraction  approximates  the  most 
primitive quiescent stem cell pool (less than 5% total CD34
+ cells).  
2.1.1.5  Cryopreservation of cells 
Primary CML CD34
+ cells and cell lines were cryopreserved in liquid nitrogen for long-
term  storage.  Newly  selected  CML  CD34
+  cells  were  suspended  in  4.5%  human 
albumin (ALBA
®) and aliquoted in cryotubes, then an equal volume of 20% dimethyl 
sulphoxide (DMSO) in 4.5% ALBA
® was added to give a final DMSO concentration of 
10%. Cell lines in exponential growth phase were collected and resuspended with Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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10% DMSO in foetal calf serum (FCS) (5-10 x 10
6 cells/mL), and were aliquoted into 
cryotubes. The cryotubes were then transferred into a Mr. Frosty freezing container 
and kept in a -80
°C freezer overnight to achieve a -1
°C per minute cooling rate then 
transferred to liquid nitrogen for long-term storage.  
2.1.1.6  Recovery of frozen cells 
Primary CD34
+ cells were removed from liquid nitrogen and immediately thawed at 
37
°C in a water bath until the ice crystals had disappeared. The cells were transferred 
to a 15mL sterile tube and recovered by slowly adding 10mL of warm DAMP solution 
(  2.3.7.2) drop-wise over a 20-minute period with a pastette. This step was performed 
at room temperature to enhance the activity of the DNase I, with gentle shaking to 
prevent  clumping  of  the  cells.  After  centrifugation  at  120  x  g  for  10  minutes,  the 
supernatant was carefully removed without disturbing the pellet, and then the pellet 
was loosened by flicking the tube. The pellet was washed twice more in DAMP to get 
rid of all DMSO. The CML cells were resuspended in SFM + 5GFs medium (  2.3.7.4) 
and  plated  in  a  25cm
3  non-adherent  tissue  culture  flask  at  5  x  10
5  cells/mL  for 
overnight recovery. Then the recovered cells were plated in SFM + PGFs medium 
(  2.3.7.5) when the experiment required.  
 
Cell lines were thawed in a 37
°C water bath and recovered slowly as above but in 
RPMI
++  instead  of  DAMP.  The  cells  were  then  washed  twice  with  RPMI
++  and 
resuspended in 20mL of RPMI
++. Finally cells were plated in a 75cm
3 tissue culture 
flask (2 x 10
5 cells/mL unless otherwise stated). Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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2.1.2  Flow Cytometry 
Flow  cytometry  is  able  to  characterize  individual  cells  with  fluorochrome-labelled 
antibodies. It supplies excitation energy with lasers and detects fluorescent emissions 
with a range of filters and detectors. It can also measure the size of a cell using 
forward scatter (FSC), and the granularity of a cell using side scatter (SSC).    
2.1.2.1  Surface antibody staining 
1 x 10
5 primary cells were collected and washed in PBS/2% FCS (2mL FCS with 
98mL PBS; 120 x g for 10 minutes). The washed cells were resuspended in 100 L 
PBS/2% FCS with appropriate antibody solution. Then the cells were incubated in the 
dark for 15 minutes. After incubation, the cells were washed twice in PBS/2% FCS 
(120 x g for 10 minutes), and analysed by FACS immediately, or kept at 4
°C until 
analysis. Appropriate isotype controls were used as negative controls.   
2.1.2.2  Intracellular antibody staining 
1 x 10
5 cells were washed with PBS and resuspended in 100 L of fixing reagent 
(Reagent A of Fix & Perm
® kit) and incubated for 15 minutes. The fixed cells were 
then  washed  with  PBS/1%  BSA  (1g  BSA  in  100mL  PBS),  and  supernatant  was 
completely removed. Appropriate volume of primary antibody was diluted (e.g. anti-p-
CrkL; 1:10 dilution) in the permeabilising reagent (Reagent B of Fix & Perm
® kit), and 
the cell pellet was resuspended in the primary antibody dilution. The cells were then 
incubated for 45 minutes at room temperature in the dark. After incubation, cells were 
washed twice in PBS/1% BSA (120 x g for 10 minutes) to get rid of excessive primary Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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antibody.  Then  the  cells  were  resuspended  with  100 L  appropriate  secondary 
antibody  (e.g.  anti-rabbit  IgG  FITC-conjugate;  1:50  dilution  in  PBS/1%  BSA)  and 
incubated at room temperature for 30 minutes in the dark. Finally cells were washed 
twice in PBS and analysed by flow cytometry. A matched isotype control was used 
instead of primary antibody in a separate sample as a negative control.   
2.1.2.3  Viability analysis with Annexin V and Via-Probe 
Cell viability was assessed by flow cytometry with Annexin V and Via-Probe staining. 
One of the features of early apoptosis is the translocation of phosphatidylserine from 
the  inner  layer  of  plasma  membrane  to  the  outer  layer,  where  the  cell  surface 
phosphatidylserine is available for binding by Annexin V before the integrity of plasma 
membrane has been lost. In addition, cells continue to bind Annexin V after loss of 
plasma membrane integrity in late apoptosis. Via-Probe
TM (7-Amino-actinomycin D; 7-
AAD) is a dye of nucleic acid. Late apoptotic cells are stained with 7-AAD as the 
integrity of plasma membrane is lost. Staining cells simultaneously with Annexin V-
FITC (green fluorescence) and 7-AAD (far red fluorescence) enables distinguishing of 
viable, early apoptotic and late apoptotic (or necrotic cells) by flow cytometry (Annexin 
V
– 7AAD
–, Annexin V
+ 7AAD
– and Annexin V
+ 7AAD
+, respectively) (Figure   2-1).    
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Figure    2-1:  Assessment  of  cell  viability  by  flow  cytometry  with  Annexin  V  and  Via-
Probe staining.  
 
For detection of viability, cells were collected at the stated times of drug exposure and 
pelleted  by  centrifugation  (120  x  g  for  10  minutes).  After  that,  pellets  were 
resuspended in 85 L Annexin V Binding Buffer (1X) with 5 L Annexin V and 10 L 
Via-Probe
TM (100 L in total per 1 x 10
5 cells). Cells were then incubated in the dark 
for 15 minutes at room temperature. After incubation, 400 L 1X Annexin V Binding 
Buffer was added to each sample, and analysed immediately by flow cytometry.  
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2.1.3  Western blotting 
2.1.3.1  Protein lysate preparation 
Western blotting was used to separate, detect and quantify specific proteins from cell 
lysate. NP-40 lysis buffer (  2.3.7.6) was prepared prior to use and kept on ice. Cells 
were taken from culture and washed twice with ice-cold PBS (120 x g for 5 minutes) 
in 1.5mL eppendorf tubes. Alternatively, cells taken from culture were pelleted rapidly 
at 21,000 x g for 30 seconds at 4
°C. After removal of supernatant, the NP-40 lysis 
buffer was added to the cell pellets (2 x 10
5 cells/50 L) and mixed up by pipetting up 
and down at least five times and incubated on ice for 15 minutes. Subsequently, the 
cell lysates were centrifuged at 21,000 x g for 10 minutes at 4
°C to pellet chromatins 
and debris. Finally, the supernatants were transferred to new eppendorf tubes and 
kept at -20
°C until use.  
2.1.3.2  Protein quantification 
Bicinchoninic  acid  (BCA)  protein  assay  was  used  to  quantify  protein  lysate 
concentrations according to the manufacturer’s instructions. This assay reduces Cu
2+ 
to Cu
1+ by protein in an alkaline medium and detects Cu
1+ by a reagent containing
 
BCA in a colorimetric way. Chelation of one Cu
1+ ion
 with two BCA molecules forms 
purple-coloured reaction product. This product is water soluble and absorbs strongly 
at  562  nm  and  its  absorbance  almost  linearly  correlates  with  increasing 
concentrations from 20 to 2000 g/mL. 
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Bovine serum albumin (BSA) standards were prepared by serially diluting 2000 g/mL 
BSA in distilled water. The following BSA concentrations were prepared: 2000, 1500, 
1000, 750, 500, 250, 125, 50, 25 and 5 g/mL. These BSA standards were kept at -
20
°C  and  used  in  multiple  times.  BCA  working  solution  was  prepared  by  mixing 
reagents A and B (50:1) thoroughly, and then 200 L of BCA working solution was 
added to each well of a 96-well plate. 10 L of each BSA standards were added to 
each well in triplicate, and 10 L of protein samples were added in duplicate. Then the 
plate was incubated at 37
°C for 30 minutes and read by an ELISA plate reader for 
absorbance  at  562  nm.  Although  the  colour  development  continues,  following 
incubation at 37
°C the colour development rate is slow enough for the samples to be 
read. Finally, protein concentrations were calculated according to the BSA standards 
and equal amounts of protein lysates were loaded for Western blotting.  
2.1.3.3  SDS-PAGE 
Sodium  dodecyl  sulphate-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  was 
employed to separate proteins based on their size. After protein quantification, protein 
lysates were mixed with same volumes of Laemmli 2X sample buffer (supplemented 
with 5% 2-mercaptoethanol) in a 1.5mL eppendorf tube and heated to 95
°C for 10 
minutes. SDS, contained within the sample buffer, is a negatively charged anionic 
detergent. It binds to hydrophobic regions of protein and denatures protein into its 
primary structure as soluble polypeptide chains. It also applies negative charge to 
protein molecules in proportion to its mass, leading to migration of protein towards the 
positive electrode if an electric field is applied.   Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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After short centrifugation, the samples were loaded into a Nupage
® Novex
® Bis-Tris 
4-12% gradient gel. 10 L of Novex
® Sharp
TM Pre-stained protein standard marker 
was  loaded  into  a  lane  for  protein  size  measurement.  The  gel  was  run  in  1X 
NuPAGE
® MOPS SDS Running Buffer (20X Running Buffer diluted in dH2O) at 200V 
for  60  minutes  with  Invitrogen  XCell  SureLock
TM  Mini-Cell  electrophoresis  system. 
During  the  electrophoresis,  proteins  run  through  a  polyacrylamide  gel,  a  polymer 
meshwork of acrylamide monomers. With electric field applied, proteins with different 
sizes move at different rates. Smaller proteins run faster that larger ones, leading to 
separation of proteins according to their size.   
2.1.3.4  Transfer to PVDF membrane 
After  gel  electrophoresis,  separated  proteins  on  the  gel  were  transferred  to  a 
Polyvinylidene fluoride (PVDF) membrane with the XCell II
TM Blot Module. The PVDF 
membrane was soaked in methanol briefly for its activation, and then the membrane 
was  soaked  in  transfer  buffer  for  several  minutes  until  it  is  completely  wet.  The 
sponges and filter papers were all pre-wet in transfer buffer (  2.3.7.7) before use. Then 
the  transfer  sandwich  was  assembled  as  shown  in  Figure    2-2.  Proteins  were 
transferred at 30V for 60 minutes.  
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Figure   2-2. Assemble of sandwich for transfer of proteins to PVDF membrane. 
 
10% methanol was included in the transfer buffer, and it has two important functions 
during  the  protein  transfer.  Firstly,  methanol  can  maintain  dimensional  stability  of 
gels. Polyacrylamide gel is able to absorb water. Thus the gel size increases a lot in 
water, resulting in loss of protein resolution in transfer. The presence of methanol in 
transfer buffer can minimize gel swelling. Secondly, methanol is capable of removing 
SDS from proteins and increase protein binding to the membrane. Since SDS adds a 
large  amount  of  negative  charges  to  proteins,  protein  molecules  move  very  fast 
through the membrane and their interactions with PVDF decrease. Thus, removal of 
SDS by methanol retains proteins in the membrane.  
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2.1.3.5  Antibody labelling 
After transfer, the PVDF membrane was stained with 0.1% Ponceau S for a minute to 
visualize protein bands and to examine transfer efficiency. Then the membrane was 
washed with distilled water several times to de-stain Ponceau S. Following that, the 
membrane  was  blocked  in  the  5%  BSA/TBST  blocking  buffer  (5g  BSA  in  100mL 
TBST)  at  room  temperature for  1  hour  with  constant  agitation. After  blocking,  the 
membrane was incubated with primary antibody solution diluted in the blocking buffer 
overnight at 4
°C with gentle rotation. The next morning, the membrane was washed in 
the 1X TBST buffer (  2.3.7.9) four times (10 minutes each time) to get rid of unbound 
primary  antibody  and  reduce  background.  After  washes,  the  membrane  was 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibody dilution 
for 1 hour at room temperate with agitation. Then the membrane was washed in the 
1X TBST buffer four times (10 minutes each time) to remove unbound secondary 
antibody. Finally, the membrane was developed with the Immuno-Star
TM WesternC
TM 
Kit  according  to  the  manufacturer’s  instruction.  Briefly,  equal  amounts  of 
luminol/enhancer solution and peroxide solutions were mixed just prior to use. The 
membrane was incubated with the mixture for about three minutes. HRP oxidises 
luminol in the presence of hydrogen peroxide. Then the oxidized luminol goes back to 
its  initial  state,  and  light  is  emitted.  The  enhancer  increases  signal  intensity  and 
length. At last, digital pictures of protein bands were taken by the Molecular Imager
® 
ChemiDoc
TM XRS machine.  Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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2.1.3.6  Stripping  
In  order  to  incubate  the  PVDF  membrane  with  a  different  primary  antibody,  the 
membrane was incubated in 1X Re-Blot
TM Plus Strong Antibody Stripping Solution 
(diluted  with  distilled  water)  for  about  15  minutes  with  constant  shaking  at  room 
temperature. Then the membrane was washed briefly in TBST and re-blocked in 5% 
BSA/TBST for 1 hour before incubation with another primary antibody. The stripping 
solution removes antibodies bound in the membrane without removing proteins.  
2.1.4  Immunoprecipitation 
Immunoprecipitation is used to concentrate and separate a specific protein from a 
lysate with lots of different proteins. In the beginning, 1 x 10
7 cells were collected and 
washed twice with ice-cold PBS, and then the cell pellet was resuspended and lysed 
with  1mL  ice-cold  NP-40  lysis  buffer,  then  incubated  on  ice  for  30  minutes  with 
occasional  agitation  for  complete  cell  lysis.  After  incubation,  the  lysate  was 
centrifuged at  21,000  x  g  for  15  minutes at  4
°C  to  pellet  insoluble  materials. The 
supernatant was then transferred to a new eppendorf tube and 1 g of appropriate 
primary antibody was added followed by overnight incubation at 4
°C with constant 
agitation. In this stage, the primary antibody specifically bound to a particular protein 
and indirectly to other proteins complexed with that particular protein. After that, 40 L 
of Protein A-Sepharose beads (50% slurry, pre-washed with NP-40 lysis buffer) was 
added to the lysate and incubated at 4
°C for 2 hours with constant agitation. The 
primary antibody sticks to the beads during this incubation. Beads complexed with the 
antibody and proteins were then washed three times with the NP-40 lysis buffer to get Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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rid  of  non-specifically  bound  proteins  (1000  x  g  for  2  minutes).  Finally,  40 L  of 
Laemmli  2X  sample  buffer  was  added  to  the  beads,  and  boiled  at  95
°C  for  10 
minutes. In this step, proteins were denatured, separated from the beads and were 
then  dissolved  in  the  sample  buffer.  Finally,  the  beads  were  pelleted  and  the 
supernatant was subject to analysis by Western blotting.  
2.1.5  Immunofluorescence microscopy 
Poly-L-lysine coated multi-spot microscope slides were prepared in advance. Briefly, 
poly-L-lysine solution was diluted 1:10 in distilled water, and multi-spot microscope 
slides  were  immersed  in  the  dilution  in  a  coplin  jar  for  10  minutes.  After  that, 
excessive poly-L-lysine dilution was removed from slides, and these slides were air-
dried  and  kept  in  a  box  for  future  use.  Poly-L-lysine  is  adhesive  and  it  facilitates 
suspension cells binding to glass microscope slides.  
 
CML cells were pipetted onto poly-L-lysine coated multi-spot microscope slides (2 x 
10
4 cells/spot) and left for 90 minutes. Then the suspension CML cells should be 
attached  to  microscope  slides  facilitated  by  poly-L-lysine.  Subsequently,  culture 
medium on the cells was removed by blotting with tissue paper without touching the 
cells. After that cells were fixed by 3.65% formaldehyde in PBS for 15 minutes at 
room temperature and then permeabilized by 0.5% Triton-X100 in PBS (5µL Triton-
X100 in 95µL PBS) for 10 minutes. Formaldehyde fixes cells by cross-linking protein 
molecules. Triton-X100 is a detergent which can dissolve cellular lipid membranes to 
allow antibody access of internal proteins.   Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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After permeabilization, cells were incubated with 5% BSA/PBS (5g BSA in 100mL 
PBS) for one hour at room temperature to block non-specific binding of antibodies. 
After  blocking,  cells  were  incubated  with  0.5  µg/mL  primary  antibodies  in  5% 
BSA/PBS  for  one  hour  at  room  temperature.  Isotype  control  antibodies  (class 
matched with primary antibodies) were used as negative controls. Then the cells were 
washed four times (5 minutes each time) with PBS to get rid of unbound primary 
antibodies in a coplin jar, isotype controls were washed in a separate coplin jar to 
avoid  any  antibody  cross-contamination.  After  washing,  cells  were  incubated  with 
fluorochrome conjugated secondary antibodies for one hour at room temperature in 
the dark. After four washes (5 minutes each time) in PBS in a coplin jar, cells were 
air-dried  and  mounted  in  VECTASHIELD
®  mounting  medium  containing  4,6-
diamidino-2-phenylindole (DAPI) and visualized by a Zeiss Imager M1 fluorescence 
microscope at 10x100 times magnification using oil immersion. Images were captured 
with multiple layers from the top to the bottom of cells and with the optimal distance 
(0.25µM) between adjacent layers. Captured images were subjected to deconvolution 
to  remove  non-specific  fluorescence  and  sharpen  images.  Deconvolution  was 
performed  by  the  deconvolution  module  of  the  AxioVision  software,  the  iterative 
algorithm and clip normalisation method was used.  
 
Alexa  Fluor
®  488  phalloidin  was  added  (1:250  dilution)  into  the  primary  antibody 
dilution to co-stain F-actin. Phalloidin is a mushroom toxin which binds with F-actin 
specifically.  Alexa  Fluor
®  488  cholera  toxin  subunit  B  (CTxB)  conjugate  was 
employed  to  stain  lipid  rafts.  CTxB  is  commonly  used  as  a  marker  for  lipid  rafts. Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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Briefly, cells were incubated with the CTxB conjugate (1:500 dilution) at 4
°C for 30 
minutes before fixation. Then cells were washed with PBS once (5 minutes at 4
°C) to 
get  rid  of  excessive  CTxB  conjugate  and  fixed  by  formaldehyde.  The  following 
procedures are as above.  
 
Fluorescence  was  measured  as  grey  values  by  ImageJ  software.  The
  region  of 
nucleus was selected manually according to the DAPI staining in order to quantify
 the 
red fluorescence within the nucleus. In the red channel, mean grey values and area 
sizes of the nuclear and whole cell were then measured. Mean grey value is the sum 
of all grey values in the selected area divided by the size of the area. The percentage 
of nuclear fluorescence was calculated using the equation Fn% = 100% An (Mn − 
Mb)/Aw  (Mw  −  Mb).  In  this  equation,  Mn,  Mb,  and  Mw  represent  the  nuclear, 
background,  and  whole  cell  mean  grey  values,  respectively.  An  and  Aw  represent 
nuclear and whole cell areas, respectively. Three background areas were randomly 
selected around each cell, and the mean of these background mean grey values was 
calculated as Mb. 
2.1.6  Uptake of sLDL by cell lines and primary cells 
Synthesis of sLDL particles was performed by our collaborators in Cancer Research 
UK  Formulation  Unit,  University  of  Strathclyde.  CML  cell  line  K562  (2.5  x  10
5 
cells/mL)  and  primary  CML  patient  cells  (5  x  10
5  cells/mL)  were  incubated  in  the 
presence or absence of sLDL particles. At the end of incubation, 5 x 10
4 cells were 
sampled from each condition and washed with PBS.  Mean fluorescence intensity of Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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the cells was then measured by flow cytometry in the FITC channel. For fluorescence 
microscopy, 2 x 10
4  cells from each condition were left on a poly-L-lysine coated 
multi-spot microscope slide for 90 minutes to allow cell attachment. Then cells were 
fixed with 3.65% formaldehyde in PBS for 15 minutes at room temperature, and air-
dried.  Finally,  fixed  cells  were  mounted  in  VECTASHIELD
®  mounting  medium 
containing DAPI, and examined by the fluorescence microscope.  
2.1.7  Polymerise chain reaction (PCR) 
PCR is a powerful technique to amplify a single or a few DNA copies to billions of 
copies. It contains 20-40 thermal cycles, with each cycle consisting of three steps 
including  denaturation  of  double-stranded  DNA  into  single  strands,  annealing  of 
primers to the single-stranded DNA and extension of primers by the Taq polymerase. 
2.1.7.1  Primer design 
Primers were designed with NCBI/Primer-Blast. The cDNA sequences were identified 
by searches on the Pubmed website, and then the sequences were used to design 
appropriate  primers.  The  primers  were  about  20  base  pairs  with  similar  melting 
temperatures between forward and reverse primers, and no internal loops or primer 
dimers.       
2.1.7.2  RNA extraction and cDNA synthesis by reverse transcription 
Total  cellular  RNA  was  extracted  using  the  RNeasy  Mini  Kit  according  to  the 
manufacturer’s  instructions.  The  concentration  and  quality  of  extracted  RNA  was Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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measured with a NanoDrop ND-1000 spectrophotometer. An absorbance at 260nm 
quantified nucleic acid concentration, and RNA purity was determined by the ratio of 
260/280 (1.8 to 2.0) and 260/230 (1.8 or greater). This is because nucleic acid is 
detected  at  260nm,  while  solvents,  salts  and  protein  are  detected  at  230nm  and 
280nm.  
 
RNA  was  reverse  transcribed  into  cDNA  by  the  High  Capacity  cDNA  Reverse 
Transcription  Kit  according  to  the  manufacturer’s  instruction.  Briefly,  10 L  of  the 
extracted  RNA  was  mixed  with  10 L  of  2X  Reverse  Transcription  Master  Mix 
(  2.3.7.10) in a PCR tube. Then the 20 L mixture was run in a PCR Thermo Cycler. 
The program was 25
°C for 10 minutes, 37
°C for 120 minutes and 85
°C for 5 seconds. 
Synthesised cDNA was kept at 4
°C for short-term storage or at -20
°C for long-term 
storage.  
2.1.7.3  PCR 
PCR Mix (  2.3.7.11) was prepared in a PCR tube with GeneAmp
® RNA PCR Core Kit 
according to the manufacturer’s instruction. The PCR tube was heated to 94
°C for 5 
minutes at first to denature all the double-stranded cDNA, and then the PCR Thermo 
Cycler was set up to run 35 cycles of 94
°C for 30 seconds, 52
°C for 1 minute and 
72
°C  for  1  minute.  After  all  cycles  finished,  the  tubes  were  heated  to  72
°C  for  5 
minutes for final extension, and then held at 4
°C.   Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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2.1.7.4  Gel electrophoresis 
The PCR products were electrophoresed in gels in order to visualize individual DNA 
bands. Basically, a 1% agarose gel was prepared with 0.5g agarose powder in 50mL 
of  1X  TBE  buffer  (  2.3.7.12;  10X  TBE  buffer  diluted  in  dH2O).  It  was  melted  in  a 
conical  flask  in  a  microwave  until  the  agarose  powder  had  completely  dissolved. 
When  the  gel  cooled  down  to  about  60
°C,  1 L  ethidium  bromide  (10mg/mL)  was 
added  and mixed  well.  Then  the  gel  was  poured  into a  casting  tray  with  a  comb 
inserted to create loading wells. The gel was left to set for about 30 minutes. The 
comb was removed and the gel was placed in a gel tank with 1X TBE buffer. The TBE 
buffer should cover the gel and be 2-5 mm higher). 10 L of PCR product mixed with 
2 L loading dye (6X) was loaded into each well of the gel (2 L of 100bp DNA ladder 
was loaded in a separate lane), and then the gel was run at 50V constant voltage. 
After  running,  the  gel  was  viewed  by  a  UV  transilluminator  (ChemiDoc)  and 
photographed.   
2.1.8  ROS measurement 
Intracellular  reactive  oxygen  species  (ROS)  was  measured  with  2'-7'-
dichlorofluorescin diacetate (DCFDA). The non-fluorescent DCFDA can be cleaved 
into green fluorescent 2',7'-dichlorofluorescein (DCF) by intracellular esterases and 
oxidation. DCFDA is commonly used to detect the generation of ROS in cells. To 
measure intracellular ROS level with drug treatments, fresh cells were washed with 
PBS and incubated with 5 M DCFDA / PBS at 37
°C in the dark for 30 minutes. Cells 
were loaded with DCFDA at this stage as DCFDA was cell-permeable. After that, Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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cells were washed with PBS and plated in fresh medium, and then cells were left to 
recover in a cell culture incubator for 2 hours. Subsequently, appropriate drugs were 
added to the cell culture, and at the end of the treatment the level of fluorescent DCF 
was measured by flow cytometry in the FITC channel. Cells without drug treatment 
(either unloaded or loaded with DCFDA) were used as negative controls.        
2.2  Statistics 
The results are shown as the mean ± standard error of the mean (mean ± SEM). 
Unless otherwise stated, all statistical analyses were performed with the Microsoft 
Office  Excel  software  using  the  two-sided  unpaired  Student’s  t-test  and  the 
assumption  of  normality  was  checked.  P-values  less  than  0.05  were  considered 
statistically significant.  
2.3  Materials 
2.3.1  Small molecule inhibitors 
Imatinib Mesylate (IM) was provided as a white powder under a Materials Transfer 
Agreement  from  Novartis  Pharma  (Basel,  Switzerland).  It  was  dissolved  in  sterile 
water  and  stored  as  100mM  aliquots  at  4
°C.  Dasatinib,  BMS-214662  and  BMS-
225975 were provided as white powder under Materials Transfer Agreements from 
Bristol-Myers Squibb (Princeton, USA). They were dissolved in sterile DMSO to give 
a  stock  concentration  of  20mM,  100mM  and  100mM  respectively,  and  stored  as Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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aliquots  at  −20
°C.  PP2  and  sodium  stibogluconate  (SSG)  were  purchased  from 
Calbiochem,  Merck  Biosciences  (Nottingham,  UK)  as  white  powder.  PP2  was 
dissolved in DMSO to give a stock concentration of 10mM and stored as aliquots at 
−20
°C.  SSG  was  dissolved  in  sterile  water  (10mg/mL)  and  heat  to  75
°C  until 
completely  dissolved  immediately  prior  to  use.  All  small  molecule  inhibitors  were 
diluted to the appropriate concentrations prior to use. 
2.3.2  Tissue culture materials 
Chugai Pharma 
London, UK 
Recombinant human G-CSF 
Gilson  
Middleton, USA 
Yellow and Blue pipette tips 
Greiner Bio-One 
Gloucestershire, UK 
Cryo.s
TM cryotubes  
Tissue culture flasks (25cm
2, 75cm
2 and 
175cm
2) 
Tissue culture plates (6-well, 12-well, 24-
well and 96-well) 
Pipettes (5mL, 10mL and 25mL) 
Invitrogen 
Paisley, UK 
2-mercaptoethanol 
Foetal calf serum (FCS) 
L-glutamine 200mM 
IMDM medium 
Penicillin-streptomycin solution 5000u/mL 
RPMI 1640 medium 
Dulbecco’s PBS  
Nalgene Labware 
Roskilde, Denmark 
25 and
 75cm
3 non-adherent tissue culture 
flasks 
Cryo freezing container “Mr. Frosty” 
Vacubottles 
Startorius 
Hannover, Germany 
Minisart 0.2 M Sterile filters 
Minisart 0.45 M sterile filters Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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Scottish National Blood Transfusion 
Glasgow, UK 
20% Human Serum Albumin 
4.5% human albumin solution (ALBA
®) 
Sigma-Aldrich 
Dorset, UK 
Bovine serum albumin (BSA) 
Dimethyl sulphoxide (DMSO) 
Hydrochloric acid (HCl) 
Magnesium chloride (MgCl2) 
PBS tablets 
Poly-L-lysine 
Potassium Chloride (KCl) 
Trypan Blue Solution (0.4%) 
Trisodium citrate 
Stem Cell Technologies 
British Columbia, Canada 
Bovine pancreatic deoxyribonuclease 
(DNase 1) 1mg/mL 
Bovine serum albumin/insulin/transferrin 
(BIT) serum substitute 
Flt-3 ligand 
Interleukin-3 (IL-3) 
Interleukin-6 (IL-6) 
Stem Cell Factor (SCF) 
Sterilin Ltd 
Hounslow, UK 
Pastettes 
5mL, 10mL and 25mL disposable 
pipettes 
15 and 50mL sterile plastic falcon tubes 
Weber Scientific International 
West Sussex, UK 
Hawksley Neubauer counting chamber 
 
2.3.3  Flow cytometry materials 
Becton Dickinson 
Oxford, UK 
Annexin V Binding Buffer (10X) 
FACS flow 
FACS clean 
Mouse anti-human-annexin-V-FITC  
Mouse anti-human-CD34-APC 
Mouse anti-human-CD34-PE Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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Mouse anti-human-CD38-PE 
Mouse anti-human-CD45-PE  
Mouse anti-human-CD133-APC  
Mouse IgG-APC isotype control 
Mouse IgG-FITC isotype control 
Mouse IgG-PE isotype control 
Via-Probe
TM   
Caltag Laboratories 
Silverstone, UK 
Fix and Perm
® A and B 
Cell Signaling, New England Biolabs  
Hitchin, UK 
Rabbit anti-p-CrkL antibody 
 
Greiner Bio-One 
Gloucestershire, UK  
FACS tubes 
Sigma-Aldrich 
Dorest, UK 
Goat anti-rabbit IgG FITC-linked 
secondary antibody 
 
2.3.4  Fluorescence microscopy supplies 
Abcam 
Cambridge, UK 
Mouse IgG2a isotype control 
Rabbit IgG isotype control 
Carl Zeiss 
Jena, Germany 
AxioVision software 
Imager 1 fluorescence microscope 
Cell Signalling, New England Biolabs 
Hitchin, UK 
Mouse anti-Bcr-Abl (b2a2 junction 
specific) antibody 
Hendley 
Essex, UK 
Multi-spot microscope slides 
 
Invitrogen 
Paisley, UK 
Alexa Fluor
® 488 cholera toxin subunit B 
conjugate 
Alexa Fluor
® 488 goat anti-rabbit IgG  
Alexa Fluor
® 594 goat anti-mouse IgG 
Alexa Fluor
® 488 phalloidin 
Santa Cruz 
Santa Cruz, USA 
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Sigma-Aldrich 
Dorest, UK 
Poly-L-lysine solution  0.1 % (w/v) in H2O 
Triton-X100 
Vector Laboratories 
Burlingame, CA, USA 
VECTASHIELD
® mounting medium with 
DAPI 
 
2.3.5  Molecular biology materials 
Lonza 
Basel, Switzerland 
Nucleofector
® II Device  
Amaxa
® Cell Line Nucleofector
® Kit V 
Applied Biosystem 
Foster City, CA, USA 
GeneAmp
® RNA PCR Core Kit 
High Capacity cDNA Reverse 
Transcription Kit 
Nuclease free water 
Bio-Rad  
Hercules, CA, USA 
Combs for gel casting 
Gel casting trays 
Immuno-Blot
TM PVDF membrane 
Immuno-Star
TM WesternC
TM Kit 
Laemmli 2X sample buffer  
Molecular Imager
® ChemiDoc
TM XRS 
PVDF membrane 
Becton Dickinson 
Oxford, UK 
Anti-PTP1B antibody  
Anti-SHP1 antibody 
Anti-SHP2 antibody 
Cell Signalling, New England Biolabs 
Hitchin, UK 
Goat anti-mouse IgG HRP-linked 
secondary antibody 
Goat anti-rabbit IgG HRP-linked 
secondary antibody 
Mouse anti-Bcr-Abl (b2a2 junction 
specific) antibody  
Rabbit anti-c-Abl antibody  
Rabbit anti-GAPDH antibody 
Rabbit anti-p-CrkL antibody  
Rabbit anti-Ubiquitin antibody  
Chemicon International   Re-Blot
TM Plus Strong Antibody Stripping Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
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Temecula, CA, USA  Solution 
Chemical Store, University of Glasgow 
Glasgow, UK 
Ethanol 
Methanol 
Eurofins MWG Operon 
Wolverhampton, UK 
PCR Primers 
Helena Biosciences 
Gateshead, UK 
Agarose Powder 
Invitrogen 
Paisley, UK 
Novex
® Sharp
TM Pre-stained Protein 
Standard  
NuPage
® MOPS SDS Running Buffer 
(20X) 
Nupage
® Novex
® Bis-Tris 4-12% gel 
NuPage
® Transfer Buffer (20X) 
XCell II
TM Blot Module  
XCell SureLock
TM Mini-Cell 
electrophoresis system 
Labtech International  
East Sussex, UK 
NanoDrop ND-1000 spectrophotometer  
Lonza  
Basel, Switzerland 
Amaxa
® Cell Line Nucleofector
® Kit V 
Nucleofector
® Device 
Qiagen 
West Sussex, UK 
RNeasy Mini Kit 
QIAshredder Kit 
Sigma-Aldrich 
Dorset, UK 
0.1% Ponceau S solution 
2-glycerophosphate  
Aprotinin 
Boric acid 
Dichlorofluorescin diacetate (DCFDA) 
Ethylenediaminetetraacetic acid (EDTA) 
Formaldehyde solution (36.5%) 
Leupeptin  
NP-40 
PMSF 
Protein A-Sepharose
® 4B 
Sodium chloride  
Sodium fluoride 
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Sodium pyrophosphate  
Tris base 
TWEEN 20 for electrophoresis 
Thermo-Scientific 
Hertfordshire, UK 
Albumin standard  
BCA
TM Protein Assay Kit 
SG Wasseraufbereitung und  
Regenerierstation GmbH  
Barsbuttel, Germany 
Ultra Pure Water system (sterile water) 
Upstate (Millipore) 
Watford, UK 
Anti-Phosphotyrosine (4G10
®) antibody 
Promega, 
Southampton, UK 
100bp DNA ladder  
PCR loading dye (6X)  
 
2.3.6  PCR primer sequences 
Actin Forward  GTGCGTGACATTAAGGAGAA 
Actin Reverse  GGAGGGGCCGGACTCGTCA 
Bcr-Abl Forward  GATGCTGACCAACTCGTGTG 
Bcr-Abl Reverse  AGCAGATACTCAGCGGCATT 
 
 
2.3.7  Media and solutions 
2.3.7.1  RPMI
++ 
RPMI 1640  440mL 
FCS  50mL 
L-glutamine (200mM)  5mL 
Penicillin/streptomycin solution  
(10,000 UmL
-1/ 10,000 gmL
-1) 
5mL 
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2.3.7.2  ‘DAMP’ solution 
DNase I (2 vials at ~2500 U/vial (1mL)  2mL 
Magnesium chloride (400X, 1.0 M stock)  1.25mL 
Trisodium citrate (0.155M)  53mL 
Human Serum Albumin (20%, SNBTS)  25mL 
Dulbecco’s PBS (magnesium/calcium free)  418.75mL 
 
2.3.7.3  Serum free medium (SFM) 
BIT  25mL 
L-glutamine (200mM)  1.25mL 
Penicillin/streptomycin solution 
(10,000 UmL
-1/ 10,000 gmL
-1) 
1.25mL 
2-mercaptoethanol (50mM)  250 L 
Low density lipoprotein (10 mg/mL)    500 L 
IMDM  97.25mL 
Make up in a sterile bottle then filter sterilise using a Vacubottle. 
2.3.7.4  SFM supplemented with five growth factors (SFM + 5GFs) 
Serum free medium  10mL 
IL-3 (50 g/mL)  4 L 
IL-6 (50 g/mL)  4 L 
G-CSF (20 g/mL)  10 L 
Flt3L (50 g/mL)  20 L 
SCF (50 g/mL)  20 L 
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2.3.7.5  SFM supplemented with physiological growth factors (SFM + PGFs) 
Serum free medium  10mL 
SCF (0.5 g/mL)  4 L 
G-SCF (2 g/mL)  5 L 
GM-CSF (0.1 g/mL)  20 L 
IL6 (5 g/mL)  2 L 
LIF (0.1 g/mL)  5 L 
MIP-a (0.1 g/mL)  20 L 
Filter through 0.22 M filter   
 
2.3.7.6  NP-40 Protein lysis buffer 
dH2O  8.7mL 
NaCl  (5M)  300 L 
Hepes-NaOH (1M, pH 7.5)  200 L 
EDTA (100mM)  200 L 
NP-40   50 L 
PMSF (100mM)  100 L 
Sodium fluoride (500mM)  40 L 
Sodium orthovanadate (500mM)  20 L 
Sodium pyrophosphate (100mM)  100 L 
2-glycerophosphate (1M)  200 L 
Leupeptin (1mg/mL)  50 L 
Aprotinin (1mg/mL)  22 L 
 
 Peixun Zhou, 2011                                                                                          Chapter 2                                                                               
 
 
102 
2.3.7.7  Transfer buffer 
NuPAGE
® Transfer Buffer (20X)  30mL 
dH2O  510mL 
Methanol  60mL 
 
2.3.7.8  10X TBS buffer 
NaCl  876.6g 
Tris   121.1g 
dH2O  10L 
Adjust pH to 8.0 
 
2.3.7.9  1X TBST buffer 
10X TBS buffer  1L 
TWEEN 20  10mL 
dH2O  8.99L 
 
2.3.7.10  2X Reverse Transcription Master Mix (10µL) 
10X RT Buffer   2 L 
25X dNTP Mix  0.8 L 
10X RT Random Primers  2 L 
Reverse Transcriptase  1 L 
Nuclease free H2O  4.2 L 
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2.3.7.11  PCR Mix (50µL)  
10X PCR Buffer   5 L 
dNTP Mix (1000 M)  10 L 
Taq polymerase  0.25 L 
Forward primer (100 M)  0.25 L 
Reverse primer (100 M)  0.25 L 
MgCl2 (25mM)  5 L 
cDNA  1 L 
Nuclease free H2O  28.25 L 
 
 
2.3.7.12  10X TBE buffer 
Boric Acid  55g 
EDTA (0.5M, pH8.0)  40mL 
Tris Base  108g 
dH2O  1L 
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3  Results 1: Treatment of CML cells with IM and LMB  
3.1  Introduction 
Despite  the  success  of  TKI  in  treating  CML,  Bcr-Abl  mRNA  and  DNA  are  still 
detectable in CML patients who have achieved CCgR and even CMR (143;182). In 
addition, the primitive CML stem cell population is insensitive to TKI treatment (201), 
and may lead to disease relapse. Therefore, new strategies must be developed to 
eradicate this TKI-insensitive CML stem cell population in order to cure CML. 
 
There are three NLSs and one NES in the Abl protein, and Abl constantly shuttles 
between the cytoplasm and the nucleus (72;245), and these localisation signals are 
intact in the Abl portion of the Bcr-Abl fusion protein. However,  Bcr-Abl protein is 
exclusively located in the cytoplasm of expressing fibroblasts and K562 cells (198), 
but Vigneri and Wang have reported that inhibition of phosphorylation of Bcr-Abl by 
IM  could  induce  nuclear  import  of  Bcr-Abl  protein  (198).  In  their  study,  nuclear 
entrapment of Bcr-Abl by LMB resulted in apoptosis of transfected fibroblasts and 
K562 cells induced by reactivation of Bcr-Abl tyrosine kinase activity in the nucleus 
(198). In addition, they treated K562 cells with IM and LMB for 72 hours followed by 
drug washout, and K562 cells were eliminated six days after drug removal, but not 
with IM or LMB alone treatment (198). These findings suggest that long term drug 
exposure was not required. However, they did not test this combination in human 
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Furthermore,  Aloisi  et  al  reported  that  sequential  treatment  of  CML  myeloid 
progenitors with IM then LMB effectively reduced the number of Bcr-Abl
+ colonies 
with limited effects on normal CD34
+ cells (246). Their rational was that the initial 12-
hour  IM  treatment  inhibited  Bcr-Abl  tyrosine  kinase  activity,  and  induced  nuclear 
localisation of Bcr-Abl protein. The addition of LMB for another 12 hours trapped Bcr-
Abl inside the nucleus. Finally, drug washout at the end of the treatment reactivated 
Bcr-Abl tyrosine kinase in the nucleus, and induced apoptosis via the p73 pathway 
(198;246). In that report Aloisi et al demonstrated a cytostatic effect of the sequential 
IM  and  LMB  treatment  on  CML  myeloid  progenitors  by  colony-forming  assay. 
However,  the  cytotoxicity  of  the  sequential  regimen  on  CML  cells  has  not  been 
investigated.  
 
Thus, the aims of this chapter were to investigate the cytotoxic efficacy of 72-hour 
continuous IM and LMB combined treatment in human primary CML progenitors, and 
evaluate the cytotoxic effect of the sequential IM and LMB treatment on CML cells.  
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3.2  IC50 of LMB in K562, KCL22 and HL60 cells 
In  order  to  assess  the  cytotoxicity  of  LMB,  the  50%  proliferation  inhibitory 
concentrations (IC50) of LMB were investigated in Bcr-Abl
+ CML cell lines K562 and 
KCL22,  and  in  Bcr-Abl
–  AML  cell  line  HL60.  Cells  were  treated  with  LMB  with 
concentrations from 0.625 to 40nM for 24 and 72 hours. The number of viable cells 
was counted with trypan blue (Figure   3-1), and the IC50 values are shown in Table 
  3-1.  
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KCL22 Cells
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Figure   3-1: Determination of IC50 for LMB in K562, KCL22 and HL60 cells.  
Viable cells were counted by trypan blue at 24 and 72 hours. The percentage of cells in 
each  treatment  compared  with  no  drug  control  (NDC,  100%,  the  untreated  at  each 
corresponding time-point) were calculated and is presented as mean ± SEM (n=3). LMB 
concentrations are plotted in Log2 scale.  
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  Leptomycin B (LMB) IC50 (nM) 
Time (hours)  K562  KCL22  HL60 
24  26  7  5 
72  7  3  2 
 
Table   3-1: IC50 for LMB in K562, KCL22 and HL60 cells at 24 and 72 hours.  
Estimated from mean values in the above figure.  
 
Vigneri and Wang used 10µM IM and 10nM LMB in their cell survival assays (198), as 
did Aloisi et al in their colony-forming assays (246). Since the experiments in this 
chapter  were  designed  as  follow-up  of  their  investigations  and  the  observed  IC50 
values for LMB were also in the low nM range, 10µM IM and 10nM LMB were used in 
the subsequent experiments.   
3.3  Continuous treatment of IM and LMB in CML cells  
To investigate the cytotoxicity of IM and LMB combined treatment in human primary 
CML CD34
+ progenitors, cells were treated with 10µM IM, 10nM LMB or both drugs 
continuously for 72 hours. Then drugs were washed out and cells were plated into 
fresh medium. The number of cells in each treatment was counted with trypan blue 
every 2 or 3 days. Fresh medium was added after cell counting and cell density was 
adjusted to the original seeding density if necessary. Dilution factors were calculated 
every time when fresh media was added, and the total number of counted viable cells Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
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multiplied by the corresponding dilution factors. Non-CML (Lymphoma) CD34
+ cells 
were used as a Bcr-Abl
– control. 
 
As shown in Figure   3-2A, the 72-hour IM and LMB continuous treatment regimen did 
not eliminate CML CD34
+ cells. Although it caused a one-log reduction of cell counts 
compared with input three days after drug washout, these cells then recovered and 
continue  to  grow.  An  alternative  scheduling  regimen  of  the  two  drugs,  such  as 
sequential  treatment,  might  be  effective  in  killing  primary  CML  CD34
+  cells.  In 
addition, the LMB alone arm showed very similar effect as the combined treatment 
arm in CML CD34
+ cells (Figure   3-2A), indicating the combined treatment does not 
improve  cytotoxic  effect  with  respect  to  LMB  alone.  Furthermore,  LMB  inhibited 
proliferation of non-CML CD34
+ cells (Figure   3-2B), demonstrating the non-specific 
cytotoxicity  of  this  compound.  However,  CML  CD34
+  cells  did  appear  to  be  more 
sensitive to LMB than non-CML CD34
+ cells.  
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CML CD34
+ (A) and non-CML CD34
+ (B) cells were treated with 10µM IM, 10nM LMB or 
both  drugs  for  72  hours.  Drugs  were  washed  out  with  PBS  at  the  end  of  72-hour 
treatment, and cells were plated in fresh medium. The number of viable cells in each 
treatment was counted with trypan blue at Day 3, 6, 8, 11, 13 and 16. Cell counts were 
plotted in log10 scale and presented as mean ± SEM (n=3, CML samples 223, 236 and 
255. Non-CML samples 006, 007 and 011). CD34
+ cells were plated at 5 X 10
5 cells/mL in 
2 mL cultures in SFM + 5GFs medium.  
3.4  Sequential treatment of IM and LMB in CML cell lines 
After the failure of IM and LMB continuous treatment to eliminate CML progenitors, 
the  effects  of  IM  and  LMB  sequential  treatment  were  investigated  in  CML  cells, 
initially in CML cell lines. K562 and KCL22 cells were treated with 10µM IM for 12 
hours, and then 10nM LMB was added in without change of culture medium. The 
cells were incubated with both IM and LMB for another 12 hours, after that, drugs 
were washed out with PBS and the cells were plated into fresh medium (as illustrated 
in Figure   3-3A). This sequential regimen was adopted from the report by Aloisi et al 
(246).  
 
The adjusted total cell counts in each treatment are shown in Figure   3-3B and C. It 
was shown that 10µM IM significantly inhibited proliferation of both K562 and KCL22 
cell lines (p<0.05 since Day 3 and p<0.05 since Day 6, respectively; Figure   3-3B and 
C). In addition, K562 cells, but not KCL22 cells, were eliminated by IM at the end of 
the experiments, indicating that K562 is more sensitive to IM than KCL22. Although Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
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the  IM+LMB  treatment  arm  had  lower  cell  counts  than  the  IM  alone  arm,  the 
difference was not statistically significant in either K562 or KCL22 cells (p>0.07 at all 
time-points).  This  suggested  that  the  sequential  IM  and  LMB  treatment  did  not 
significantly reduce the proliferation of CML cell line cells compared to IM alone. 
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C 
 
Figure   3-3: IM and LMB scheduling treatment in K562 and KCL22 cells.  
Diagram illustrating the scheduling treatment strategy with IM and LMB in CML cells. 
Drugs were washed out at the end of 24-hour treatment, and cells were plated in fresh 
medium. The number of viable cells in each treatment was counted with trypan blue at 
Day 1, 3, 6, 8 and 10. Cell counts were plotted in log10 scale in graph B (K562 cells) 
and C (KCL22 cells), and presented as mean ± SEM (n=4). Cells were plated at 2 X 10
5 
cells/mL in 2 mL cultures.   
 
0 2 4 6 8 10
1
10
100
1000
10000
Untreated
10mM IM
10nM LMB
10mM IM+10nM LMB
Drugs washed out
Days of Treatment
T
o
t
a
l
 
C
e
l
l
 
C
o
u
n
t
s
 
(
X
1
0
4
)Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
 
 
114 
3.5  Sequential treatment of IM and LMB in BaF3 wild type and Bcr-
Abl expressing cells 
In order to assess whether sequential IM and LMB treatment differentially affect Bcr-
Abl positive and negative cells, the sequential treatment was applied to Ba/F3 wild 
type  and  Ba/F3  Bcr-Abl  expressing  cells  (Ba/F3  p210).  LMB  (10nM)  inhibited 
proliferation of both Ba/F3 wild type and p210 cells by about one log compared to the 
untreated arm, again showing the non-specific cytotoxicity of this drug. As expected, 
10µM IM eliminated Ba/F3 p210 cells at Day 8 (Figure   3-4B), but had mild though 
significant inhibition of proliferation of Ba/F3 wild type cells compared to the untreated 
(p<0.05 at every time-point; Figure   3-4A).  
 
However,  there  was  no  statistical  significant  difference  between  IM+LMB  and  IM 
treatment arms in Ba/F3 p210 cells (p>0.07 at every time-point; Figure 3-3B). This 
result confirms that sequential IM and LMB treatment did not induce more cell death 
compared to IM only in the Bcr-Abl transduced cell line in a similar way to the Ph
+ 
CML cell lines. Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
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Ba/F3 wild type (A) and Ba/F3 Bcr-Abl expressing cells (B) were treated with IM and 
LMB  in  the  schedules  shown  in  Figure    3-3A.  The  number  of  viable  cells  in  each 
treatment was counted with trypan blue. Cell counts were plotted in log10 scale, and 
presented as mean ± SEM (n=4).  Cells were plated at 2 X 10
5 cells/mL in 2 mL cultures.  
10ng/mL IL-3 was added as a supplement to parental Ba/F3 cell culture medium. 
3.6  Sequential treatment of IM and LMB in CML primary cells 
In order to test the effect of the sequential treatment on CML progenitors, primary 
CML CD34
+ cells were treated with the same scheduling regimen as in CML cell lines, 
and it was found that both IM and IM+LMB treatment arms significantly inhibited cell 
proliferation  compared  to  the  untreated  arm  at  Day  3  (p=0.002  and  p=0.014, 
respectively), Day 6 (p=0.004 and p=0.009, respectively) and Day 10 (p=0.05 and 
p=0.01, respectively). Unlike in CML cell lines, IM and IM+LMB treatment arms did 
not reduce cell counts of primary CD34
+ cells to lower than input at later time-points, 
showing just a mild cytostatic effect (Figure   3-5A).  
 
On  the  other  hand,  there  was  no  statistical  significant  difference  between  IM  and 
IM+LMB treatment arms at each time-point (p>0.35 at every time-point; Figure   3-5A), 
suggesting  that  sequential  IM  and  LMB  treatment  did  not  preferentially  inhibit 
proliferation of primary CML CD34
+ cells compared to IM alone.  
 
In addition, the percentage of viable cells in each treatment was measured by flow 
cytometry  of  staining  cells  with  Annexin  V  and  Via-Probe  (Figure    3-5B).  Cells Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
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negative  for  both  Annexin  V  and  Via-Probe  staining  were  considered  viable.  It 
showed that the difference between IM+LMB and LMB treatments was not statistically 
significant (p>0.32 at every time-point), although significant difference was observed 
between IM+LMB and IM treatments on Day 1 and Day 3 (p=0.028 and p=0.022, 
respectively). These data suggested that sequential IM and LMB treatment did not 
further induce apoptosis of primary CML CD34
+ cells compared to LMB alone.   
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Figure   3-5: IM and LMB scheduling treatment in primary CML CD34
+ cells.  
(A) Viable cell counts with trypan blue were plotted in log10 scale  (B) Percentage of 
viable cells in each treatment compared with untreated as analyzed by flow cytometry 
with Annexin V and Via-Probe (mean ± SEM, n=2, CML235 and CML255, each sample 
was plated in duplicates). Cells were plated at 5 X 10
5 cells/mL in 2 mL cultures in SFM 
+ 5GFs medium. (*p<0.05)  
3.7  Nuclear localisation of Bcr-Abl in IM and LMB treated CML cells 
To determine whether the Bcr-Abl protein was translocated into cell nucleus after IM 
and LMB exposure as per the hypothesis, KCL22 cells were treated with 10 M IM 
and 10nM LMB for 4 hours. Subsequently, cells were stained with a Bcr-Abl b2a2 
junction specific antibody and prepared for immunofluorescence microscopy. It was 
observed that the vast majority of the Bcr-Abl protein was located in the cytoplasm of Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
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untreated  KCL22  cells  (Figure    3-6).  However,  after  treatment  with  IM  and  LMB  a 
significant proportion of Bcr-Abl protein was observed in the nucleus of KCL22 cells.  
 
 
 
 
Figure   3-6: Nuclear localisation of Bcr-Abl in KCL22 cells treated with IM and LMB.  
KCL22 cells were treated with 10 M IM and 10nM LMB for 4 hours and then stained 
with  Bcr-Abl  b2a2  junction  specific  antibody  (Red)  for  examination  by 
immunofluorescence microscopy. DNA was stained with DAPI (Blue).  
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3.8  Summary and Discussion 
Overall, these findings demonstrated that neither continuous nor sequential regimens 
with  IM  and  LMB  in  CML  cell  lines  or  primary  CD34
+  cells  significantly  increased 
inhibition  of  cell  proliferation  more  than  IM  alone.  It  was  also  shown  that  the 
sequential treatment did not significantly induce more apoptosis than LMB alone in 
primary CML CD34
+ cells.  
 
Previously  researchers  showed  that  72-hour  continuous  IM  and  LMB  treatment 
regimen  could  preferentially  induce  apoptosis  and  eliminate  K562  cells  (198). 
However, it is observed in this chapter that the combination strategy does not kill 
primary CML CD34
+ cells more effectively than LMB alone (247). In addition, Aloisi et 
al  showed that sequential IM and LMB treatment (as illustrated in Figure   3-3A) had 
greater reduction in the colony-forming ability of CML myeloid progenitors compared 
with  IM  or  LMB  alone,  and  the  sequential  treatment  preferentially  targeted  CML 
myeloid progenitors compared to their healthy counterparts in terms of clonogenicity 
(246).  Here  in  this  chapter,  the  cytotoxic  effect  of  the  sequential  IM  and  LMB 
treatment was investigated in CML cell lines and progenitors, and it was determined 
that the sequential regimen did not improve the cytotoxic effect of IM in Bcr-Abl
+ cell 
lines and primary CML CD34
+ cells, although this regimen demonstrated cytostatic 
effect by colony-forming assays in CML myeloid progenitors (246).  
 
Patel et al showed the presence of Bcr-Abl protein in the nucleus of primary CML 
CD34
+ cells, but not in the nucleus of CML cell line BV173 (248), implying that CML Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
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progenitors are able to tolerate nuclear Bcr-Abl tyrosine kinase to a certain extent. 
This  might  explain  the  ineffectiveness  of  continuous  and  sequential  IM  and  LMB 
treatment in this chapter. Another explanation is the de novo synthesis of CRM1 after 
drug washout, leading to the impairment of LMB effect with subsequent transportation 
of Bcr-Abl protein back out of the cell nucleus.   
   
In the sequential regimen, cell counts of Bcr-Abl
+ cells were reduced to less than 
input by exposure to IM, and IM eliminated K562 and Ba/F3 p210 cells (Figure   3-3B 
and  C;  Figure    3-4B),  demonstrating  the  cytotoxic  effect  of  IM  on  these  cell  lines. 
However,  IM  showed  mild  cytostatic  effect on  CML  CD34
+  cells in  both  regimens 
(Figure    3-2A  and  Figure    3-5A),  demonstrating  the  persistence/resistance  of  these 
progenitor cells to IM. In addition, 72-hour continuous LMB treatment led to a one-log 
reduction of cell counts three days after drug washout, showing the cytotoxicity of 
LMB  in CML CD34
+ cells (Figure   3-2A), while no reduction was observed in the LMB 
alone treatment arm after drug washout in the sequential treatment (Figure   3-5A). 
This may be because cells were only treated with LMB for 12 hours in the sequential 
regimen. Furthermore, since the sequential IM and LMB treatment did not enhance 
kill of primary CML bulk CD34
+ cells compared with IM and LMB alone, the rare, more 
primitive  CD34
+CD38
–  stem  cell  subset  or  normal  primary  CD34
+  cells  were  not 
tested with the sequential regimen.  
 
Nuclear accumulation of Bcr-Abl protein was observed in IM and LMB treated KCL22 
cells (Figure   3-6), but the majority of Bcr-Abl was still retained in the cytoplasm. This Peixun Zhou, 2011                                                                                          Chapter 3                                                                                                       
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is consistent with our previous observation (247). We reported increase of nuclear 
Bcr-Abl protein in K562 cells after 4-hour IM and LMB exposure as measured by 
Western  blotting  with  nuclear  extraction,  but  the  cytoplasmic  Bcr-Abl  level  was 
maintained  as  high  as  the  untreated  (247).  In  addition,  Vigneri  and  Wang  made 
similar observations. They demonstrated that only 25-35% Bcr-Abl was trapped in the 
nucleus of the Bcr-Abl expressing fibroblasts treated with IM and LMB (198).  
 
Copland et al reported the resistance of primary CML CD34
+ cells to IM treatment, 
and  showed  the  second  generation  TKI  dasatinib  was  much  more  effective  in 
inhibiting Bcr-Abl tyrosine kinase activity in the primitive CML population (163). This 
led to the speculation that the IM used in the continuous and sequential regimens did 
not sufficiently block Bcr-Abl tyrosine kinase, and dasatinib may be a better TKI to 
use in these regimens. However, Vigneri and Wang observed the nuclear fraction of 
Bcr-Abl was around the same level in kinase-defective Bcr-Abl expressing fibroblasts 
treated with LMB only, or NES-inactivated Bcr-Abl expressing fibroblasts treated with 
IM for 24 hours (198), eliminating the possibilities of incomplete inhibition of Bcr-Abl 
tyrosine  kinase  activity  by  IM  or  nuclear  exportation  by  LMB.  These  observations 
indicate other mechanisms apart from Bcr-Abl tyrosine kinase activity retaining Bcr-
Abl protein in the cytoplasm of CML cells.  
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4  Results 2: Subcellular localisation of Bcr-Abl protein in 
CML progenitor cells  
4.1  Introduction 
In the previous chapter, it was observed that most of the Bcr-Abl protein was in the 
cytoplasm of KCL22 cells after IM and LMB exposure, although a fraction of Bcr-Abl 
was  accumulated  in  the  nucleus  (Figure    3-6).  Retention  of  Bcr-Abl  protein  in  the 
cytoplasm of IM and LMB treated K562 cells (247) and Bcr-Abl expressing fibroblasts 
(198) has also been reported. The mechanism of cytoplasmic retention of Bcr-Abl in 
CML cells when Bcr-Abl tyrosine kinase activity is inhibited is still not clear. However, 
cytoplasmic Bcr-Abl is known to promote cell proliferation and survival (44;68), while 
nuclear Bcr-Abl tyrosine kinase activity induces apoptosis (198). Thus, cytoplasmic 
retention  of  Bcr-Abl  is  a  possible  survival  mechanism  in  CML  cells  against  TKI 
treatment,  and  impairment  of  Bcr-Abl  cytoplasmic  retention  may  provide  a  novel 
therapeutic approach to cure CML.  
 
It was hypothesised that the Bcr-Abl protein was retained in the cytoplasm of TKI 
insensitive  primary  CML  CD34
+  cells,  and  that  this  retention  was  caused  by  its 
cytoplasmic binding partners. Therefore, the aims of the study in this section were to 
examine the subcellular localisation of Bcr-Abl protein in human primary CML CD34
+ 
cells with or without TKI treatment, and investigate its cytoplasmic binding partners 
which potentially retain Bcr-Abl protein in the cytoplasm.        Peixun Zhou, 2011                                                                                          Chapter 4                                                                                                       
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4.2  Validation of the Bcr-Abl b2a2 junction specific antibody  
In  order  to  visualize  subcellular  localisation  of  Bcr-Abl  protein  in  CML  cells, 
immunofluorescence  microscopy  was  employed  with  a  specific  Bcr-Abl  antibody. 
Since the only commercially available Bcr-Abl antibody is b2a2 junction specific and 
was released onto the market relatively recently, the specificity of this novel antibody 
was initially tested. Figure   4-1A shows the examination of the specificity of the Bcr-
Abl b2a2 junction specific antibody by Western blotting. It is known that KCL22 cells 
express Bcr-Abl protein with b2a2 junction and K562 cells with b3a2 junction. HL60 
cells are Bcr-Abl negative. It was shown that Bcr-Abl protein was detected in KCL22 
cell  lysate,  but  not  in  K562  or  HL60  cell  lysate  (Figure    4-1A),  demonstrating  the 
specificity of the Bcr-Abl b2a2 junction specific antibody.   
 
However, the background of the Western blot was high and the Bcr-Abl protein band 
was  quite  weak  and  not  very  sharp.  Thus,  immunoprecipitation  (IP)  was  used  to 
concentrate Bcr-Abl protein. As shown in Figure   4-1B, the b2a2 Bcr-Abl protein in 
KCL22  cell  lysate  was  immunoprecipitated  by  the  b2a2  junction  specific  Bcr-Abl 
antibody, but not by its corresponding mouse IgG2a isotype control. In addition, no 
b3a2  Bcr-Abl  protein  was  pulled  down  from  the  K562  cell  lysate.  These  results 
demonstrated  that  the  Bcr-Abl  antibody  specifically  detected  Bcr-Abl  protein  with 
b2a2 junction. Peixun Zhou, 2011                                                                                          Chapter 4                                                                                                       
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Figure   4-1: Validation of the Bcr-Abl b2a2 junction specific antibody by (A) Western 
blotting and (B) immunoprecipitation.  
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(A) Western blotting with K562, KCL22 and HL60 cell lysates, and the blot was probed 
with the Bcr-Abl b2a2 junction specific antibody.  Actin was used as a loading control. 
(B) Immunoprecipitation with the Bcr-Abl b2a2 junction specific antibody in KCL22 and 
K562  lysates,  as  well  as  mouse  IgG2a  isotype  in  KCL22  lysate.  The 
immunoprecipitates  were  analysed  by  Western  blotting  and  probed  with  c-Abl 
antibody.         
 
Moreover, to investigate subcellular localisation of Bcr-Abl protein, CML cells need to 
be  stained  with  the  Bcr-Abl  b2a2  junction  specific  antibody  and  observed  with  a 
fluorescence microscope. Thus, the specificity of this antibody was examined with 
fluorescence microscopy as well. KCL22, K562 and HL60 cells were stained with the 
antibody,  and  only  KCL22  cells  showed  positive  staining  (Figure    4-2D,  red 
fluorescence). KCL22 cells stained with mouse IgG2a isotype was negative (Figure 
  4-2A). This result concludes that the Bcr-Abl antibody is b2a2 junction specific, and it 
is compatible with fluorescence microscopy.   
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Figure   4-2: Validation of Bcr-Abl b2a2 specific antibody with fluorescence microscopy.  
(A) KCL22 cells stained with IgG2a isotype control. (B) HL60 cells, (C) K562 cells and 
(D) KCL22 cells stained with the Bcr-Abl b2a2 junction specific antibody (Red). Cell 
nuclei were stained with DAPI (blue).  
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4.3  Identification of CML CD34
+ samples expressing b2a2 Bcr-Abl   
In order to stain primary CML CD34
+ samples using this Bcr-Abl b2a2 junction specific 
antibody, CML samples expressing b2a2 Bcr-Abl protein rather than b3a2 need to be 
identified. A pair of Bcr-Abl primers were designed which spanned the junction region 
of the Bcr-Abl gene (as illustrated in Figure   4-3A). Total mRNA was extracted from 
primary CML CD34
+ cells and reversed transcribed into complementary DNA (cDNA). 
Polymerase chain reaction (PCR) was performed with the Bcr-Abl primers and the 
cDNA.  In  theory,  the  PCR  products  are  486  base  pairs  (bp)  with  b3a2  Bcr-Abl 
templates,  and  411bp  with  b2a2  Bcr-Abl  templates.  Thus,  b3a2  and  b2a2  CML 
samples  are  able  to  be  distinguished  by  the  size  of  their  PCR  products  after 
separation  by  gel  electrophoresis.  As  shown  in  Figure    4-3B,  primary  CML  CD34
+ 
samples 250, 273, 274 and 281 were identified as b2a2 Bcr-Abl samples. K562 and 
KCL22 cells were used as controls, as they were known as b3a2 and b2a2 Bcr-Abl 
expressing cells respectively.   
 
In  addition,  the  specificity  of  the  Bcr-Abl  b2a2  junction  specific  antibody  in  these 
primary b2a2 CML cells was validated by immunoprecipitation. It was demonstrated 
that Bcr-Abl protein was pulled down by the antibody, as well as c-Abl protein (Figure 
  4-4). The presence of c-Abl in the pull-down lysate was probably due to the binding of 
Bcr-Abl with c-Abl in these cells. It was reported that there is a SH2 binding domain in 
the Bcr part of Bcr-Abl, and the SH2 domain of c-Abl can associate with Bcr-Abl in a 
phosphotyrosine independent manner (63).      
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Figure   4-3: Identification of primary CML CD34
+ samples with b2a2 Bcr-Abl by PCR.  
(A)  Diagram  illustrating  the  annealing  of  the  primers  on  b2a2  and  b3a3  Bcr-Abl 
templates.  (B)  Partial mRNA  sequence  of  b3a2  Bcr-Abl,  showing  annealing  sites  of 
forward  (blue)  and  reverse  (pink)  primers.  The  sequence  was  obtained  from  NCBI 
GenBank with Accession No. AJ131466. (C) Gel electrophoresis of PCR products to 
identify b2a2 Bcr-Abl samples. Actin was used as a positive control.  
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Figure   4-4: Validation of Bcr-Abl b2a2 specific antibody by immunoprecipitation.  
The  specificity  of  the  Bcr-Abl  b2a2  junction  specific  antibody  was  validated  in  the 
lysates  of  primary  CML  CD34
+  cells  expressing  b2a2  Bcr-Abl  protein.  Mouse  IgG2a 
isotype  was  used  as  a  negative  control.  The  immunoprecipitates  were  analysed  by 
Western blotting and probed with c-Abl antibody.               
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4.4  12-Day Dasatinib Treatment of CML CD34
+ cells 
After  identification,  b2a2  positive  CML  samples  250,  273  and  281  were  used  to 
investigate the subcellular localisation of Bcr-Abl protein in primary CML CD34
+ cells 
by  immunofluorescence  microscopy.  Hamilton  et  al  treated  CML  CD34
+  cells  with 
150nM dasatinib continuously for 12 days in vitro, and found about 10% of CML cells 
survived (249). This method of drug selection was adopted here in order to get TKI 
resistant/persistent cells. CML CD34
+ cells were thawed and cultured in serum free 
medium with five growth factors overnight to recover. Then the cells were washed 
and replated in serum free medium with physiological growth factors, with the addition 
of 150nM dasatinib (Day 0). Cells were replated with fresh medium and dasatinib 
every two or three days for 12 days. Physiological growth factors were used to mimic 
in  vivo  conditions.  Cells  without  dasatinib  treatment  were  also  cultured  in  similar 
conditions for 12 days as a control.  
 
At the end of treatment, the untreated cells and cells surviving dasatinib treatment 
were  stained  with  the  Bcr-Abl  b2a2  junction  specific  antibody  and  the  subcellular 
localisation  of  Bcr-Abl  protein  was  visualized  by  fluorescence  microscopy  (Figure 
  4-5A).  The  percentages  of  nuclear  Bcr-Abl  protein  relative  to  the  whole  cell  were 
measured by ImageJ software based on the red fluorescence (Figure   4-5B). It was 
shown that the percentages of nuclear Bcr-Abl protein in the untreated and dasatinib 
treated CML cells at the end of the 12-day treatment were 41.8 ± 2.2% and 50.5 ± 
3.0%  respectively  (n=18,  6  cells  from  each  CML  sample,  mean  ±  SEM),  and  the 
difference  between  them  is  statistically  significant  (p=0.024).  This  indicates  that Peixun Zhou, 2011                                                                                          Chapter 4                                                                                                       
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dasatinib treatment induced a fraction of Bcr-Abl protein to translocate into the cell 
nucleus from the cytoplasm, but a large proportion (almost half) of Bcr-Abl protein 
was still located in the cytoplasm of these treated cells.  
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Figure   4-5: Subcellular localisation of Bcr-Abl protein.  
(A) Localisation of Bcr-Abl protein in the untreated cells (NDC) and 150nM dasatinib 
treated primary CML CD34
+ cells at Day 12. Bcr-Abl protein was stained with the Bcr-
Abl b2a2 junction specific antibody (red) and cell nuclei were stained with DAPI (blue). 
(B) A scatter plot demonstrating the percentage of nuclear Bcr-Abl protein in NDC and 
150nM dasatinib treated primary CML CD34
+ cells at Day 12. The nuclear and whole cell 
red fluorescence intensities were measured with the ImageJ software (n=18, 6 cells 
from each CML sample), and the percentages of red fluorescence in the nuclei relative 
to in the whole cells were shown in the scatter plot.  
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In  the  mean  time,  the  effectiveness  of  dasatinib  as  a  TKI  in  this  experiment  was 
examined by measuring p-CrkL level in these cells. p-CrkL is a downstream effector 
of Bcr-Abl, and has been used as a convenient surrogate marker to measure Bcr-Abl 
tyrosine  kinase  activity  (161).  As  shown  in  Figure    4-6A,  p-CrkL  completely 
disappeared in the 150nM dasatinib treated CML CD34
+ cells at Day 4 and Day 12, 
with or without physiological growth factors. This indicates that the tyrosine kinase 
activity of Bcr-Abl protein was completely inhibited by dasatinib in this experiment.  
 
 
Figure    4-6:  A  representative  Western  blot  showing  the  inhibition  of  CrkL 
phosphorylation with 150nM dasatinib in primary CML CD34
+ cells.  
 
Although the subcellular localisation of Bcr-Abl has been revealed in the surviving 
cells, it is not clear whether they are still CD34
+ and at what stages of maturation they 
are at. In order to determine the phenotype of cells visualized in Figure   4-5A, the 
expression of the cell surface markers CD34, CD45 and CD133 were analysed by 
flow cytometry. CD45 is a common marker of leucocytes (250), CD34 is a marker of 
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haemopoietic  progenitor  cells  and  CD133  is  a  marker  of  primitive  haemopoietic 
progenitor  cells  (251).  At  Day  0, all  the  CML  cells  are  CD34
+ and  CD45
+  (Figure 
  4-7A), indicating all the cells are haemopoietic progenitors at this stage. At the end of 
12-day dasatinib treatment, the percentage of CD34
+ cells
 decreased to 7.2 ± 3.5% 
(n=3, mean ± SEM), while the vast majority of cells are still CD45
+. On the other 
hand, the primitive CD133
+ cells decreased from 14.1 ± 1.1% at Day 0 to 3.1 ± 0.21% 
at Day 12 of dasatinib treatment (Figure   4-7D). These data shows that the surviving 
cells from 12-day dasatinib treatment are mainly CD45
+, CD34
low/– and CD133
low/–. In 
addition,  there  is  no  statistical  significant  difference  between  NDC  and  dasatinib 
treatment arms regarding percentage of CD34
+ cells or CD133
+ cells at Day 4 and 
Day 12 (p≥0.082, Figure   4-7D). 
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Figure   4-7:  Representative flow cytometry plots.  
CML281 cells were stained with surface-markers and analyzed at Day 0 (A), Day 4 (B) 
and Day 12 (C) of 150nM dasatinib treatment. (D) Average percentages of CD34
+ cells 
and CD133
+ cells with CML samples 250, 273 and 281 in different treatment conditions.  
4.5  Bcr-Abl binding partners  
Previously it was shown that 50.5 ± 3.0% of Bcr-Abl protein was in the nucleus of 
dasatinib treated cells (Figure   4-5), suggesting that about 50% of Bcr-Abl protein was 
still retained in the cytoplasm of these cells. The cytoplasmic retention of Bcr-Abl may 
be due to its cytoplasmic binding partners. If these binding partners were identified, 
disruption of their binding with Bcr-Abl may induce nuclear translocation of the rest of 
cytoplasmic  Bcr-Abl  protein.  Thus,  the  co-localisation  of  Bcr-Abl  and  its  binding 
partners was investigated in the Day 12 dasatinib treated primary CML CD34
+ cells. 
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F-actin is a known Bcr-Abl binding partner and there is an F-actin binding domain in 
the  C-terminus  of  Bcr-Abl  protein  (73).  Impairment  of  F-actin  binding  has  been 
reported to decrease the transforming ability of Bcr-Abl protein (73). However, the 
role of F-actin retaining Bcr-Abl in the cytoplasm of TKI-insensitive primary CML cells 
is not clear. Thus, co-localisation of Bcr-Abl and F-actin was investigated in Day 12 
dasatinib  treated  primary  CML  CD34
+  cells  by  immunofluorescence  microscopy 
(Figure    4-8). Another possible group of binding partner is the 14-3-3 family it has 
been reported that nucleocytoplasmic shuttling of c-Abl protein was regulated by 14-
3-3 proteins whereby 14-3-3 sequestered c-Abl protein in the cytoplasm by binding to 
its phosphorylated Thr735 residue (231). Upon DNA damage or oxidative stress, JNK 
is phosphorylated which in turn phosphorylates 14-3-3, resulting in the release and 
nuclear translocation of c-Abl (231). Since the Abl part of Bcr-Abl protein contains the 
14-3-3  binding  site  (i.e.  Thr735  residue),  it  could  be  hypothesized  that  14-3-3 
associate with Bcr-Abl and sequester it in the cytoplasm. Therefore, Bcr-Abl and 14-
3-3 proteins were stained and visualized by immunofluorescence microscopy (Figure 
  4-9), in order to examine if they co-localised in the Day 12 dasatinib treated primary 
CML  CD34
+  cells.  It  was  observed  that  a  small  proportion  of  Bcr-Abl  protein  co-
localised with F-actin or 14-3-3 proteins in both NDC and dasatinib treated cells. 
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Figure    4-8:  Co-staining  of  Bcr-Abl  and  F-Actin  in  12-Day  150nM  dasatinib  treated 
primary CML CD34
+ cells, as well as the 12-Day untreated cells (NDC).  
Bcr-Abl protein was stained with the Bcr-Abl b2a2 junction specific antibody (red), F-
Actin  was  stained  with  Alexa  Fluor  488
®  phalloidin  (green),  and  overlay  shows  the 
merge  of  red  and  green  channels.  Cell  nuclei were  stained with DAPI  (blue). White 
arrows indicate some of the co-localised pixels.  
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Figure    4-9:  Co-staining  of  Bcr-Abl  and  14-3-3  in  12-Day  150nM  dasatinib  treated 
primary CML CD34
+ cells, as well as the 12-Day untreated cells (NDC).  
Bcr-Abl protein was stained with the Bcr-Abl b2a2 junction specific antibody (red), 14-
3-3 proteins were stained with a Pan-14-3-3 antibody (green), and overlay shows the 
merge  of  red  and  green  channels.  Cell  nuclei were  stained with DAPI  (blue). White 
arrows indicate some of the co-localised pixels.  
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In order to confirm the association of Bcr-Abl and 14-3-3 proteins in CML cells, and 
investigate  if  IM  can  disrupt  their  association,  Bcr-Abl  and  14-3-3  proteins  were 
immunoprecipitated  by  Bcr-Abl  b2a2  junction  specific  antibody  and  pan  14-3-3 
antibody respectively in KCL22 cells with or without 1 M IM treatment for 2 hours. It 
was observed that 14-3-3 proteins were detected in the Bcr-Abl immunoprecipitates, 
and that Bcr-Abl was also detected in the 14-3-3 immunoprecipitates as well (Figure 
  4-10). This demonstrates the binding of Bcr-Abl and 14-3-3 proteins in KCL22 cells. In 
addition, Bcr-Abl and 14-3-3 are still associated with each other in the presence of IM 
(Figure   4-10), indicating that IM treatment in KCL22 cells did not disrupt Bcr-Abl/14-3-
3 complex and their association was independent of Bcr-Abl tyrosine kinase activity.  
 
Figure   4-10: Immunoprecipitation showing Bcr-Abl/14-3-3 association in KCL22 cells.  
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KCL22  cells  were  treated  with  or  without  1 M  IM  for  2  hours.  Bcr-Abl  and  14-3-3 
proteins  were  pulled  down  by  the  Bcr-Abl  b2a2  junction  specific  and  pan  14-3-3 
antibodies respectively. c-Abl and 14-3-3 antibodies were used on Western blotting. 
WCL: Whole Cell Lysate.  
 
It  was  observed  that  some  Bcr-Abl  protein  was  located  in  close  proximity  to  the 
plasma  membrane  in  CML  cells  (Figure    4-8  and  Figure    4-9).  Lipid  rafts  are 
glycolipoprotein  microdomains  in  the  cytoplasmic  membrane,  which  serve  as 
integrating centres for the assembly of signalling molecules (252). Therefore, it was 
interesting  to  investigate  if  Bcr-Abl  associated  with  lipid  rafts  as  they  are  both 
integrators of signalling molecules.  
  
Monosialotetrahexosylganglioside  (GM1)  is  a  component  of  the  cytoplasmic 
membrane  and  is  enriched  in  lipid  rafts,  and  clustering  of  GM1  can  be  used  to 
indicate  the  presence  of  lipid  rafts  (253).  Cholera  toxin  subunit  B  (CTxB)  binds 
specifically to GM1 and fluorophore-conjugated CTxB is commonly used to detect 
GM1, and therefore lipid rafts (253). A fraction of Bcr-Abl was found co-localised with 
GM1 clusters in KCL22 cells and primary CML cells (Figure   4-11, as indicated by 
white arrows). With 12-day dasatinib treatment, some GM1 aggregates are still co-
localised with Bcr-Abl (Figure   4-11B). This indicates that lipid rafts might be involved 
in the cytoplasmic retention of Bcr-Abl in CML cells.  
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Figure   4-11: Co-staining of Bcr-Abl and GM1. 
Bcr-Abl (red) and GM1 (green) were stained in KCL22 cells (A) and CML281 primary 
cells (B). Bcr-Abl protein was detected by the Bcr-Abl b2a2 junction specific antibody 
and  GM1  was  visualized  by  Alexa  Fluor  488  conjugated  CTxB.  CML281  cells  were 
sampled from the end of 12-Day 150nM dasatinib treatment experiment. White arrows 
indicate some of the co-localised pixels. 
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4.6  Summary and discussion 
In  summary,  the  specificity  of  the  Bcr-Abl  b2a2  junction  specific  antibody  was 
validated  by  Western  blotting,  immunoprecipitation  and  immunofluorescence 
microscopy.  Then  the  subcellular  localisation  of  Bcr-Abl  protein  in  TKI 
resistant/persistent primary CML CD34
+ cells was measured by immunofluorescence 
microscopy. It was shown that there was a significant increase in nuclear Bcr-Abl in 
12-Day 150nM dasatinib treated cells with respect to NDC, while about 50% of Bcr-
Abl was stilled retained in the cytoplasm of treated cells. Cell surface marker staining 
showed the surviving cells had greatly reduced CD34 and CD133 surface expression, 
implying that these cells were losing ‘stemness’. In addition, a small proportion of Bcr-
Abl protein was found co-localised with F-actin or 14-3-3 proteins in the surviving 
cells, indicating the cytoplasmic retention of Bcr-Abl might be due to its binding with 
F-actin  or  14-3-3  proteins.  The  association  of  Bcr-Abl  and  14-3-3  proteins  was 
confirmed by immunoprecipitation in KCL22 cells, while IM treatment did not disrupt 
their association. Furthermore, the molecular signalling organizing centres, lipid rafts, 
might be involved in the cytoplasmic retention of Bcr-Abl. 
 
Bcr-Abl  protein  had  been  previously  found  located  in  the  cytoplasm  of  Bcr-Abl 
expressing fibroblasts, K562, and BV173 cells (198;248), while nuclear Bcr-Abl was 
visualized in 12-Day cultured primary CML CD34
+ cells which showed a significant 
increase in nuclear Bcr-Abl on dasatinib treatment (Figure   4-5). This is consistent with 
report by Patel et al where they showed the presence of nuclear Bcr-Abl protein in 
CML  CD34
+  cells,  and  an  increase  in  nuclear  Bcr-Abl  after  IM  treatment  (248). Peixun Zhou, 2011                                                                                          Chapter 4                                                                                                       
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However,  it  is  not  clear  why  nuclear  Bcr-Abl  is  absent  in  Bcr-Abl
+  cells  lines  and 
fibroblasts,  but  present  in  primary  CML  CD34
+  cells.  These  observations 
demonstrated  that  primary  CML  CD34
+  cells  are  able  to  tolerate  the  presence  of 
nuclear  Bcr-Abl  protein,  which  could  potentially  induce  apoptosis  in  these  cells. 
Another consistent finding was the focal distribution of Bcr-Abl protein observed in 
KCL22  (Figure    3-6)  and  primary  CML  CD34
+  cells  (Figure    4-5A),  which  was  also 
demonstrated by Patel et al (248). They argued that Bcr-Abl foci might be sites for 
signalling protein assembly, since a proportion of Bcr-Abl foci are co-localised with 
other proteins such as p-CrkL, Grb2 and Cbl (248).        
  
There is a possibility that at the end of 12-Day dasatinib treatment, point-mutation 
may occur in the kinase domain of Bcr-Abl protein, conferring resistance to dasatinib 
treatment  and  preventing  nuclear  translocation  of  Bcr-Abl.  However,  Figure    4-6A 
demonstrated  complete  inhibition  of  p-CrkL  by  dasatinib,  indicating  the  Bcr-Abl 
tyrosine kinase activity was blocked. In addition, Hamilton et al showed that at the 
end of 12-Day 150nM dasatinib treatment there was no Bcr-Abl gene mutation (254), 
and they also observed maximal inhibition of p-CrkL, which is a downstream effector 
of Bcr-Abl. Thus, it is unlikely that there is TKI resistance induced by Bcr-Abl kinase 
domain mutation.  
 
It is also possible that the Day 12 surviving cells are Ph
– cells, which could explain 
their insensitivity to dasatinib treatment. However, immunofluorescence microscopy 
demonstrated positive Bcr-Abl protein staining in those surviving cells (Figure   4-5A). Peixun Zhou, 2011                                                                                          Chapter 4                                                                                                       
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In addition, Hamilton et al confirmed the presence of Bcr-Abl exclusively within the 
surviving cells by FISH (249;254), eliminating the possibility of presence of non-CML 
cells in the Day 12 surviving population. Furthermore, they showed the surviving cells 
from  12-Day  150nM  dasatinib  treatment  were  able  to  form  colonies  in  LTC-IC 
(249;254).  Since  LTC-IC  is  the  most  stringent  in  vitro  assay  to  assess  stem  cell 
function, it indicated the presence of stem cells in the survived population. However, 
cell  surface  staining  demonstrated  the  survived  cells  are  CD45
+,  CD34
low/–  and 
CD133
low/– (Figure   4-7), indicating most of these cells might not be haematopoietic 
stem/progenitor cells. One possible explanation, however, is that the human HSCs 
can be CD34
– (255;256). Another explanation is that only a small proportion of the 
surviving cells are stem cells which form colonies in LTC-IC.  
 
Since there was no LMB to trap Bcr-Abl in the nucleus in this experiment, Bcr-Abl 
could shuttle freely out of the nucleus via its NES. Wang et al demonstrated IM alone 
did  not  induce  nuclear  accumulation  of  Bcr-Abl  protein  in  the  Bcr-Abl  expressing 
fibroblasts,  while  IM  and  LMB  combination  led  to  accumulation  of  Bcr-Abl  in  the 
nucleus (198). This indicates that although inhibition of tyrosine kinase targeted Bcr-
Abl into the nucleus, Bcr-Abl shuttles out of nucleus very quickly in the absence of 
LMB. In the case of 12-Day dasatinib treated CML cells, nuclear translocated Bcr-Abl 
protein  is  quite  possible  to  shuttle  back  into  the  cytoplasm  quickly.  This  shuttling 
potentially  explains  why  only  about  50%  Bcr-Abl  was  observed  in  the  nucleus  of 
surviving CML cells as it is a single point in a dynamic system.           
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Interestingly,  ectopically  expressed  Bcr-Abl  protein  with  four  additional  NLSs  was 
shown to be able to translocate into the nucleus and induced apoptosis in K562 cells, 
but not wild type Bcr-Abl or Bcr-Abl with only one additional NLS (257). This indicates 
that  the  NLSs  of  wild  type  Bcr-Abl  may  be  masked  to  prevent  its  nuclear 
translocation. 14-3-3 proteins sequester proteins in the cytoplasm by blocking their 
NLSs (258). It was shown that Bcr-Abl and 14-3-3 interacted with each other in CML 
cells  (Figure    4-9  and  Figure    4-10).  Dong  et  al  also  demonstrated  14-3-3/Bcr-Abl 
association by immunoprecipitation (259). Thus, it is quite possible that 14-3-3/Bcr-
Abl association masks NLSs of Bcr-Abl, and holds it in the cytoplasm.   
 
Hamilton et al showed that, in the surviving CML cells of 12-Day dasatinib treatment 
in the absence of growth factors, there was maximal inhibition of Bcr-Abl tyrosine 
kinase as measured by p-CrkL and no Bcr-Abl kinase domain mutation (249;254). 
This suggests that the survival of CML cells is independent of Bcr-Abl tyrosine kinase 
activity. The survival mechanisms of CML cells fall into two broad categories, Bcr-Abl 
dependent  and  independent  mechanisms  (157).  It  was  shown  that  normal  human 
quiescent haemopoietic progenitors could not survive in the absence of IL-3 or GM-
CSF in culture (18), while 10% of Bcr-Abl
+ primary CML CD34
+ cells survived 12-Day 
dasatinib treatment in the absence of any growth factor (249;254). This suggests that 
the survival of CML cells is dependent on the presence of Bcr-Abl protein, but not on 
the tyrosine kinase activity of Bcr-Abl. The mechanism by which kinase-inhibited Bcr-
Abl protein enables CML cells survive in the absence of growth factors is not clear. 
Since  the  Bcr-Abl  protein  retained  in  the  cytoplasm  of  surviving  cells  is  in  focal Peixun Zhou, 2011                                                                                          Chapter 4                                                                                                       
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formation (Figure   4-5), it is possible that the tyrosine kinase inhibited Bcr-Abl may 
serve  as  a  scaffolding  protein  which  integrate  other  signalling  molecules  in  the 
cytoplasm, and provide a survival mechanism for dasatinib treated CML CD34
+ cells.   
If  this  is  the  case,  impairment  of  the  cytoplasmic  Bcr-Abl  retention  will  lead  to 
increased  accumulation  of  nuclear  Bcr-Abl,  disruption  of  its  scaffolding  role  in  the 
cytoplasm, and elimination of resistant/persistent CML progenitor cells. One possible 
way of doing this is to dissociate Bcr-Abl from its cytoplasmic binding partners. It has 
been shown here that 14-3-3 proteins complexed with Bcr-Abl in the cytoplasm of 
Day 12 surviving CML cells (Figure   4-9). It was reported that 14-3-3 proteins were 
linked to diverse signalling molecules (229), and they interacted with Bcr-Abl (61). 
Thus, disruption of the association between 14-3-3 and Bcr-Abl may increase nuclear 
accumulation of Bcr-Abl, and impair cytoplasmic signalling of Bcr-Abl.  
 
BV02, a newly discovered inhibitor of 14-3-3, was reported to be able to dissociate c-
Abl from 14-3-3 and induce nuclear translocation of c-Abl (260). BV02 also induced 
apoptosis in Ba/F3 cells expressing wild type Bcr-Abl or T315I mutant Bcr-Abl. It also 
demonstrated anti-proliferative effect in CD34
+ CML cells sampled from CML patients 
at BC stage that developed in vivo resistance to IM (147). However, it is not clear 
whether  BV02  is  able  to  disrupt  14-3-3/Bcr-Abl  complex  in  CML  cells,  or  if  it  can 
increase nuclear accumulation of Bcr-Abl. The combination effect of TKI and BV02 in 
resistant/persistent CML progenitors is worthy of further investigation.       
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5  Results 3: p-CrkL is not a surrogate of Bcr-Abl activity in 
vitro at short time-points 
5.1  Introduction 
In previous study, CML cells were treated with IM to induce nuclear localisation of 
Bcr-Abl protein through inhibition of its tyrosine kinase (Figure   3-6). Due to the rapid 
nature  of  kinase  inhibition  and  nuclear  transportation,  an  appropriate  time-point 
should be chosen after IM treatment, at which time Bcr-Abl kinase activity is inhibited 
to allow its nuclear transportation, but cells should not be apoptotic. Thus, studies are 
required to measure the earliest time-point of inhibition of Bcr-Abl tyrosine kinase by 
IM. 
 
p-CrkL has been commonly used to assess Bcr-Abl tyrosine kinase activity (160-163), 
as  p-CrkL  is  a  downstream  substrate  of  Bcr-Abl  (166)  and  is  the  major  tyrosine 
phosphorylated protein in CML cells, but not in normal cells (93). In addition, the level 
of CrkL phosphorylation correlates well with the level of Bcr-Abl protein in CML cells, 
while p-CrkL is not detected in Bcr-Abl negative samples (165). Recently, p-CrkL has 
begun to be used as a surrogate marker of Bcr-Abl tyrosine kinase activity due to its 
convenience  to  be  detected  and  low  cell  number  requirement  by  flow  cytometry 
(161;162).   
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However, the accuracy of p-CrkL as a reflection of Bcr-Abl tyrosine kinase status at 
early time-points during in vitro TKI treatment has not been examined. Although Bcr-
Abl is the prominent driving force of tyrosine phosphorylation in CML cells, p-CrkL 
level does not necessarily equate to p-Tyr Bcr-Abl level. Therefore, the aims of this 
chapter were to reveal the kinetic of Bcr-Abl kinase inhibition by measuring p-CrkL 
and p-Tyr Bcr-Abl levels after TKI treatment, and investigate if p-CrkL is an accurate 
surrogate marker of Bcr-Abl tyrosine kinase activity in Ph
+ cells at early time-points of 
TKI treatment.       
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5.2  Assessment of the accuracy of p-CrkL as a surrogate marker of 
Bcr-Abl kinase activity in K562 cells after IM treatment at early 
time-points 
IM is currently the first line drug for treating CP CML patients. Its IC50 in K562 cells is 
600nM as measured by 
3H-thymidine uptake proliferation assay at 72 hours (172). In 
order  to  investigate  if  p-CrkL  is  an  accurate  surrogate  marker  of  Bcr-Abl  kinase 
activity after IM treatment at early time-points (≤48 hours), K562 cells were treated 
with 1 M IM. 1 M IM is higher than the IC50 concentration in K562 cells, and it was 
chosen to assure kinase inhibition. At each time-point of IM treatment (0, 0.5, 1, 2, 4, 
8,  24,  48  hours),  cells  were  collected  and  prepared  for  Western  blotting.  p-CrkL 
(Tyrosine 207), tyrosine phosphorylated Bcr-Abl (p-Tyr Bcr-Abl) and Bcr-Abl protein 
levels were measured. GAPDH was used as a loading control as described in the 
Materials and Methods.  
 
After 1 M IM treatment, p-Tyr Bcr-Abl level dropped quickly to 24.9 ± 7.7% (n=3, 
mean  ±  SEM)  of  baseline  (NDC  at  0  time-point)  by  1  hour  time-point  and  then 
plateaued around this level out to the 48 hours time-point. Interestingly, p-CrkL level 
dropped to 59.3 ± 13.5% at 0.5 hour time-point, but then recovered to 94.4 ± 17.3% at 
4  hours  time-point  (p=0.012,  paired  t-test),  and  subsequently  declined  to  39.0  ± 
13.4% at 48 hours time-point. This phasic response of p-CrkL was unexpected and 
different to the response of Bcr-Abl after IM treatment. This strongly demonstrates 
that p-CrkL may not mirror the response of Bcr-Abl. The difference between protein Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
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levels of p-CrkL and p-Tyr Bcr-Abl was statistically significant at several time-points 
(p<0.05 at 4 hours time-point; p<0.01 at 8 hours time-point; p<0.001 at 24 hours time-
point). 
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Figure   5-1: Levels of p-Tyr Bcr-Abl, Bcr-Abl, p-CrkL in 1 M IM treated K562 cells.  
(A) Western blots showing protein levels of p-Tyr Bcr-Abl, Bcr-Abl, p-CrkL and GAPDH 
at different time-points (0, 0.5, 1, 2, 4, 8, 24, 48 hours) after IM treatment (n=3). (B) Plots 
showing normalized densitometry values of Western blot protein bands, as well as p-
CrkL levels measured by intracellular flow cytometry. Densitometry was performed on 
each Western blot protein band to measure pixel intensity. P-Tyr Bcr-Abl, Bcr-Abl and 
p-CrkL protein band densitometry values were normalised against their corresponding 
GAPDH values. Values are shown as percentage of baseline. (C) Histograms showing 
the  same  percentages  as  in  plot  B with  p-values  indicated  (* p<0.05,  ** p<0.01,  *** 
p<0.001). Results are shown as mean ± SEM, n=3 
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These results show that p-CrkL is not an accurate indicator of p-Tyr Bcr-Abl level in 
K562 cells after 1 M IM treatment at early time-points (≤24 hours). Since Bcr-Abl 
protein is auto-phosphorylated, p-Tyr Bcr-Abl level is a direct measurement of Bcr-Abl 
tyrosine kinase activity. Thus, p-CrkL is not an accurate surrogate marker of Bcr-Abl 
tyrosine kinase activity in this case. In addition, it was observed that the p-Tyr Bcr-Abl 
level dropped sharply within 0.5 hour of IM treatment in K562 cells (Figure   5-1B), thus 
it  was  interesting  to  investigate  further  how  rapidly  p-Tyr  Bcr-Abl  levels  could  be 
reduced  and  if  the  p-CrkL  response  was  a  surrogate  marker  of  Bcr-Abl  tyrosine 
kinase activity within minutes of IM treatment. K562 cells were treated with 1 M IM, 
and cells were sampled at very short time-points (0, 1, 5, 10, 15 minutes). Western 
blotting  was  employed  to measure  p-CrkL and  p-Tyr  Bcr-Abl  levels  (Figure   5-2A). 
GAPDH was used as a loading control.  
 
It was observed that there was a rapid reduction of p-Tyr Bcr-Abl to less than 50% of 
baseline by 10 minutes of 1 M IM treatment in K562 cells, while p-CrkL remained 
around baseline level during this period (Figure   5-2B). The difference between p-CrkL 
and  p-Tyr  Bcr-Abl  levels  are  statistically  significant  (p<0.05  at  5  and  10  minutes; 
p<0.01 at 15 minutes) (Figure   5-2C). These results demonstrate that p-CrkL is not an 
accurate surrogate marker of Bcr-Abl tyrosine kinase activity after IM treatment at 
very short time-points in K562 cells (≤ 15 minutes).    
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Figure   5-2: p-Tyr Bcr-Abl and p-CrkL levels in 1 M IM treated K562 cells (≤ 15 minutes). 
(A)  Western  blots  showing  protein  levels  of  p-Tyr  Bcr-Abl,  p-CrkL  and  GAPDH  at 
different time-points (0, 1, 5, 10, 15 minutes) after IM treatment (n=3). (B) Plots showing 
normalized densitometry values of Western blot protein bands. Values are shown as 
percentage of no drug control. (C) Histograms showing the same percentages as in 
plot B with P-values indicated (*p<0.05, ** p<0.01). Results are shown as mean ± SEM, 
n=3. 
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In the first study (Figure   5-1), K562 cells were centrifuged at low speed (120 x g) and 
washed with PBS to prepare cell lysates. Since time-points as short as 1 minute were 
examined in the study above, the preparation of the cells had to be amended and 
cells were centrifuged at high speed (21,000 x g) without washing in PBS (Figure 
  5-2). As the responses seen at very short time-points were quite dramatic, it was 
possible  that  this  change  in methodology  could have  affected  the  phosphorylation 
status of CrkL and Bcr-Abl. Therefore, the full time course was repeated with the high 
speed centrifugation method, and the results are shown in Figure   5-3. Similar to low 
speed methodology (Figure   5-1), p-Tyr Bcr-Abl level dropped quickly within 1 hour of 
1 M IM treatment to 14.5 ± 1.3% (n=3, mean ± SEM) and then plateaued around this 
level to 24 hours. p-CrkL level dropped to 50.6 ± 3.6% at 0.5 hour time-point, and 
recovered to 99.3 ± 11.8% at 4 hours time-point (p=0.041), finally dropping slightly at 
24 hours time-point. The differences between p-CrkL and p-Tyr Bcr-Abl levels at all 
time-points are statistically significant (p<0.01 at 0.5, 1, 2, 4, 8 and 24 hours time-
points).  Taken  together,  the  low  speed  (Figure    5-1)  and  high  speed  (Figure    5-3) 
methods were very similar to each other. In general, the high speed centrifugation 
method  produced  results  with  smaller  error  bars,  so  this  method  was  used  in 
subsequent Western blotting experiments.  
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Figure   5-3: p-Tyr Bcr-Abl and p-CrkL levels in 1 M IM treated K562 cells up to 24 hours.  
Cells were centrifuged at 21,000 x g for 30 seconds at each time-point and then subject 
to Western blotting analysis. Results are shown as mean ± SEM (n=3). 
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Based on these observations, a three-phase model was formed to illustrate the level 
of p-CrkL after 1 M IM treatment. As shown in Figure   5-4, there is a rapid reduction of 
p-CrkL after IM treatment in the first phase as p-CrkL levels drop to about half of the 
baseline  level  at  0.5  hour  time-point.  In  phase  two,  the  p-CrkL  level  recovers  to 
around the baseline level by 4 hours. Finally, p-CrkL level declines slowly in the third 
phase.  
 
 
 
 
 
 
 
 
 
Figure   5-4: Model of p-CrkL level after IM treatment in K562 cells.  
(1) A sharp drop of p-CrkL immediately after IM treatment. (2) Re-phosphorylation of 
CrkL from 0.5 hour to a peak at 4 hours time-point. (3) Gradual decrease of p-CrkL level 
from 4 hours time-point.    
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5.3  Investigation  of  the  role  of  protein  tyrosine  phosphatases  in 
Bcr-Abl dephosphorylation after IM treatment in K562 cells 
5.3.1  Effect of SSG and IM co-treatment on p-Tyr Bcr-Abl in K562 cells 
The initial rapid reduction of p-Tyr Bcr-Abl within minutes of TKI treatment suggests 
there may be an active dephosphorylation of Bcr-Abl protein after TKI treatment, and 
it was hypothesized the initial sharp drop of p-Tyr Bcr-Abl level after TKI treatment 
may  be  due  to  protein  tyrosine  phosphatase  (PTP)  activity.  Therefore,  K562  cells 
were treated with both IM and PTP inhibitor, sodium stibogluconate (SSG), which 
inhibits activity of PTPs including SHP-1, SHP-2 and PTP1B (261). SSG inhibits 99% 
of SHP-1 activity at 10 g/mL, and inhibits 99% of SHP-2 and PTP1B activities at 
100 g/mL with in vitro PTP assays (261). Thus, K562 cells were treated with 1 g/mL, 
10 g/mL or 100 g/mL SSG with 1 M IM for 1 hour, and it was observed that the 
combination of IM with 10 g/mL or 100 g/mL SSG resulted in significantly higher 
levels of p-Tyr Bcr-Abl than IM alone (p=0.007 and p=0.046, respectively), but not as 
high as the baseline level (Figure   5-5). These results suggest that SSG can partially 
inhibit the initial drop of p-Tyr Bcr-Abl level caused by IM, indicating PTPs play a role 
in Bcr-Abl dephosphorylation.  
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Figure   5-5: Combination treatment of 1 M IM and SSG in K562 cells for 1h.  
(A) A representative Western blot showing p-Tyr Bcr-Abl and GAPDH protein levels in 
these  treatments  including  untreated,  SSG  alone,  1 M  IM  alone,  IM  with  1 g/mL, 
10 g/mL and 100 g/mL SSG, and (B) Histograms showing normalized densitometry 
p-Tyr Bcr-Abl 
GAPDH 
  0      1     10    100    0      1     10    100 ( g/ml) 
 
SSG 
1  M IM Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
 
 
163 
values  of  Western  blot  protein  bands.  Values  are  shown  as  percentage  of  no  drug 
control. Results are shown as mean ± SEM (n=3). 
 
5.3.2  Expression of protein tyrosine phoshpatases in K562 cells 
Since PTPs are involved in the dephosphorylation of Bcr-Abl protein and SSG targets 
SHP1,  SHP2  and  PTP1B,  the  next  aim  was  to  specify  which  one(s)  of  the  three 
possible PTPs were relevant in K562 cells. At first, expression of the three PTPs were 
examined by Western blotting with K562 cell lysate, and it was found that SHP1 was 
almost absent in K562 cells, while SHP2 and PTP1B proteins were highly expressed 
(Figure   5-6). This result is consistent with previous reports that K562 cells did not 
express SHP1 mRNA and protein (214;262). In addition, it has been reported that 
differentiated K562 cells express SHP1, while expression of both SHP2 and PTP1B is 
not changed upon differentiation of K562 cells (262).    
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Figure   5-6: Expression of PTPs in K562 cells.  
Protein expression of three PTPs, including SHP1, SHP2 and PTP1B, was assessed in 
K562 cells by Western blotting. K562 whole cell lysates were resolved by SDS-PAGE 
and incubated with anti-SHP1, anti-SHP2 or anti-PTP1B antibodies individually. GAPDH 
was used as the loading control.   
5.4  Assessment of the accuracy of p-CrkL as a surrogate marker of 
Bcr-Abl kinase activity in K562 cells after dasatinib treatment at 
early time-points 
Dasatinib is a second line TKI for treating CML. It is a dual Abl/Src inhibitor and 325 
times more potent than IM in inhibiting wild type Bcr-Abl activity (173). Thus, it is 
interesting to study if p-CrkL is a surrogate marker of Bcr-Abl tyrosine kinase activity 
after dasatinib treatment in K562 cells. Similar to the previous experiments in Chapter 
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  5.2, K562 cells were treated with 10nM dasatinib, and cells were sampled at several 
time-points (0, 0.5, 1, 2, 4, 8 hours).  
 
It was observed that, with 10nM dasatinib, the p-Tyr Bcr-Abl response was similar to 
that seen with IM, which dropped rapidly to 14.3 ± 2.0% at 1 hour and then remained 
around this level. However, unlike IM, dasatinib caused a strong reduction in p-CrkL 
to 18.8 ± 4.7% by 1 hour, although this reduction slightly recovered to 28.8 ± 6.3% at 
4 hours time-point (p=0.035, paired t-test). The difference between p-CrkL and p-Tyr 
Bcr-Abl  are  not  statistically  significant  at  each  time-point  (p≥0.070).  These  results 
indicate  that  p-CrkL  accurately  reflects  Bcr-Abl  tyrosine  kinase  activity  after  10nM 
dasatinib  treatment  in  K562  cells,  which  is  quite  different from  IM  treatment.  This 
could be due to the additional inhibition of Src kinases by dasatinib. 
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Figure    5-7:  Protein  levels  of  p-Tyr  Bcr-Abl,  Bcr-Abl  and  p-CrkL  in  10nM  Dasatinib 
treated K562 cells up to 8 hours by Western blotting, and p-CrkL level by FACS.  
(A) Western blots showing protein levels of p-Tyr Bcr-Abl, Bcr-Abl, p-CrkL and GAPDH 
at  different  time-points  (0,  0.5,  1,  2,  4,  8  hours)  after  IM  treatment  (n=3).  (B)  Plots 
showing normalized densitometry values of Western blot protein bands, as well as p-
CrkL  levels  measured  by  FACS  (n=3).  Values  are  shown  as  percentage  of  no  drug 
control. Results are shown as mean ± SEM, n=3. 
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5.5  Effect of PP2 and IM co-treatment on p-Tyr Bcr-Abl and p-CrkL 
As shown above, the dual Abl/Src kinase inhibitor dasatinib significantly reduced p-
CrkL level in K562 cells, while p-CrkL maintained at high level with IM treatment. 
Thus, Src kinases could be involved in CrkL phosphorylation. In order to test if Src 
kinases phosphorylate CrkL, the effects of Src inhibitor PP2 on p-CrkL level with or 
without IM was assessed in K562 cells.  
5.5.1  Measurement of IC50 for the Src inhibitor PP2 in K562 cells 
PP2 is a potent inhibitor of the Src tyrosine kinase family (263), and it was reported 
that the IC50 of PP2 was 10 M in K562 cells at 72 hours (264). Since the CrkL re-
phosphorylation occurred within 24 hours, IC50 of PP2 at 24 hours in K562 cells was 
measured by viable cell count with trypan blue. It was shown that PP2 had an IC50 of 
approximately 30 M (Figure   5-8), which was used in subsequent experiments.  
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Figure   5-8: Determination of IC50 for PP2 in K562 cells at 24 hours.  
50% inhibition of K562 cell proliferation was achieved by 30 M PP2 at 24 hours. Viable 
cells were counted by trypan blue and are shown as percentage to NDC (mean ± SEM, 
n=3). 
 
5.5.2  PP2 and IM co-treatment in K562 cells 
In order to examine the effect of Src inhibition on p-CrkL, K562 cells were treated with 
30 M  PP2  and  1 M  IM.  It  was  observed  that  (Figure    5-9)  p-CrkL  level  was 
significantly decreased within 0.5 hour of the IM and PP2 co-treatment, and reached 
the lowest level of 7.0 ± 0.6% of baseline at 1 hour time-point. The p-CrkL level then 
recovered to 31.1 ± 5.1% by 8 hours and slightly dropped to 27.8 ± 3.2% at 24 hour 
time-point. On  the other  hand, p-Tyr  Bcr-Abl  level  decreased  to 24.1  ±  1.8% and Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
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remained around this level. p-CrkL level was significant lower than p-Tyr Bcr-Abl level 
at 0.5 hour and 1 hour time-points (p=0.006 and p=0.0009, respectively), while there 
was no significant difference between p-CrkL and p-Tyr Bcr-Abl levels at later time-
points.  The  increase  of  p-CrkL  from  1  hour  to  4  hour  time-point  is  statistically 
significant (p=0.011, paired t-test). The pattern of p-CrkL response in the IM and PP2 
co-treatment  (Figure    5-9)  is  similar  to  the  response  in  dasatinib  treatment  (Figure 
  5-7), as they both have an initial strong reduction, followed by a slight but significant 
recovery of p-CrkL level, and p-CrkL reached similar levels as p-Tyr Bcr-Abl at later 
time-points.    
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Figure   5-9: Co-treatment of 1 M IM and 30 M PP2 in K562 cells for up to 24 hours.  
(A)  Western  blots  showing  protein  levels  of  p-Tyr  Bcr-Abl,  p-CrkL  and  GAPDH  at 
different time-points (0, 0.5, 1, 2, 4, 8 and 24 hours) after IM and PP2 co-treatment. (B) 
Plots  showing  normalized  densitometry  values  of  Western  blot  protein  bands  as 
percentage to baseline. Results are shown as mean ± SEM (n=3).  
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5.6  Effects of hydroxyurea treatment on p-Tyr Bcr-Abl and p-CrkL 
It was concerning that the observation of rapid reduction of p-CrkL and p-Tyr Bcr-Abl 
after TKI treatments, as well as recovery of p-CrkL (Figure   5-1 and Figure   5-3), might 
be a technical issue. In order to ensure that this was not a technical artefact, a non-
Bcr-Abl targeting drug need to be tested with K562 cells to make sure there was no 
such observation. Hydroxyurea, an inhibitor of DNA synthesis, was used to treat CML 
patients before the era of IM (135), and it is not known to target Bcr-Abl protein. 
Therefore, K562 cells were treated with 400 M hydroxyurea, a concentration which is 
around the proliferation inhibitory IC50 as shown in Figure   5-10A. It was found that p-
CrkL and p-Tyr Bcr-Abl levels were maintained (Figure   5-10B and C). Cell counts at 
24 hours showed hydroxyurea inhibited K562 cell proliferation by about 42% (Figure 
  5-10A),  indicating  the  hydroxyurea  used  in  this  experiment  is  active.  This  result 
eliminates the possibility of technical artefact, such as lack of access of the antibodies 
to epitope target, in the previous experiments.  Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
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Figure   5-10: p-Tyr Bcr-Abl and p-CrkL levels in K562 cells with 400 M hydroxyurea.  
(A) Cell counts by trypan blue dye exclusion at 24-hour 400 M hydroxyurea treatment 
in K562 cells. (B) Western blots showing protein levels of p-Tyr Bcr-Abl, Bcr-Abl, p-
CrkL and GAPDH at different time-points (0, 0.5, 1, 2, 4, 8 hours) after hydroxyurea 
treatment (n=3). (C) Histograms showing normalized densitometry values of Western 
blot protein bands. Values are shown as percentage of baseline. All results are shown 
as mean ± SEM (n=3). 
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5.7  Summary and Discussion 
These results demonstrate that p-CrkL is not a reliable indicator of Bcr-Abl kinase 
activity within 24 hours of IM treatment and indicate that the early responses to IM 
and dasatinib differ significantly. Importantly, these data also show that in addition to 
inhibition of the Bcr-Abl kinase activity there is a rapid and active dephosphorylation 
of Bcr-Abl within 1 hour of TKI treatment, driven at least in part, by PTP activity. This 
dephosphorylation is only revealed on switching off Bcr-Abl kinase activity with TKI. 
 
The initial aim was to examine the accuracy of p-CrkL as a surrogate marker of Bcr-
Abl tyrosine kinase activity. Thus, p-CrkL and p-Tyr Bcr-Abl levels were compared 
after IM treatment in K562 cells. It was observed that p-CrkL level dropped to about 
39% of baseline level at 48 hours (Figure   5-1), which is consistent with the literature 
(162), but it was clearly shown that p-CrkL level was significantly different from p-Tyr 
Bcr-Abl level within 24 hours (Figure   5-1, Figure   5-2 and Figure   5-3). The differences 
between p-CrkL and p-Tyr Bcr-Abl levels could be due to incomplete inhibition of Bcr-
Abl  by  IM,  i.e.  a  small  proportion  of  active  Bcr-Abl  protein  is  sufficient  to 
phosphorylate CrkL. Since IM only targets Bcr-Abl protein in an inactive conformation 
(146), it is possible that a low level of active Bcr-Abl tyrosine kinase exists after IM 
treatment. In addition, it was shown by Khorashad et al that when CD34
+ cells from 5 
newly diagnosed CML patients were treated with high concentration IM (5 M) that p-
CrkL level decreased dramatically at 2 hour time-point to about 20% of baseline and 
was maintained around this level out to 16 hours (265). This report indicated that the 
significant difference between p-CrkL and p-Tyr Bcr-Abl levels after low concentration Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
 
 
175 
IM (1 M) treatment may be abolished by a higher IM dose. This could be due to 
inhibition of other tyrosine kinases, which might phosphorylate CrkL, by a high dose 
of IM.  
 
In addition, the differences could result from phosphorylation of CrkL by other kinases 
other than Bcr-Abl. It was reported that CrkL may be a substrate of Src kinases (266). 
If this is the case, the dual Abl/Src inhibitor dasatinib should have a better effect on p-
CrkL  inhibition  compared  with  IM.  Indeed,  it  was  observed  that  there  was  no 
significant difference between p-CrkL and p-Tyr Bcr-Abl levels in dasatinib treated 
K562 cells (Figure   5-7), suggesting Src kinases could be involved in phosphorylating 
CrkL. In was further demonstrated that treatment of K562 cells with IM and  PP2 (an 
inhibitor  of  Src  kinases)  induced  rapid  reduction  of  p-CrkL  to  levels  which  were 
significantly lower than p-Tyr Bcr-Abl at early time-points, then CrkL phosphorylation 
recovered  to  approximately  the  same  levels  as  p-Tyr  Bcr-Abl  at  later  time-points 
(Figure   5-9). Co-treatment of K562 cells with IM and PP2 dramatically reduced p-CrkL 
compared  with  IM  only  treatment,  indicating  that  Src  kinases  play  a  role  in 
phosphorylating CrkL. 
 
Interestingly,  p-CrkL  level  was  significantly  recovered  after  an  initial  drop  with  IM 
treated  K562  cells  (Figure    5-1  and  Figure    5-3),  suggesting  that  there  were  other 
kinases phosphorylating CrkL after inhibition of Bcr-Abl kinase activity. At first, this 
recovery was thought to be mediated by Src kinases, as it was known that CrkL could 
be a substrate for Src kinases (266). However, there was still a recovery of CrkL Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
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phosphorylation after dasatinib treatment in K562 cells (Figure   5-7), while the degree 
of recovery is smaller than with IM treatment. Similarly, the recovery of p-CrkL was 
observed in IM and PP2 co-treatment in K562 cells. These results indicate that there 
are other kinases that phosphorylate CrkL in addition to Bcr-Abl and Src.   
 
Unexpectedly, it was observed that p-Tyr Bcr-Abl is reduced to a minimum within 1 
hour of TKI treatment (Figure   5-1, Figure   5-3 and Figure   5-7), and reduced to less 
than 50% of  baseline level within just 10 minutes of IM treatment (Figure   5-2). The 
rapid  reduction  of  p-Tyr  Bcr-Abl  lead  to  the  hypothesis  that  Bcr-Abl  was  actively 
dephosphorylated by PTPs after TKI treatment. It has been reported that Bcr-Abl is a 
substrate of PTP1B, and co-expression of PTP1B and Bcr-Abl proteins in COS cells 
resulted in significantly lower level of p-Tyr Bcr-Abl compared with expression of Bcr-
Abl  only  (225).  In  addition,  it  was  shown  that  inhibition  of  PTP1B  activity,  by 
expression  of  a  dominant-negative  substrate-trapping  PTP1B  mutant  (binding  to 
substrates, but without catalyzing activity), confers resistance to IM treatment in K562 
cells (224;264). Therefore, the rapid drop of p-Tyr Bcr-Abl level within 1 hour of TKI 
treatment may be caused by PTP1B activity in K562 cells, and a future direction to 
confirm this is to knock down PTP1B in CML cells by siRNA to examine if there is any 
inhibition of Bcr-Abl dephosphorylation after IM treatment. 
 
Furthermore, since all experiments in this Chapter were performed in the human CML 
cell line K562 cells, a future perspective is to confirm these findings in human primary 
CML cells, as primary cells might be different to cell line cells in this regard. Finally, Peixun Zhou, 2011                                                                                          Chapter 5                                                                                                       
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based on the findings in this Chapter, one could say that high p-CrkL level does not 
necessarily indicate high Bcr-Abl tyrosine kinase activity in CML cells. Thus, using p-
CrkL as a surrogate marker of Bcr-Abl activity can generate false positive results in 
some cases, and it may be mistaken to conclude that there is high Bcr-Abl activity 
when high p-CrkL level is observed. 
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6  Results 4: Does BMS-214662 induce CML cell apoptosis 
by proteasome inhibition? 
6.1  Introduction 
BMS-214662 is a FTI, which was developed as an inhibitor of Ras signalling pathway 
(206). Cytosolic Ras protein is post-translationally modified to enable its membrane 
association,  which  is  critical  for  the  signalling  functions  of  Ras  (206),  and 
farnesylation of the C-terminal cysteine residue of Ras by farnesyltransferase is the 
key step of this process (208). Therefore, inhibition of the farnesyltransferase activity 
by FTI prevents membrane association of cytosolic Ras and its signalling function. 
BMS-214662  has  been  shown  to  induce  apoptosis  potently  in  tumour  cells,  but 
another  highly  related  FTI,  BMS-225975,  does  not  (211).  Since  BMS-214662  and 
BMS-225975  have  very  similar  FTI  activity  (211),  it  is  thought  that  BMS-214662 
induces  apoptosis  in  tumour  cells  by  a  mechanism  apart  from  its  FTI  activity. 
Additionally,  BMS-214662  exhibits  apoptotic  effect  in  primary  CML  stem  and 
progenitor cells, making it a potential drug to eradicate CML (212;213), but it is not 
clear how exactly BMS-214662 activates the intrinsic apoptotic pathway in CML cells. 
 
In the previous chapter, hydroxyurea was tested in K562 cells as a control showing 
that p-CrkL and p-Tyr Bcr-Abl levels were maintained. In the mean time, BMS-214662 
was tested for the same purpose in K562 cells, and surprisingly it was found that 
BMS-214662 elevated p-Tyr Bcr-Abl and total Bcr-Abl levels (Figure   6-1). It has been Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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reported that c-Abl and Bcr-Abl protein could be ubiquitinated and degraded by the 
proteasome pathway (267;268). Thus, inhibition of proteasome activity may lead to 
the  accumulation  Bcr-Abl  protein,  and  BMS-214662  may  therefore  act  as  a 
proteasome inhibitor leading to the accumulation of Bcr-Abl protein as observed in 
Figure   6-1. 
 
 
Figure   6-1: Accumulation of p-Tyr Bcr-Abl and total Bcr-Abl protein in K562 cells after 
BMS-214662 treatment.  
 
It has been reported that Bcr-Abl
+ cells had much higher proteasome activity than 
their  normal  counterparts  (269),  suggesting  that  Bcr-Abl  protein  increases 
proteasome activity. In addition, it was reported that intracellular ROS is up-regulated 
by  Bcr-Abl  tyrosine  kinase  (270).  Furthermore,  inhibition  of  proteasome  elevates 
intracellular ROS level in leukaemic cells. Therefore, it was hypothesised that if BMS-
214662 inhibited proteasome activity, this could result in the accumulation of Bcr-Abl 
protein  and  further  elevation  of  intracellular  ROS  level,  which  CML  cells  can  not 
tolerate  leading  to  apoptosis.  The  aim  of  study  in  this  section  was  to  examine  if 
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inhibition of proteasome activity is a novel mechanism of action of BMS-214662 which 
preferentially induces apoptosis in CML cells compared with the related FTI BMS-
225975.  
6.2  Determination of IC50 values in K562 cells 
If proteasome inhibition is the novel mechanism of action of BMS-214662 which BMS-
225975 does not have, it should induce accumulation of ubiquitinated proteins in CML 
cells in a similar pattern as a known proteasome inhibitor bortezomib, and different 
from BMS-225975. Since Bcr-Abl increases proteasome activity (269), inhibition of 
Bcr-Abl  kinase  by  IM  should  decrease  proteasome  activity  and  accumulate 
ubiquitinated proteins, which could be measured by Western blotting. Before doing 
that, the cytotoxicity of these drugs needed to be examined in CML cells and suitable 
drug concentrations should be chosen. Therefore, the IC50 values of BMS-214662, 
BMS-225975, bortezomib and IM were measured in the CML cell line K562. Cells 
were  treated  with  various  concentrations  of  each  drug  for  24  and  72  hours.  The 
number of viable cells in each treatment was counted with trypan blue (Figure   6-2), 
and the IC50 values are shown in Table   6-1.  
 
BMS-214662 has an IC50 value about 47 times lower than BMS-225975 in K562 cells 
at 24 hours, demonstrating a much more potent cytotoxic effect of BMS-214662 and 
confirming the existence of a non-FTI related mechanism of action of BMS-214662 
(Table   6-1). Since the levels of ubiquitinated proteins were measured within 24 hours Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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of drug treatments, 40 M BMS-214662, which is slightly higher than the IC50 at 24 
hours,  was  chosen  to  be  used  in  the  subsequent  experiments  to  make  sure  the 
effects of the drug could be seen but before the degree of apoptosis was too great to 
allow analysis of the cells. As BMS-214662 and BMS-225975 have very similar FTI 
activity,  40 M  BMS-225975  was  tested  as  a  negative  control.  If  BMS-214662 
treatment arm had a significant difference from BMS-225975 arm, it should be due to 
the  additional  mechanism  of  action  of  BMS-214662.  In  addition,  the  established 
proteosome  inhibitor  bortezomib  (20nM)  was  also  used  as  a  positive  control. 
Additionally, 1 M IM was used in the following experiments to examine if inhibition of 
Bcr-Abl  tyrosine  kinase  leads  to accumulation of ubiquitinated proteins  and  down-
regulation of intracellular ROS.  
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Figure   6-2: IC50 for BMS-214662, BMS-225975, bortezomib and IM in K562 cells.  
Viable cells were counted by trypan blue at 24 and 72 hours. The percentage of cells in 
each treatment compared with NDC (100%) were calculated and is presented as mean ± 
SEM (n=3). Drug concentrations are plotted in Log10 scales.     
 
 
 
 
     Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
 
 
183 
IC50 in 
K562 
BMS-214662 
( M) 
BMS-225975 
( M) 
Bortezomib 
(nM)  IM ( M) 
24h  14.5  680  22  2.75 
72h  0.5  3.4  9.5  0.4 
 
Table   6-1: IC50 for BMS-214662, BMS-225975, bortezomib and IM in K562 cells.  
Estimated from mean values in the above figure.  
6.3  Accumulation of ubiquitinated proteins and Bcr-Abl  
To test if BMS-214662 is a proteasome inhibitor, K562 cells were treated with 40 M 
BMS-214662, 40 M BMS-225975, 20nM bortezomib or 1 M IM. Cells were sampled 
at various time-points up to 8 hours, and subjected to Western blotting analysis. At 
first,  the  total  ubiquitinated  proteins  were  examined  in  each  treatment  condition 
(Figure    6-3A).  It  was  observed  that  BMS-214662  and  BMS-225975  accumulated 
ubiquitinated proteins in a very similar manner, but quite different from bortezomib at 
later time-points (Figure   6-3B). All three drugs began to up-regulate the level of total 
ubiquitinated  proteins  from  0.5  hour  time-point,  and  all  reached  about  2-fold  of 
baseline level at 1 hour time-point. However, bortezomib accumulated more and more 
ubiquitinated proteins with increasing time, and reached 5-fold of baseline level at 8 
hour time-point. In contrast, the level of ubiquitinated proteins was maintained around 
or under 2-fold of baseline in BMS-214662 and BMS-225975 treatment arms. There 
was  no  statistical  significant  difference  between  BMS-214662  and  BMS-225975 
treatment  arms  in  terms  of  the  level  of  ubiquitinated  proteins  at  any  time-point Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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(p>0.55). On the other hand, bortezomib treatment arm had a significantly higher level 
of ubiquitinated proteins than BMS-214662 and BMS-225975 treatment arms at later 
time-points (p<0.05 at 4 hours time-point, p<0.01 at 8 hours time-point).  
 
There is a gradual accumulation of ubiquitinated proteins in the IM treatment arm, and 
achieved statistical significance at 4 and 8 hours time-points with respect to baseline 
(p=0.033 and p=0.046, respectively. Paired t-test). There is also a significant increase 
of ubiquitinated proteins from 0.5 hour to 4 hours time-point (p=0.026, paired t-test) 
(Figure   6-3B). This is consistent with the idea that IM reduces proteasome activity by 
inhibiting  Bcr-Abl  tyrosine  kinase.  In  addition,  there  is  no  statistically  significant 
change  in  the  levels  of  ubiquitinated  proteins  in  NDC  arm  compared  to  baseline 
(p>0.12,  paired  t-test),  suggesting  that  the  untreated  cells  did  not  alter  their 
ubiquitinated-protein levels within the 8 hour of cell culture.    
 
Furthermore,  Bcr-Abl  protein  was  accumulated  in  both  BMS-214662  and  BMS-
225975 treatment arms (Figure   6-3C and D), and there was no statistical significant 
difference  between  these  treatment  arms  at  any  time-points  (p>0.20).  Since  both 
BMS-214662 and BMS-225975 consistently accumulated total ubiquitinated proteins 
and Bcr-Abl protein in K562 cells, it is likely that the protein accumulation is due to 
their  common,  presumed  FTI  activity.  In  the  bortezomib  treatment  arm,  Bcr-Abl 
protein was accumulated in the early time-points, but returned to baseline level at 
later time-points (Figure   6-3D). 
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Figure   6-3: Ubiquitination and Bcr-Abl protein levels after BMS-214662, BMS-225975 or 
Bortezomib treatment in K562 cells.  
(A) Western blots showing total ubiquitin levels at each time-point of drug treatments. 
GAPDH was used as a loading control. (B) Normalized total ubiquitin levels against 
GAPDH, and plotted as percentage to baseline (NDC at 0 hour time-point). (C) Western 
blots showing Bcr-Abl protein levels. (D) Normalized Bcr-Abl levels against GAPDH, 
Bcr-Abl 
GAPDH 
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and plotted as percentage to baseline. Graphs were plotted as mean ± SEM, n=3. Ub 
stands for ubiquitin.    
6.4  Measurement of ROS in K562 cells 
According  to  the  hypothesis,  BMS-214662  induced  apoptosis  of  CML  cells  by 
elevating  intracellular  ROS  level.  In  order  to  test  if  BMS-214662  increases 
intracellular ROS level, DCFDA was employed, and was loaded into K562 cells prior 
to drug treatments. In the presence of ROS, DCFDA is cleaved into DCF, which is a 
green fluorescent dye and can be detected by flow cytometry in the FITC channel. 
Thus, the level of DCF fluorescence indicates the level of intracellular ROS. It was 
shown in Figure   6-4 that the BMS-214662 treatment arm had significantly higher DCF 
levels with respect to BMS-225975 at 1 hour and 4 hours time-points (p=0.0037 and 
p=0.00025, respectively). Bortezomib arm had baseline level DCF from 0.5 hour to 4 
hour time-points, and had an increase to more than 2-fold of baseline at 8 hour time-
point. On the other hand, the DCF level in the IM treatment arm was always around 
the baseline level at any time-point. In addition, hydrogen peroxide (H2O2) was used 
as a positive control to mimic oxidative stress, and it was observed that the H2O2 
treatment arm had dramatic increase of DCF fluorescence from the earliest time-point 
(Figure   6-4).  
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Figure   6-4: Intracellular ROS level in K562 cells after drug treatments.  
K562 cells were pre-loaded with DCFDA, and then treated with each drug individually. 
Cells were sampled at each time-point and analyzed by flow cytometry to measure DCF 
fluorescence level with the FITC channel.  DCF fluorescence was shown as percentage 
to the NDC at each time-point. Results are shown as mean ± SEM, n=3 (**p<0.01, *** 
p<0.001). 
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6.5   Determination of IC50 values in serum-starved K562 cells 
As shown above, BMS-214662 induced significantly higher level of intracellular ROS 
than BMS-225975 in proliferating K562 cells. It then raised the question if this was the 
case  in  quiescent  K562  cells.  In  order  to  synchronise  cell  cycle  and  arrest  cell 
division, K562 cells were starved in serum free medium for 16 hours. Cell counting 
showed that these serum-starved K562 cells did not proliferate. As shown in Figure 
  6-5, the serum-starved K562 cells were re-plated and cultured for another 24 hours in 
serum  free  medium,  and  the  cell  density  did  not  increase  compared  with  input 
(p=0.23, paired t-test). In contrast, the density of proliferating K562 cells increased 
about 3-fold when they were cultured in serum-containing medium for 24 hours, and it 
is significantly different from the density of serum-starved K562 cells (p=0.0012) This 
demonstrated that the 16-hour serum-starvation had made K562 cells exit the cell 
cycle and stop proliferating.    
 
Subsequently, IC50 values of BMS-214662, BMS-225975, bortezomib and IM were 
measured  in  the  non-proliferating  K562  cells,  since  they  may  have  different  IC50 
values from proliferating K562 cells.  As shown in Table   6-2, the IC50 of BMS-214662 
at  24  hours  is  more  than  13  times  less  than  BMS-225975,  demonstrating  the 
preferential apoptotic effect of BMS-214662 in non-proliferating CML cells. In addition, 
BMS-214662,  BMS-225975  and  bortezomib  had  similar  IC50  values  between 
proliferating  and  non-proliferating  K562  cells  at  24-hour  treatment  (Table    6-1  and 
Table   6-2). Thus, the same concentrations of these drugs as used with proliferating 
K562  cells  were  used  in  the  subsequent  experiment  with  serum-starved  non-Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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proliferating K562 cells. The IC50 of IM in non-proliferating K562 cells at 24 hours is 
about five times higher than in proliferating K562 cells (Table   6-1 and Table   6-2), 
demonstrating the resistance of quiescent CML cells to TKI treatment.   
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Figure   6-5: Serum-starved K562 cells stopped proliferation.  
Proliferating K562 cells were starved in serum free medium for 16 hours to induce cell 
cycle arrest, and then the cells were re-plated at 2 x 10
5 cells/mL in serum-free medium 
for  another  24  hours.  As  a  control,  proliferating  K562  cells  were  plated  at  2  x  10
5 
cells/mL in serum-containing medium for 24 hours.  
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Figure   6-6: Determination of IC50 for BMS-214662, BMS-225975, Bortezomib and IM in 
serum-starved K562 cells by trypan blue viable cell counts at 24 hours.  
K562 cells were starved in serum free medium for 16 hours, and then the cells were re-
plated and treated with each drug for another 24 hours. The percentage of cells in each 
treatment compared with NDC were calculated and is presented as mean ± SEM (n=3). 
Drug concentrations are plotted in Log10 scales.  
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IC50 in serum-
starved K562 
BMS-214662 
( M) 
BMS-225975 
( M) 
Bortezomib 
(nM)  IM ( M) 
24h  37.5  500  25  13 
 
Table   6-2: IC50 for BMS-214662, BMS-225975, Bortezomib and IM in starved K562 cells.  
Estimated from mean values in the above figure.  
6.6  Measurement of ROS in serum-starved K562 cells 
Intracellular ROS levels were measured in non-proliferating K562 cells to investigate 
if BMS-214662 preferentially induced generation of intracellular ROS compared with 
BMS-225975. It was  observed that both BMS-214662 and BMS-225975 treatment 
arms  had  elevated  DCF  levels,  while  BMS-214662  treatment  arm  generally  had 
higher  DCF  level  than  the  BMS-225975  arm  at  each  time-point  that  achieved 
statistical significance at 8 hours and 24 hours time-points (p=0.0012 and p=0.031, 
respectively).  In  contrast, bortezomib  did  not  significantly  increase  DCF  level  over 
baseline (p>0.16, paired t-test) (Figure   6-7).  
 
The DCF level in IM arm is significantly decreased at 24 hours time-point with respect 
to baseline and 8 hours time-point (p=0.013 and p=0.031, respectively. Paired t-test) 
(Figure   6-7). H2O2 was used as a positive control, and it was observed that the H2O2 
treatment arm had gradual increase of DCF fluorescence and reached about 2-fold of 
baseline at 24 hours time-point (Figure   6-7).  Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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Figure   6-7: Intracellular ROS level in serum-starved K562 cells with drug treatments.  
Proliferating K562 cells were cultured in serum free medium for 16 hours, then loaded 
with DCFDA and treated with each drug in serum free medium. DCF fluorescence was 
measured by flow cytometry, and shown as percentage to the NDC at each time-point. 
Results are shown as mean ± SEM, n=3 (*p<0.05, ** p<0.01). 
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6.7  Summary and Discussion  
In  summary,  these  results  demonstrated  that  BMS-214662  is  not  a  proteasome 
inhibitor like bortezomib. Although BMS-214662 treatment induced accumulation of 
total ubiquitinated proteins and specifically Bcr-Abl protein in K562 cells, another FTI 
BMS-225975  had  very  similar  effects.  This  indicates  that  accumulation  of  total 
ubiquitinated proteins and Bcr-Abl protein is not the novel mechanism of action of 
BMS-214662 which preferentially induces apoptosis in CML cells. It is likely that the 
observed protein accumulation results from the common mechanism of BMS-214662 
and  BMS-225975,  which  is  their  FTI  activity.  On  the  other  hand,  BMS-214662 
induced significantly higher levels of intracellular ROS in both proliferating and non-
proliferating  K562  cells  than  BMS-225975,  demonstrating  the  involvement  of 
significant ROS production in the novel mechanism of action of BMS-214662.  
 
It was shown that the IC50 values of BMS-214662 are much lower than BMS-225975 
in both proliferating and non-proliferating K562 cells (Table   6-1 and Table   6-2), which 
is  consistent  with  previous  reports  that  BMS-214662  has  a  much  more  potent 
cytotoxic  effect  against  tumour  cells  compared  with  BMS-225975.  Manne  et  al 
demonstrated BMS-214662 preferentially induced apoptosis in tumour cells in vitro 
other  than  BMS-225975  (211).  In  addition,  BMS-214662  caused  dramatic  tumour 
regression in vivo, while BMS-225975 only had a mild inhibition of tumour growth 
(211). Copland et al showed that BMS-214662 significantly reduced the number of 
quiescent  CML  CD34
+  cells,  and  increased  the  percentage  of  caspase-3  positive 
CML CD34
+ cells, but the effects of BMS-225975 was not different from NDC (212). Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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Since BMS-214662 and BMS-225975 have very similar FTI activity, these reports and 
observations  consolidate  the  notion  that  BMS-214662  has  a  novel  mechanism  of 
action against tumour cells, including CML cells.   
 
Pellicano et al showed that BMS-214662 increased intracellular ROS level compared 
with NDC in CML CD34
+ cells, but the effect of BMS-225975 on ROS was not studied 
in their report (213). In this chapter, the induction of ROS by both BMS-214662 and 
BMS-225975 was studied, and was found that both drugs up-regulated intracellular 
ROS  levels  in  proliferating  and  non-proliferating  K562  cells,  but  the  level  of  ROS 
induced by BMS-214662 was significantly higher than by BMS-225975. This indicates 
that the FTI activity of BMS-225975 is able to increase intracellular ROS to a certain 
level, and that the much greater increase of ROS induced by BMS-214662 was due in 
part to its FTI activity but also by its novel non-FTI related activity.      
 
Bcr-Abl can increase proteasome activity (269). Consistent with this, it was observed 
that inhibition of Bcr-Abl tyrosine kinase by IM accumulated ubiquitinated proteins in 
proliferating  K562  cells  (Figure    6-3A  and  B),  indicating  IM  decreased  proteasome 
activity by Bcr-Abl inhibition. In addition, Bcr-Abl can up-regulate intracellular ROS 
level (270), so inhibition of Bcr-Abl tyrosine kinase is supposed to down-regulate ROS 
level.  However,  1 M  IM  did  not  significantly  decrease  ROS  level  with  8-hour 
treatment in proliferating K562 cells (Figure   6-4). This may be because the length of 
treatment or drug concentration is not sufficient. On the other hand, the intracellular Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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ROS level significantly decreased with 24-hour 10 M IM treatment in non-proliferating 
K562 cells (Figure   6-7),  
  
Previous reports have shown that BMS-214662 was able to activate JNK signalling 
pathway (211), and up-regulate PKCβ level (213), whereas BMS-225975 could not 
activate these signalling pathways. In addition, co-treatment of CML progenitor and 
stem cells with BMS-214662 and PKCβ inhibitor greatly reduced apoptosis compared 
to BMS-214662 single treatment (213). In this chapter, it was illustrated that BMS-
214662 induced significantly higher level of intracellular ROS compared with BMS-
225975 in both proliferating and non-proliferating CML cells. However, further studies 
are required to link these findings together in order to uncover the novel mechanism 
of  action  of  BMS-214662  against  CML  cells,  which  will  facilitate  novel  drug 
development to eliminate CML disease.  
 
One  possible  model  to  link  these  observations  is  that  BMS-214662  treatment 
generated  sufficient  amount  of  intracellular  ROS  to  activate  JNK  (Figure    6-4  and 
Figure   6-7). It is known that JNK is activated upon exposure to oxidative stress and 
DNA  damage,  and  then  activated  JNK  phosphorylates  14-3-3  and  results  in  the 
release  of  c-Abl  (and  possibly  Bcr-Abl  as  well  in  CML  cells)  from  14-3-3,  hence 
nuclear  translocation  of  c-Abl  and  induction  of  apoptosis  by  Abl  tyrosine  kinase 
(231;234).  In  addition,  14-3-3/PKC  association  inhibits  PKC  enzymatic  activity, 
including PKCβ (271), and expression of functionally inactivated 14-3-3 in mice is 
accompanied with elevated expression of PKCβ2 (272). Additionally, phosphorylating Peixun Zhou, 2011                                                                                          Chapter 6                                                                                                       
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of  14-3-3  by  activated  JNK  disrupts  14-3-3/ligands  association  (229).  Thus, 
phosphorylating of 14-3-3 by JNK in response to oxidative stress may lead to 14-3-
3/PKCβ dissociation, recovery of PKCβ activity and enhanced expression of PKCβ, 
which could explain the observations made by Pellicano et al (213). Thus, the future 
perspective is to examine the subcellular localization of c-Abl and Bcr-Abl proteins in 
BMS-214662 treated CML cells, as well as 14-3-3/PKCβ interaction.  
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7  Results 5: Targeted drug delivery by sLDL particles 
7.1  Introduction 
With the failure of efforts so far to eliminate CML stem cells, a new approach was 
developed  based upon  one  possible explanation  of  TKI  insensitivity,  which  is  that 
there  may  be  insufficient  intracellular  drug  concentration  in  insensitive  CML  stem 
cells.  The  expression  level  and  kinase  activity  of  Bcr-Abl  is  greatly  elevated  in 
primitive CML CD34
+CD38
– cells compared to mature MNC (163). In addition, the 
clinically achievable steady state peak plasma concentration of IM is about 4.6 M at 
the  standard  400mg  once  daily  dosing  (149),  and  it  was  demonstrated  that  this 
concentration  of  IM  did  not  significantly  reduce  CrkL  phosphorylation  in  CML 
CD34
+38
–  cells  in  vitro  (163).  Therefore,  insufficient  inhibition  of  Bcr-Abl  tyrosine 
kinase activity in the primitive CML CD34
+38
– cells could be an explanation of IM 
insensitivity, and an increased intracellular IM concentration may overcome this drug 
resistance, and kill CML stem cells.  
 
However,  simple  escalation  of  IM  oral  dose  may  not  be  the  best  choice,  as  the 
therapeutic window could be lost and side effects become intolerable with high levels 
of  IM.  On  the  other  hand,  a  CML  stem  cell  targeted  drug  delivery  approach  may 
overcome  this  resistant  mechanism  with  limited  toxicity.  Natural  LDL  particles  are 
preferentially  uptaken  by  leukaemic  cells  (237).  sLDL  particles  are  functionally 
equivalent to LDL and do not have issues associated with natural LDL (240;241). Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
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Therefore, sLDL particles are suitable for targeted drug delivery in CML stem cells.      
The ultimate aim of this study was to determine if the drug loaded sLDL particles may 
overcome insufficient intracellular drug levels in CML stem cells. The first step of this 
investigation,  however,  was  to  examine  the  ability  of  CML  stem  cells  to  uptake 
unloaded sLDL particles in vitro. 
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7.2  Uptake of sLDL by CML cells 
Competent  sLDL  particles  were  prepared  with  a  green  fluorescence  tracer  dye 
dioctadecyloxacarbocyanine (DiO), and synthetic apoprotein B receptor peptide which 
is recognized by LDLR inducing active cellular uptake. Control particles lacking the 
Apo-B receptor peptide were also prepared (peptide free sLDL). Since the tracer dye 
DiO  emits  green  fluorescence,  the  level  of  sLDL  uptake  by  CML  cells  could  be 
measured by flow cytometry in the FITC channel.  
 
In order to study if CML cells were able to uptake sLDL particles and determine an 
optimal  sLDL  concentration  and  incubation  time  for  the  subsequent  experiments, 
K562  cells  were  treated  with  sLDL  for  various  lengths  of  time  and  sLDL 
concentrations. It was demonstrated that sLDL treated K562 cells (equivalent to 5 g 
cholesterol/mL  culture  medium)  accumulated  sLDL  particles  with  increased 
incubation  time,  and  there  was  a  one-log  elevation  of  FITC  mean  fluorescence 
intensity  (MFI)    at  24  hours  of  treatment  compared  to  the  untreated  cells  (Figure 
  7-1A). In addition, an increased uptake of sLDL by K562 cells with increasing sLDL 
concentrations  at  24  hours  of  treatment  was  also  observed  (Figure    7-1B).  Taken 
together, these data demonstrated firstly the uptake of sLDL particles by K562 cells, 
and that this uptake was in a time and concentration dependent manner. Treatment 
for 24 hours with 5 g cholesterol/mL was chosen for the subsequent experiments.  
 
In addition, uptake of sLDL particles by CML CD34
+38
low/− cells was also examined. 
Similarly  to  K562  cells,  sLDL  treated  (equivalent  to  5 g  cholesterol/mL)  CML Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
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CD34
+38
low/− cells had approximately one-log increase in FITC MFI compared to the 
untreated cells, demonstrating the uptake of sLDL particles by these cells (Figure 7-
2). Cells treated with peptide free sLDL also had a slightly increased FITC MFI, but 
not as high as the competent sLDL treated cells, indicating a low level of passive 
sLDL uptake.     
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Figure   7-1: Uptake of sLDL particles by K562 cells.  
(A)  K562  cells  were  treated  with  sLDL  (5 g  cholesterol/mL),  and  analyzed  by  flow 
cytometry at 2, 4 and 24 hours of treatment. (B) K562 cells were treated with 0.5, 5 and 
50 g cholesterol/mL, and measured by flow cytometry at 24 hours of treatment. 
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Figure   7-2: Uptake of sLDL particles by CML CD34
+38
low/− cells.  
CD34
+38
low/− cells were incubated with sLDL or peptide free sLDL (equivalent to 5 g 
cholesterol/mL) for 24 hours, and then analyzed by flow cytometry.  
7.3  Internalization of sLDL by CML cells 
It was demonstrated by flow cytometry that sLDL particles were taken up by CML 
cells. However, a fluorescent signal by flow cytometry does not necessarily mean 
sLDL  particles  had  been  internalized  by  these  cells,  since  cell  surface associated 
fluorescent  dye  would  be  detected  by  flow  cytometry  as  well.  Therefore, 
deconvolution microscopy was employed to confirm the internalisation of the sLDL 
particles  in  CML  cells.  K562  and  CML  CD34
+38
low/−  cells  were  treated  with  sLDL 
particles (equivalent to 5 g cholesterol/mL) for 24 hours, and Z-Stack images were 
taken with multiple slices and then deconvolved to remove non-specific fluorescence. Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
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As shown in Figure   7-3, intracellular sLDL particles were visualized in the cytoplasm 
of K562 and CML CD34
+38
low/− cells. The internalised sLDL particles appeared to be 
associated with cellular organelles such as the endosomes (indicated by white arrows 
in  Figure    7-3).  When  the  cells  were  treated  with  apoprotein  B  peptide-free  sLDL 
particles,  very  weak  green  fluorescence  was  observed  in  the  cytoplasm  by 
fluorescence microscopy, again indicating a low level of passive sLDL uptake. Green 
fluorescence was not detected in the untreated cells. This result confirmed that the 
majority  of  fluorescence  signals  detected  by  flow  cytometry  were  intracellular. 
Furthermore, the internalisation of the sLDL particles was confirmed by transmission 
electron microscopy (Figure   7-4; pictures were taken by Ms Abraham in the Glasgow 
Caledonian University). 
A 
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B 
 
Figure   7-3: Fluorescence microscopy of sLDL.   
K562  (A)  and  CML  CD34
+38
low/−  (B)  cells  were  treated  with  sLDL  to  confirm  the 
internalization  of  sLDL  particles.  Z-stacks  were  captured  then  subjected  to 
deconvolution  to  remove  non-specific  fluorescence.  FITC  channel  shows  sLDL 
particles  (Green),  DAPI  channel  shows  cell  nucleus  (Blue),  differential  interference 
contrast (DIC) channel is to show the phase contrast images of cells.   
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Figure   7-4: Electron microscopy of CML CD34
+ cells after treatment with sLDL.                     
CML CD34
+ progenitors were treated with sLDL particles for 24 hours, and then fixed 
for transmission electron microscopy to confirm the internalisation of sLDL particles. 
White arrows indicate engulfed sLDL particles within intracellular vesicles/endosomes. 
Cells were fixed with 2.5% glutaraldehyde and sent to Glasgow Caledonian University 
for electron microscopy. 
 
 Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
 
 
208 
7.4  Summary and Discussion 
In  this  study,  the  cell  targeting  potential  of  sLDL  particles  was  assessed.  These 
results  demonstrate  uptake  and  internalization  of  sLDL  particles  by  CML  cell  line 
K562 and for the first time by CML stem cells.  
 
Tumour  cells  were  considered  to  require  more  cholesterol  for  increased  cell 
proliferation  compared  to  their  normal  counterparts.  It  was  reported  that  cancer 
patients had significantly decreased serum cholesterol levels than matched normal 
controls, except breast cancer in women. (273-275). Reports demonstrated elevated 
uptake of LDL in cancer cells than normal cells (237;239;276). We recently showed 
that tumour prostate cells uptake significantly more sLDL particles than normal cells 
in vitro (277). These observations support the notion that tumour cells require more 
cholesterol than normal cells. In addition, we also demonstrated that Ph
+ myeloid cell 
lines  and  CD34
+  cells  uptake  significantly  more  sLDL  particles  compared  to  Ph
– 
myeloid cell lines and CD34
+ cells respectively (277). Thus, sLDL particles can be 
preferentially uptaken by tumour cells and Ph
+ cells, achieving some level of targeted 
drug delivery when sLDL particles are loaded with specific drug(s). 
 
It might be argued that CML quiescent stem cells do not uptake sLDL particles due to 
their quiescence, but our observations demonstrated that these cells do uptake sLDL 
particles. Primary CML CD34
+38
low/− cells were shown to take up and internalize sLDL 
particles in Figure   7-2 and Figure   7-3B. In addition, we demonstrated the primary 
CML CD34
+38
low/− cells took up sLDL particles at about the same level as bulk CML Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
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CD34
+  cells,  which  was  significantly  higher  than  non-CML  CD34
+  cells  (277). 
Furthermore, we also showed CML quiescent stem cells, which were identified by 
maintenance of maximal CESE fluorescence, also were able to uptake sLDL particles 
(277). These results showed that sLDL particles could be used as a drug delivery 
vehicle targeting CML CD34
+38
low/− cells.     
 
However, studies revealed that the second generation TKI, dasatinib, was able to 
inhibit Bcr-Abl tyrosine kinase activities in CML cells, but did not eliminate CML stem 
cells  (157;163).  This  indicates  that  there  are  other  mechanisms  keeping  primitive 
CML stem cells alive against dasatinib treatment, such as autophagy (186). It was 
shown that combination of TKI with the autophagy inhibitor chloroquine significantly 
reduced the number of colonies formed by CML stem cells (186). Therefore, sLDL 
particles  would  be  used  to  delivery  other  drugs  together  with  TKI  in  order  to 
completely eliminate CML stem cells.  
 
Another  potential  advantage  of  using  sLDL  particle  as  a  drug  delivery  vehicle  is 
reduction of side effects in vivo. TKI cause many side effects in patients and these 
side effects can lead to intolerance and patient drop-out from TKI treatment (149). In 
addition,  IM  was  reported  to  be  cardiotoxic  and  caused  heart  failure,  and  this 
cardiotoxicity  was  induced  by  c-Abl  inhibition  in  cardiocytes  (278).  Nilotinib  and 
dasatinib also exhibited some degree of cardiotoxicity (279). By employment of sLDL 
as  a  targeted  drug  delivery  vehicle,  these  side  effects  might  be  reduced.  It  was 
reported that LDL-DOX (Doxorubicin) complex exhibited no toxicity to the heart in Peixun Zhou, 2011                                                                                          Chapter 7                                                                                                       
 
 
210 
nude mice bearing HepG2 cells, whereas DOX only treatment caused cardiotoxicity in 
the mice while LDL-DOX and DOX had similar anti-proliferative effects on tumour 
cells (280). 
 
The following step of this study is to incorporate TKI and /or other drugs into the sLDL 
particles and examine if there is any improvement in inducing apoptosis in leukaemic 
quiescent stem cells. Hydrophobic drugs can be incorporated into the hydrophobic 
core of LDL, while hydrophilic drugs can be chemically modified into hydrophobic pro-
drugs and then incorporated (244). LDL has been shown to be successfully coupled 
with  several  drugs  (280-282),  indicating  the  feasibility  of  coupling  sLDL  with  TKI 
and/or other drugs. Furthermore, using sLDL as a targeted drug delivery vehicle could 
potentially benefit treatment of other cancers of stem cell origin besides CML.       
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8  Final discussion and future perspectives 
Overall,  these  studies  provide  further  insight  into  how  CML  cells  may  be  fully 
eradicated. Although TKIs revolutionized the treatment of CML in the last decade and 
successfully eliminate differentiated CML cells, primitive quiescent CML stem cells 
still survive even with maximal inhibition of Bcr-Abl tyrosine kinase activity. In this 
thesis, we studied alternative strategies to eliminate these TKI-insensitive CML stem 
cells by addressing the aims specific in the Introduction (Chapter   1.7). Firstly, the 
efficacy  of  nuclear  entrapment  of  Bcr-Abl  to  induce  apoptosis  in  CML  cells  was 
investigated, and it was found that neither continuous nor sequential IM and LMB 
treatment significantly increased the cytotoxic or cytostatic effect of IM in Bcr-Abl
+ cell 
lines  and  primary  CML  CD34
+  cells.  Then  the  subcellular  localisation  of  Bcr-Abl 
protein was visualized in TKI-insensitive CML progenitors which survived long-term 
dasatinib  treatment,  and  it  was  observed  that  there  was  a  significant  increase  in 
nuclear Bcr-Abl level in these survived cells compared to the NDC and about 50% of 
Bcr-Abl protein was still retained in the cytoplasm of these survived cells. It was also 
found that a proportion of Bcr-Abl protein was associated with 14-3-3 proteins in the 
cytoplasm  of  these  surviving  cells,  indicating  the  cytoplasmic  retention  of  Bcr-Abl 
might be due to its binding with 14-3-3 proteins. In addition, the accuracy of p-CrkL as 
a surrogate marker of Bcr-Abl tyrosine kinase activity was studied at short time points, 
and found that p-CrkL was not a reliable indicator of Bcr-Abl kinase activity within 24 
hours of IM treatment in vitro. It was also observed that there was a rapid and active 
dephosphorylation of Bcr-Abl within 1 hour of TKI treatment, driven at least in part by Peixun Zhou, 2011                                                                                          Chapter 8                                 
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protein tyrosine phosphatase activity. Furthermore, the mechanism of action of the 
BMS-214662  in  inducing  apoptosis  of  CML  cells  was  investigated,  and  it  was 
demonstrated  that  the  non-FTI  mechanism  of  BMS-214662  was  not  proteasome 
inhibition but involved generation of a significant amount of intracellular ROS. Finally, 
the efficacy of sLDL as a drug delivery vehicle to target primitive CML stem cells was 
assessed, and it was observed that unloaded sLDL particles were preferentially taken 
up and internalized by CML cell line K562 and for the first time by CML stem cells, 
demonstrating the targeting potential of sLDL particles in CML when they are loaded 
with drugs. Additionally, novel strategies besides TKI treatment have been developed 
in recent years to target primitive CML stem cells. Examples of these strategies are 
shown in Table   8-1. 
Strategy  Drugs  Reference 
Activation of PP2A  FTY720  (283) 
Activation of quiescent CML stem cells  G-CSF or IFN-α  (284;285) 
Allosteric inhibitor of Bcr-Abl  GNF-2  (286) 
Degradation of PML   AraC and As2O3  (287) 
Inhibition of Alox5 pathway  Zileuton  (288) 
Inhibition of anti-apoptotic Bcl2 family member – 
Mcl1  Omacetaxine   (289;290) 
Inhibition of autophagy  Hydroxychloroquine  (186) 
Inhibition of JAK2 kinase  TG101209  (222) 
Inhibition of self-renewal  Cyclopamine  (291) 
Targeting of IL-1 receptor accessory protein 
(IL1RAP) 
Anti-IL1RAP 
antibody  (292) 
Table   8-1: Novel therapies of CML.   Peixun Zhou, 2011                                                                                          Chapter 8                                 
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Neviani et al demonstrated that FTY-720 significantly reduced the number of human 
quiescent CML stem cells in vitro and murine Bcr-Abl
+ LT-HSCs in vivo compared to 
their normal counterparts (283). FTY-720 is an inhibitor of SET, and inhibition of SET 
restores  serine/threonine  phosphatase  PP2A  in  CML  cells.  Activated  PP2A  then 
activates tyrosine phosphatase SHP1 which is capable of dephosphorylating Bcr-Abl 
and JAK2 (217;218). Since both Bcr-Abl and JAK2 are substrates of another tyrosine 
phosphatase PTP1B (225;293) and it was shown in Chapter 5 that PTP1B could be 
involved  in  rapid  dephosphorylation  of  Bcr-Abl  after  TKI  treatment  in  K562  cells, 
activation of PTP1B in primitive CML stem cells may dephosphorylate both Bcr-Abl 
and JAK2 kinases and leads to apoptosis, which is worthy of further investigation.  
 
In addition, Neviani et al also demonstrated that although the expression level of Bcr-
Abl protein was much higher in quiescent CML CD34
+ cells than proliferating CML 
CD34
+ cell, the activity of Bcr-Abl (as measured by p-Abl level) is much lower in the 
former population than the latter, suggesting Bcr-Abl may serve a scaffolding role for 
other proteins that maintain survival of quiescent CML stem cells (283). Furthermore, 
Copland et al also demonstrated higher expression level of Bcr-Abl protein in primitive 
CML CD34
+CD38
– cells than total CML CD34
+ cells (163). However, Copland et al 
observed  higher  p-CrkL  and  total  phosphorylated  tyrosine  levels  in  the  former 
population than the latter (163). This may be explained by the findings in Chapter 5, 
which is that p-CrkL level does not accurately correlate with Bcr-Abl activity in CML 
cells.  
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Hamilton et al observed that 10% of primary Bcr-Abl
+ CD34
+ cells survived long-term 
dasatinib  treatment  in  the  absence  of  any  growth  factor  (249;254),  while  normal 
haemopoietic progenitors were not able to survive in the absence of IL-3 or GM-CSF 
(18).  These  observations  indicate  that  it  is  the  presence  of  Bcr-Abl  protein  that 
sustains survival of TKI-insensitive CML cells, but not its tyrosine kinase activity. This 
further  demonstrates that  Bcr-Abl may  serve  as  a  scaffold  in TKI-insensitive  CML 
cells. A possible example of the scaffolding role of Bcr-Abl was shown by Agarwal et 
al that Bcr-Abl aberrantly induced localisation of p27 in the cytoplasm in a kinase-
independent manner (294). p27 normally resides in the nucleus and serves as an 
inhibitor of cyclin dependent kinase, while in the cytoplasm it promotes oncogenesis 
(294).  Thus,  cytoplasmic  retention  of  p27  enables  Bcr-Abl  to  promote  cell  cycle 
progression.  
 
Neviani et al also showed that kinase-deficient Bcr-Abl enhanced JAK2 expression 
and kinase activity (283). On the other hand, knockdown of Bcr-Abl in primitive CML 
stem cells significantly reduced JAK2 activity (283). This demonstrates that Bcr-Abl 
elevates  JAK2  activity  in  a  kinase-independent  manner.  This  might  be  due  to 
mislocalisation of JAK2 which is caused by a non-kinase activity of Bcr-Abl protein. 
Activated  JAK2  upregulates  the  level  of  SET  and  then  inhibits  PP2A  activity, 
preventing the dephosphorylation of JAK2 (216-218). In addition, JAK2 plays a pivotal 
role in Bcr-Abl mediated cell signalling (222;223). For example, it activates STAT5 
and upregulates anti-apoptotic protein Bcl-xL (114;117). Furthermore, Neviani et al 
observed that inhibition of JAK2 significantly reduced β-catenin expression and its Peixun Zhou, 2011                                                                                          Chapter 8                                 
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transcriptional activity (283), suggesting the role of JAK2 in Wnt/β-catenin pathway, 
which  functions  to  promote  self-renewal  of  CML  stem  cells  (295).  Overall,  these 
observations may explain the inability of TKIs in eliminating primitive CML stem cells, 
as  kinase-inhibited  Bcr-Abl  is  still  able  to  promote  cell  cycle  progression,  inhibit 
apoptosis, and induce self-renewal in these stem cells. 
 
Since the presence of Bcr-Abl protein, but not its tyrosine kinase activity, is a relevant 
therapeutic  target  in  primitive  CML  stem  cells,  one  strategy  is  to  induce  nuclear 
translocation of Bcr-Abl in these cells in order to kill them. It can be speculated that 
the pro-survival scaffolding role of Bcr-Abl in the cytoplasm is impaired by inducing 
nuclear translocation of Bcr-Abl protein in primitive CML stem cells, and then nuclear 
Bcr-Abl plays a pro-apoptotic role in these cells. It was shown in Chapter 4 that Bcr-
Abl associated with 14-3-3 proteins in primary CML progenitors, as well as in TKI-
insensitive CML progenitors. It was also shown that about 50% Bcr-Abl protein still 
retained  in  the  cytoplasm  of  CML  progenitors  after  long-term  TKI  treatment.  In 
addition,  other  investigators  demonstrated  14-3-3/Bcr-Abl  association  as  well.  For 
example, 14-3-3 ζ binds with both Bcr and Abl parts of Bcr-Abl (231). Since a 14-3-3 
dimer can interact with two molecules at the same time (230) and 14-3-3 ζ is highly 
dimerized (296), it is possible that a 14-3-3 ζ homodimer can interact with two sites of 
Bcr-Abl protein simultaneously, with one site at Bcr and another at Abl part of Bcr-Abl. 
Thus, it is thought that interaction with 14-3-3 is a mechanism of cytoplasmic retention 
of Bcr-Abl.  
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R18  is  a  specific  competitive  antagonist  of  14-3-3  proteins  without  selectivity  for 
isoforms, which is capable of disrupting 14-3-3/ligand interaction in a phosphorylation 
independent  manner  (259;297;298).  However,  presence  of  R18  was  not  able  to 
accumulate Bcr-Abl into the nucleus (299). Dong et al also demonstrated that R18 
was  insufficient  to  disrupt  14-3-3/Bcr-Abl  association  in  Bcr-Abl  expressing  BaF/3 
cells, while R18 induced apoptosis in Bcr-Abl expressing BaF/3 and K562 cells by 
disrupting  14-3-3  association  with  forkhead  box  O3a  (FOXO3a)  protein  (259). 
Recently  a  small  molecule  competitive  antagonist  of  14-3-3  proteins,  BV02,  was 
identified  to  be  able  to  disrupt  14-3-3/c-Abl  association  and  induce  nuclear 
translocation of c-Abl (147). BV02 induced apoptosis in Bcr-Abl
+ cell lines and CML 
progenitors (147). However, further study is required to investigate whether BV02 is 
able to dissociate 14-3-3/Bcr-Abl complex and induce nuclear translocation of Bcr-
Abl.  
 
Another strategy is to induce quiescent CML stem cells to cycle, which, once cycling, 
can  then  be  targeted  by  TKIs.  It  was  observed  that  intermittent  G-CSF  treatment 
activated quiescent CML cells and enhanced the kill of CML progenitors by IM in vitro 
(284). However, this strategy was not effective in a pilot clinical trial with IM treated 
CML patients who had achieved CCgR (300). In addition, mathematical modelling 
predicts that addition of G-CSF may not improve the therapeutic effect of IM in CML 
patients (301). Furthermore, IFN-α is capable of promoting murine quiescent HSCs 
into cell cycle and sensitized them to the anti-proliferative drug, 5-FU in vivo (302). 
Some CML patients who switched from IFN-α to IM treatment achieved higher rate of Peixun Zhou, 2011                                                                                          Chapter 8                                 
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stable CMR compared to those who were not previously treated with IFN-α (303). 
This suggests that priming quiescent CML stem cells with IFN-α may activate these 
cells and sensitize them to IM treatment (285). However, the effectiveness of this 
strategy with human quiescent CML stem cells requires further investigation.  
 
Overall,  despite  the  success  of  TKIs  in  killing  the  majority  of  CML  cells,  primitive 
quiescent  CML  stem  cells  are  still  insensitive  to  TKI  treatment,  causing  disease 
relapse and minimal residual disease. In recent years, studies have been carried out 
to investigate why primitive CML stem cells resist or persist to TKIs, and possible 
approaches  have  been  searched  to  eliminate  them.  Since  most  CML  cells  are 
dependent on Bcr-Abl tyrosine kinase to survive, TKIs are able to get rid of leukaemic 
burden. Together with drug(s) targeting primitive CML stem cells, the possibility of 
eliminating all CML cells is greatly increased. Therefore, combination of TKIs with 
these approaches, which specifically target leukaemic stem cells, is likely to eradicate 
CP CML ultimately.  Peixun Zhou, 2011                                                                                                                                                                       
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9  Appendix 
Characteristics of CML samples used: 
Patient 
number 
CML 
stage 
WCC at 
leucapheresis 
(x 10
6/mL) 
Pre-
selection 
% CD34
+ 
Post 
selection 
% CD34
+ 
Method of 
CD34 
selection 
% Ph
+ 
in 
CD34
+ 
(FISH) 
223  Chronic  344  1.01  96.06  CliniMacs  96 
235  Chronic  500  3.2  90  CliniMacs  99.2 
236  Chronic  323  1.44  98.22  CliniMacs  98 
250  Chronic  374  2.8  97.28  CliniMacs  100 
255  Chronic  326  22.2  98.4  CliniMacs  100 
273  Chronic  400  6.4  96  CliniMacs  98 
274  Chronic  200  0.2  100  CliniMacs  98.6 
280  Chronic  230  6.3  99.7  CliniMacs  87.5 
281  Chronic  357.9  26.2  100  CliniMacs  94 
284  Chronic  250  11.2  99.6  CliniMacs  100 
 
 
Characteristics of non-CML samples used: 
Sample 
number  Disease 
WCC at 
leucapheresis  
(x 10
6/mL) 
Pre-
selection 
% CD34
+ 
Post 
selection 
% CD34
+ 
Method of 
CD34 
selection 
% Ph
+ 
in 
CD34
+ 
(FISH) 
006  T-Cell 
Lymphoma  150  7.31  99.19  CliniMacs  0 
007  Follicular 
NHL  189  2.73  99.04  CliniMacs  0 
011  Myeloma  194  3.52  99.7  CliniMacs  0 
 
 
WCC, white cell count 
NHL, non-Hodgkin's Lymphoma 
FISH, fluorescence in situ hybridization Peixun Zhou, 2011                                                                                                                                                                                                
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